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ABSTRACT 
 
The Streptococcus pneumoniae capsule is an  essential virulence factor  and it is ideally 
situated  to  modulate  interactions  between  the  bacteria  and  host  immune  cells.  Using 
isogenic unencapsulated mutants, flow cytometry assays and a mouse septicaemia model, 
this thesis has assessed the effects of the capsule on the interactions of S. pneumoniae 
serotype  2  and  4  strains  with  complement  factors  and  phagocytes.  Overall,  these  data 
demonstrate that the capsule inhibits complement activity but this only partially contributes 
to the effects of the capsule on neutrophil phagocytosis and virulence during septicaemia. 
Furthermore, interactions with macrophages were also found to be complement-dependent 
and independent, resulting in differences in both phagocytosis and inflammatory responses 
both in vitro cell line and in vivo. 
 
I also investigated whether capsular serotype affects S. pneumoniae interactions with the 
host  immune  response  using  otherwise  isogenic  TIGR4  strains  expressing  capsular 
serotypes 4, 6A, 7F, 23F. These data demonstrate that resistance to complement mediated 
immunity is associated with capsular serotype, and hence this might be one mechanism by 
which capsular serotype could affect relative invasiveness of S. pneumoniae strains. Non-
capsular genetic background was also found to affect complement mediated immunity, and 
importantly, relatively invasive strains were on average more resistant to complement than 
weakly invasive strains. 
 
Overall the results in this thesis demonstrate that the S. pneumoniae capsule aids evasion of 
both  complement  dependent  and  independent  immune  mechanisms,  and  that  serotype-
dependent  differences  in  the  effects  on  immunity  could  partially  explain  variations  in 
virulence between strains.    
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CHAPTER 1      INTRODUCTION   
 
1.1  BACKGROUND 
1.1.1  Microbiology 
Streptococcus  pneumoniae  are  pathogenic  Gram-positive,  lancet-shaped  cocci  which 
usually grow in pairs, but may form short chains or grow singly. Individual cells are 0.5-
1.25 m in diameter. S. pneumoniae is alpha-haemolytic when grown on blood plates, is 
non-motile and like other streptococci does not produce catalase, fermenting glucose to 
lactic  acid.  However,  unlike  other  streptococci,  S.  pneumoniae  does  not  display  an  M 
protein, hydrolyzes inulin and has a characteristic cell wall composition in terms of both 
teichoic acid and peptidoglycan. S. pneumoniae grows best in 5% CO2 and in all growth 
conditions an external catalase source must be provided to neutralize the large quantity of 
hydrogen  peroxide  produced  by  S.  pneumoniae.  S.  pneumoniae  is  part  of  the  oral 
streptococcal group which includes S. cristatus, S. infantis, S. mitis, S. oralis and S. peroris 
and is differentiated from other viridians group streptococci based on colony morphology, 
optochin  and  bile  sensitivity,  inulin  fermentation  and  agglutination  with  anti-capsular 
specific antibody raised in rabbits. However recent observations of pneumococci producing 
atypical reactions to these standard tests including optochin resistance (Munoz et al. 1990; 
Fenoll  et  al.  1994)  and  bile  insolubility  (Obregon  et  al.  2002)  with  the  discovery  of 
optochin-sensitive and bile soluble oral streptococci (Whatmore et al. 2000; Martin-Galiano 
et al. 2003), has presented difficulties with conventional identification methods. Alternative 
approaches to identification include the use of the pia locus, which encodes an iron uptake 
transporter, and is located in a pathogenicity island (PPI-1) (Brown et al. 2001). However it 21 
 
is likely that a combination of 2 or 3 unique loci would be needed to confirm diagnosis of 
S.  pneumoniae.  Recently  it  was  suggested  that  S.  pneumoniae,  S.  mitis  and  S. 
pseudopneumoniae evolved from a common ancestor by a process of genome reduction, 
providing an explanation as to the difficulties encountered in differentiating S. pneumoniae 
and S. mitis (Kilian et al. 2008). 
 
1.1.2  Clinical Disease 
S. pneumoniae is the second commonest bacterial cause of death worldwide, and causes a 
wide range of diseases from pneumonia, meningitis, otitis media and septicaemia (Musher 
1992; Coffey et al. 1998) (Fig 1.1). S. pneumoniae is part of the normal nasopharyngeal 
flora, and it is estimated that 40% or more of children carry S. pneumoniae in the upper 
respiratory  tract,  and  carriage  in  adults  ranges  from  5  to  70%,  depending  on  various 
environmental factors (Austrian 1986; Wu et al. 1997). Currently S. pneumoniae accounts 
for  two-thirds  of  the  cases  with  community  acquired  pneumonia  (CAP)  with  known 
aeitology, and two thirds of the cases of bacteraemia (Fine et al. 1996). In the developing 
world an estimated 2.6 million children under 5 years of age die annually as a result of 
pneumonia, with S. pneumoniae being the single most common causative pathogen (WHO 
2007). All disease states can lead to migration of S. pneumoniae from the site of infection 
into the bloodstream, resulting in pneumococcal sepsis (Gray et al. 1986). Furthermore, S. 
pneumoniae is an important cause of primary septicaemia in children in the developing 
world (Scott et al. 1996). 
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Patients particularly susceptible to pneumococcal infections include infants, the elderly, and 
those  who  are  immunocompromised  (either  due  to  HIV  infection  or  medical  treatment 
through immunosuppression or splenectomy) or have certain chronic conditions such as 
diabetes, alcohol abuse or chronic lung disease. Prior respiratory infection with influenza 
virus  is  a  major  risk  factor  for  pneumococcal  infection,  and  smokers  are  also  more 
susceptible  to  pneumonia  (Jones  et  al.  1984;  Nuorti  et  al.  2000;  Dowell  et  al.  2003). 
Interestingly, males tend to be more likely to contract invasive pneumococcal disease (IPD) 
(Robinson et al. 2001). The highest disease rates occur in children between 11 months and 
6 years old, and there is also increasing incidence of IPD in over 65 year olds, with a rate  
of approximately 75/100,000 (CDC 2000; Sleeman et al. 2001). Mortality rates exceed 20%  
are higher in the elderly and in young children range from 2% in developed countries to 
over 20% in the developing world (Plouffe et al. 1996; Robinson et al. 2001; Shibl et al. 
2009).  
 
The  clinical  importance  of  S.  pneumoniae  infections  is  compounded  by  increasing 
antibiotic resistance amongst clinical isolates (Jacobs 2004; Farrell et al. 2007). The first 
penicillin  resistant  strain  was  isolated  in  1967,  and  resistance  to  anti-pneumococcal 
antibiotics  including  macrolides  and  β-lactams  is  increasing  in  both  developed  and 
developing  countries.  Recent  studies  estimated  the  worldwide  prevalence  of  penicillin-
resistant and macrolide-resistant S. pneumoniae ranged from 18·2 to 22·1% and from 24·6% 
to 31·8% (Felmingham 2002; Jacobs et al. 2003) respectively. The most prevalent serotypes 
resistant  to  penicillin  and  erythromycin  include  6A,  6B,  9V,  14,  19A,  19F  and  23F 
(Whitney et al. 2000). Furthermore, the disease burden of S. pneumoniae is increased by 
HIV infection, which is associated  with both increased incidence of disease  and by  an 23 
 
increasing rate of antibiotic resistance in S. pneumoniae strains (McEllistrem et al. 2002).  
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Fig 1.1 Clinical disease of S. pneumoniae 
Transition  from  a  carriage  state  to  one  in  which  symptomatic  disease  occurs  is  due  to 
aspiration  of  bacteria  from  the  nasopharynx  into  the  lungs  leading  to  pneumonia. 
Alternatively  S.  pneumoniae  invade  through  the  nasopharyngeal  mucosa  into  the  blood 
causing bacteraemia. If S. pneumoniae crosses the blood-brain barrier meningitis occurs. 
Mortality  rates  associated  with  S.  pneumoniae  disease  are  currently:  otitis  media,  0%; 
meningitis, 30%; septicaemia, 20%; pneumonia, 5%; sinusitis and bronchitis, 0%. Current 
estimates suggest 10% of adults and 50% of infants have nasopharyngeal colonisation with 
S. pneumoniae.  24 
 
1.2  MOLECULAR EPIDEMIOLOGY 
1.2.1  Biochemical Serotyping  
It  is  essential  for  epidemiology  studies  that  accurate  and  specific  identification  of  S. 
pneumoniae occurs in patients suspected of having IPD. S. pneumoniae is surrounded by a 
polysaccharide capsule which is present on all strains which are isolated from patients with 
IPD. 91 antigenically different capsular types have been described, being distinguished by 
chemical differences in the type-specific capsular polysaccharides that can be identified by 
the  specificity  of  type-specific  antibody  raised  in  rabbits  (Henrichsen  1995).  The  91 
different  antigenic  types  are  divided  into  46  serotype  groups,  as  a  certain  degree  of 
antigenic cross reactivity occurs (Fig 1.2). Mixture of the bacteria with antiserum causes 
the capsule to swell on binding of homologous antibody. This determines the basis of the 
standard test known as the Quellung Reaction, in which the preparation is stained with 
India Ink to visualize the swollen capsule zone using microscopy. Different specificities of 
antisera are available, from omniserum which recognizes all S. pneumoniae strains to serum 
which  differentiates  between  the  very  similar  6A  and  6B  serotypes  (Statens  Serum 
Institute). However, the Quellung Reaction requires skillful microscopic examination and 
the recent introduction of molecular typing methodologies offers an alternative method of 
identifying capsular serotype. 25 
 
Type    Antigenic Formula 
1                           1a 
2                           2a 
3                           3a 
4                           4a 
5                           5a 
6A    6a, 6b 
6B    6a, 6c 
6C    6a, 6b 
7F    7a, 7b 
7A    7a, 7b, 7c 
7B    7a, 7d, 7e, 7h 
7C    7a, 7d, 7f, 7g, 7h 
8    8a 
9A    9a, 9c, 9d 
9L    9a, 9b, 9c, 9f 
9N    9a, 9b, 9e 
9V    9a, 9c, 9d, 9g 
10F    10a, 10b 
10A    10a, 10c, 10d 
10B    10a, 10b, 10c, 10d, 10e 
10C    10a, 10b, 10c, 10f 
11F    11a, 11b, 11e, 11g 
11A     11a, 11c, 11d, 11e 
11B    11a, 11b, 11f, 11g 
11C    11a, 11b, 11c, 11d, 11f 
11D    11a, 11b, 11c, 11e 
12F    12a, 12b, 12d 
12A     12a, 12c, 12d 
12B    12a, 12b, 12c, 12e 
13    13a, 13b 
14    14a 
15F    15a, 15b, 15c, 15f 
15A    15a, 15c, 15d, 15g 
15B    15a, 15b, 15d, 15e, 15h 
15C    15a, 15d, 15e 
16F    16a, 16b, 11d 
16A     16a, 16c 
17F    17a, 17b 
17A     17a, 17c 
18F    18a, 18b, 18c, 18f 
18A     18a, 18b, 18d 
18B    18a, 18b, 18e, 18g 
18C    18a, 18b, 18c, 18e 
19F    19a, 19b, 19d 
19A    19a, 19c, 19d 
19B    19a, 19c, 19e, 7h 
Type    Antigenic Formula 
 
19C     19a, 19c, 19f, 7h 
20    20a, 20b, 7g 
21    21a 
22F    22a, 22b 
22A    22a, 22c 
23F    23a, 23b, 18b 
23A    23a, 23c, 15a 
23B     23a, 23b, 23d 
24F    24a, 24b, 24d, 7h 
24A    24a, 24c, 24d 
24B     24a, 24b, 24e, 7h 
25F    25a, 25b 
25A    25a, 25c, 38a 
27    27a, 27b 
28F    28a, 28b, 16b, 23d 
28A    28a, 28c, 23d 
29    29a, 29b, 13b 
31    31a, 20b 
32F    32a, 27b 
32A    32a, 32b, 27b 
33F    33a, 33b, 33d 
33A    33a, 33b, 33d, 20b 
33B     33a, 33c, 33d, 33f 
33C     33a, 33c, 33e 
33D    33a, 33c, 33d, 33f, 6a 
34    34a, 34b 
35F    35a, 35b, 34b 
35A    35a, 35c, 20b 
35B     35a, 35c, 29b 
35C     35a, 35c, 20b, 42a 
36    36a, 9e 
37    37a 
38    38a, 25b 
39    39a, 10d 
40    40a, 7g, 7h 
41F    41a, 41b 
41A    41a 
42    42a, 20b, 35c 
43    43a, 43b 
44    44a, 44b, 12b, 12d 
45    45a 
46    46a, 12c, 44b 
47F    47a, 35a, 35b 
47A    47a, 43b 
48    48a 
 
Fig  1.2  Type  designations  and  antigenic  formulae  of  91  types  of  S.  pneumoniae 
The antigenic formulas represent arbitrary designations of cross-reactions as seen by the 
capsular reaction (Kauffmann et al. 1940). Adapted from Henrichsen, 1995 26 
 
1.2.2  Molecular Typing Methods 
Accurate characterization of S. pneumoniae is essential for molecular epidemiology, and 
traditional serotyping methodologies are not necessarily discriminating enough. Recently 
Multilocus sequence typing (MLST) has been developed for S. pneumoniae and has been 
very useful in characterising the epidemiology and ecology of the pneumococcus. MLST 
assigns  numbers  to  alleles  at  housekeeping  gene  loci  by  nucleotide  sequencing.  These 
housekeeping  genes  are  shikimate  dehydrogenase  (aroE),  glucose-6-phosphate 
dehydrogenase (gdh), glucose kinase (gki), transketolase (recP), signal peptidase I (spi), 
xanthine  phosphoribosyltransferase  (xpt)  and  D-alanine-D-alanine  ligase  (ddl).  Different 
polymorphisms within the nucleotide sequence of 450-500 bp internal fragments of these 7 
housekeeping genes are assigned an allele number creating a 7 figure code that defines each 
sequence type (ST). MLST has been validated in S. pneumoniae, and there is a strong 
correlation between serotype and genetic relatedness in invasive S. pneumoniae (Enright et 
al. 1999). Most serotypes are composed of a limited number of ST strains but one ST may 
have different capsular serotypes. 
 
Furthermore since MLST defines isolates based on their allelic profiles, it is possible to 
examine  clustering  between  isolates  and  identify  isolates  with  close  or  identical  allelic 
profiles. As isolates diverge they accumulate single nucleotide differences in the 7 MLST 
loci,  and  relationships  between  isolates  can  become  obscured  by  relatively  minor 
recombination  exchanges  in  these  housekeeping  genes.  However  MLST  is  sufficiently 
discriminatory to determine if isolates of S. pneumoniae from IPD in a geographical area 27 
 
are the same strain or from different strains and how closely related strains causing disease 
in one geographic area are to those isolated from IPD world-wide. 
 
Molecular  typing  methods  have  shown  that  a  serotype  of  S.  pneumoniae  is  normally 
comprised  of  several  divergent  genotypes.  Changes  in  serotype  can  occur  through 
recombination at the capsular locus (Coffey et al. 1998; Coffey et al. 1999; Ramirez et al. 
1999), creating strains with the different capsular serotypes but the same ST. In addition, 
molecular serotyping techniques may also provide insights into multiple carriage, which 
has been difficult until recently due to technical challenges with conventional serotyping 
methods (Huebner et al. 2000; Brito et al. 2003; Lawrence et al. 2003).  
 
1.2.3 Epidemiology of S. pneumoniae 
There are at least 40 serogroups of S. pneumoniae which are potentially pathogenic and 
possibly  all  are,  but  only  a  relatively  small  number  of  these  groups  accounts  for  the 
majority of IPD in children worldwide (Hausdorff et al. 2000). There are geographic and 
age-related  differences  in  the  incidence  of  S.  pneumoniae  serotypes,  and  certain  S. 
pneumoniae serotypes are recovered from IPD more frequently than others and have higher 
disease prevalence. In the USA, serogroups 4, 6, 9, 14, 18, 19 and 23 cause 80-90% of 
invasive disease, and in Europe the same serotypes cause 61-81% of invasive disease in 
children.  However,  most  childhood  pneumonia  cases  occur  in  the  developing  world, 
especially India, China, and Pakistan, whilst Bangladesh, Indonesia and Nigeria also have a 
high incidence of cases requiring hospitalization (Rudan et al. 2008). However it is likely 28 
 
that some of the data from some countries is confounded by sampling issues and weak 
analytical  technique,  especially  within  Africa.  A  recent  study  in  India  found  the  most 
common serogroups isolated from IPD to be 1, 6, 19, 7, 5, 15, 14, 4, 16, and 18, giving a 
71%  serotype  coverage  from  the  9-valent  vaccine  (INCLEN  1999).  However,  in 
Bangladesh the most common causative serogroups isolated are 2, 1, 14, 5, 7F, 45 and 12A 
which means the nine-valent vaccine will only have a 35.6% coverage (Saha et al. 2009). 
Interestingly, serotypes which tend to be associated with nasopharyngeal prevalence (eg 19 
and 24) are highly prevalent in North America and Europe, whereas the invasive serotypes 
are more common in developing countries (Scott et al. 1996). Furthermore there are both 
increase  carriage  and  higher  levels  of  multiple  carriage  in  the  developing  world 
(Greenwood 1999; Obaro et al. 2002) 
 
In older children and adults there are a larger number of S. pneumoniae serotypes which are 
responsible for IPD. These data are confounded by an extremely wide age range of subjects 
and  methodological  differences  between  studies  making  meta-analysis  unfeasible. 
However, serogroups 14, 4, 1, 3, 6 and 19 seem to cause a considerable proportion of IPD 
in this age group, and this is not limited by geographical area (Hausdorff et al. 2000).  HIV 
infected patients in Africa were more likely to be have IPD caused by serotypes 6, 14, 19 
and  23  compared  to  HIV  negative  individuals  with  IPD  (Crewe-Brown  et  al.  1997). 
However in the USA, HIV positive individuals IPD was most likely due to serotypes 6A, 
6B, 9N, 9V, 18C, 19A, 19F and 23F and this patients showed reduced incidence of IPD 
from serotype 1, 7F and 12F compared to non HIV infected individuals with IPD (Fry et al. 
2003). 29 
 
1.2.4  Invasive disease potential 
The  incidence  of  different  S.  pneumoniae  serotypes  isolated  from  IPD  in  developed 
countries has been used to make vaccine preparations. However, the prevalence of a given 
serotype  of  S.  pneumoniae  recovered  from  IPD  does  not  necessarily  take  into  account 
differences in exposure levels to that serotype. For example, serotypes which have a low 
potential to cause disease but are highly  prevalent in the  geographical  area (leading to 
greater exposure) may lead to a larger proportion of IPD when compared to a serotype 
which  is  highly  invasive  but  which  is  only  rarely  found  colonising  the  nasopharynx.  
S. pneumoniae carriage is common in children under 5 years old, but IPD is a relatively rare 
event and recently several studies have been conducted examining the relationship between 
carriage  prevalence  and  disease  incidence  in  different  populations.  Calculation  of  an 
empirical odds ratio to compare the probability of invasive disease caused by a serotype has 
enabled  the  quantification  of  the  invasive  disease  potential  of  different  serotypes  of  S. 
pneumoniae  (Brueggemann  et  al.  2003).  Simply,  this  is  a  comparison  between  the 
frequency of IPD being caused by a given serotype with the frequency of carriage of that 
serotype in the population expressed as an odds ratio (OR). Serotypes 1, 4, 7F, 18C and 14 
are consistently found to have a high OR for invasive disease potential whereas serotypes 
6A,  6B,  23F,  9V,  and  3  are  among  those  found  to  be  relatively  poor  at  causing  IPD 
(Brueggemann et  al. 2003; Sandgren  et al. 2004; Hanage  et al. 2005). Hence  although 
serotype 6B causes a considerable disease burden, in relation to its carriage levels, serotype 
6B is less likely to cause IPD than serotype 14.  
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Furthermore, as these isolates were analyzed using MLST it becomes possible to calculate 
the  invasive  potential  of  individual  strains  or  clones,  even  within  a  capsular  serotype. 
Interestingly, invasive isolates are found to be consistently less genetically diverse than 
those isolated from carriage (Hanage et al. 2005), possibly suggesting a selection pressure 
on certain genes. In the studies based in Oxford and Finland there were no statistically 
significant differences in the invasive potential of different strains within the same capsular 
serotype (Brueggemann et al. 2004; Hanage et al. 2005). However, strains from the same 
serotype but which were genetically distinct were found to have a different OR for invasive 
potential in a Swedish study (Sandgren et al. 2004). In addition, some isolates which had 
differing capsular serotypes but which belonged to the same clone were found, and these 
strains were found to have the same disease potential (Sandgren et al. 2004). Other studies 
have also suggested that disease properties associated with the particular clonal type, as 
well  as  the  capsular  serotype,  may  contribute  to  the  ability  of  S.  pneumoniae  to  cause 
disease (Sjostrom et al. 2006). Furthermore a study on serotype 6 isolates from different 
geographical areas found that some STs were more associated with invasive disease and 
some were more associated with colonizing strains (Robinson et al. 2001).  
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1.2.5  Possible explanations for differences in S. pneumoniae strains disease potential 
Given that it has been well established that a limited number of capsular serotypes are 
responsible for most IPD, there is surprisingly little data which would explain why this 
might be (Hausdorff et al. 2000). Colonization of the nasopharynx is thought to be essential 
for the development of IPD, and data from infants suggests both that IPD can occur shortly 
after exposure to S. pneumoniae and that  IPD  may develop some time after successful 
colonization (Austrian et al. 1977; Gray et al. 1986). It has been suggested that increased 
prevalence of a serotype or strain of S. pneumoniae would lead to an increased exposure to 
that particular serotype of clone and hence increased IPD would be result. This may be the 
case for serotypes such as 6B, which have a high carriage rate and an associated high 
frequency  of  disease  but  are  hence  relatively  poorly  invasive  based  on  molecular 
epidemiology studies. Host and bacterial factors which maintain patterns of nasopharyngeal 
carriage are poorly understood, although recently it was suggested that the biochemical 
structure  of  the  polysaccharides  could  affect  their  degree  of  encapsulation  and  hence 
interactions with host immunity (Weinberger et al. 2009).  
 
However, the molecular epidemiology studies have clearly shown that carriage prevalence 
does not fully explain why some serotypes of S. pneumoniae are more invasive than others. 
The polysaccharide capsule (CPS) is widely presumed to be the most important virulence 
factor  for  S.  pneumoniae.  Hence  changes  in  the  structure  of  the  polysaccharides  and 
degrees of encapsulation could affect the ability of a given strain to invade host tissue, 
evade immune mechanism and may even potentially explain why some serotypes cause 
particular disease states more frequently than others. There is a great degree of genetic 32 
 
variation between strains of S. pneumoniae, with genome variation of up to 10% of between 
strains of different serotypes and 2% between clones of the same serotype  (Hakenbeck et 
al. 2001). Since different clones of the same serotype can have different invasive potentials 
(Sandgren  et  al.  2004)  non-capsular  factors  must  also  contribute  to  invasive  disease 
potential. Therefore the presence, absence and allelic variation in virulence factors such as 
CbpA,  pneumolysin,  PspA  as  well  as  the  biochemical  structure  of  the  cell  wall  could 
influence invasive disease potential, but the relative contribution of each of these factors 
compared to the effect of the capsule is unknown. Furthermore, it remains unclear as to 
which  host-bacterial  interactions  are  important  influences  on  the  invasive  potential  of 
different S. pneumoniae strains and capsular serotypes.   
 
1.2.6  Effects of vaccines on S. pneumoniae ecology 
Current vaccine preparations utilize the antigenic nature of CPS to induce immunity in a 
given individual. The 23 valent (Pneumovax II) polysaccharide vaccine (serotypes 1, 2, 3, 
4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) 
has various drawbacks including a poor induction of immune responses in children under 2 
years,  the  elderly  and  immunocompromised  patients.  Pneumovax  does  not  significantly 
affect carriage of S. pneumoniae in adults and children (MacLeod et al. 1945; Dagan et al. 
1996). A 7-valent polysaccharide vaccine (Prevenar) (serotypes 4, 6B, 9V, 14, 18C, 19F, 
23F) uses polysaccharide from these 7 capsular serotypes conjugated to diphtheria toxoid in 
order to induce a switch from thymus-independent to thymus-dependent response, inducing 
a T-cell response. Prevenar shows an efficacy of 97.4% against IPD caused by vaccine 
serotypes and the CDC has reported that the incidence of IPD caused by vaccine serotypes 33 
 
has  decreased  by  94%  (CDC  2008).  Conjugate  vaccines  have  a  significant  impact  on 
pneumonia, as well as a reduction in asymptomatic carriage of vaccine serotypes (Obaro et 
al. 1996; Black et al. 2002). The 9‐valent pneumococcal conjugate vaccine reduces carriage 
rates of vaccine serotypes by up to 50% in South Africa and a study from the US found that 
only 3% of strains isolated from carriage were of vaccine serotypes (Mbelle et al. 1999; 
Huang et al. 2009). However, whilst Prevenar is an effective vaccine in children under 5 
years,  non-vaccine  serotypes  have  increased  in  prevalence  in  vaccinated  populations 
(Dagan et al. 1996; Obaro et al. 1996). Huang et al recently demonstrated that carriage of 
non-vaccine serotypes rose from 15% in 2000 to 29% in 2007, with common non-vaccine 
serotypes including 19A (16%), 6A (12%), 15B/C (11%), 35B (9%), and 11A (8%) (Huang 
et  al.  2009).  In  particular  serotype  19A  has  emerged  as  increasing  in  prevalence  in 
vaccinated populations (Kyaw et al. 2006; Singleton et al. 2007). Serotype replacement is 
due mainly to expansion of existing strains of  non-vaccine serotypes,  although vaccine 
escape by capsular switching also occurs, in which a vaccine serotype strain acquires the 
cps locus of a non-vaccine serotype by recombination (Beall et al. 2006; Brueggemann et 
al. 2007). The clinical effect of serotype replacement is not fully known; there seems to be 
an increase in prevalence of non-vaccine serotypes causing acute otitis media (Eskola et al. 
2001; O'Brien et al. 2003) but data on IPD is equivocal. Recently increases in non-vaccine 
serotypes causing IPD in Alaska (Singleton et al. 2007) and throughout the USA have been 
reported  (CDC  2008),  with  other  studies  finding  no  evidence  of  serotype  replacement 
(Black et al. 2004; Black et al. 2006; Black et al. 2007).  34 
 
1.3  CELLULAR IMMUNITY TO PNEUMOCOCCUS 
1.3.1  Neutrophils 
Neutrophils (PMNs) are polymorphonuclear cells which are the first immune cells recruited 
to  sites  of  inflammation  from  the  blood.  They  are  terminally  differentiated  from 
haematopoietic stem cells in bone marrow and have a life span which encompasses only a 
few hours. Upon contact with a microbe, neutrophils engulf the pathogen in a phagosome 
which  fuses  with  intracellular  granules  containing  antimicrobial  peptides  such  as  α-
defensins,  cathepsin  G,  lysozyme,  lactoferrin  and  reactive  oxygen  species  to  form  a 
phagolysosome.  Bacteria  are  killed  in  the  phagolysosome  by  a  combination  of  non-
oxidative  mechanisms  and  the  respiratory  burst,  which  forms  a  varied  set  of  reactive 
oxygen species (ROS) (Klebanoff 2005). The transmembrane and cytosolic subunits of the 
large  NADPH-oxidase  complex  assemble  at  the  phagosomal  membrane  and  transfer 
electrons  to  molecular  oxygen  producing  superoxide  (O2
–).  O2
–  reacts  to  H2O2 
spontaneously or through catalysis by superoxide dismutase. H2O2 acts as a substrate of 
myeloperoxidase  to  form  hypochlorous  acid  (which  is  the  most  bactericidal  oxidant  in 
neutrophils) in addition to hypobromous and hypoiodous acid (Hampton et al. 1998). In 
addition  to  the  intracellular  killing  mechanisms,  PMNs  release  granule  proteins  and 
chromatin  forming  fibres  called  neutrophil  extracellular  traps  (NETs).  The  major 
components of the NETs are DNA and associated histones H1, H2A, H2B, H3 and H4. 
NETs contain smooth stretches of 15–17 nm in diameter which consist of naked DNA and 
globular domains of around 25nm in which there is chromatin. The granule proteins from 
azurophilic, specific and gelatinase granules which are found in NETs and the histones are 
all bactericidal (Hirsch 1958). Neutrophils phagocytose microbes within minutes, and it is 35 
 
thought that NETs are formed after phagocytic killing mechanisms are exhausted since 
NET formation initiates after in vitro infection (Urban et al. 2006). 
 
The importance of neutrophils for the host immune response is seen in patients who are 
neutropenic and these individuals show increased incidence of IPD. PMNs are one of the 
first cells recruited to sites of S. pneumoniae infection and colonisation (Dallaire et al. 
2001; van Rossum et al. 2005). It has also been demonstrated that a S. pneumoniae strain 
which normally causes only asymptomatic carriage will become invasive when neutrophils 
are  depleted  from  mice  (Matthias  et  al.  2008).  Furthermore  patients  with  chronic 
granulomatous disease, in which there is reduced ROS generation, have increased bacterial 
infections although interestingly they do not show a particular increase in IPD incidence. 
PMNs isolated from these patients kill S. pneumoniae as efficiently as neutrophils from 
healthy individuals, and recent data has suggested that PMNs kill S. pneumoniae through 
serine proteases  (Kaplan et al. 1968; Standish et al. 2009). This is compatible with an 
increased incidence of bacterial infection in patients with Chedaki-Higashi syndrome, who 
have a deficiency in levels of microbicidals and reduced granule mobilization (Root et al. 
1972;  Ganz  et  al.  1988).  Neutrophil  NETs  are  also  capable  of  binding  S.  pneumoniae 
although the capsule may prevent NET mediated killing (Wartha et al. 2007).  
 
Mouse  models  of  pneumonia  indicate  that  S.  pneumoniae  are  found  within  neutrophils 
(Bergeron et al. 1998), however data on the role of PMNs for immunity to S. pneumoniae 
pneumonia is equivocal. Impaired PMN recruitment leads to poor control of S. pneumoniae 
pneumonia in mice (Nakasone et al. 2007; Sun et al. 2007), but other results suggest that 36 
 
disease  progresses  less  rapidly  in  neutropenic  mice  (Marks  et  al.  2007).  In  addition 
excessive PMN activity may lead to lung damage and neutrophil recruitment causes many 
features of lung disease through the release of oxidants and proteinases (Henson et al. 1987; 
Weiss 1989).  In vitro phagocytosis of S. pneumoniae by PMNs is complement dependent 
(Yuste et al. 2008) and neutrophils require complement to clear S. pneumoniae colonization 
from  the  nasopharynx  (Lysenko  et  al.  2005;  Yuste  et  al.  2008).  Although  complement 
factors are present in BALF and increase during S. pneumoniae infection (Robertson et al. 
1976; Kerr et al. 2005) the contribution of complement to the interactions of S. pneumoniae 
with neutrophils during the development of pneumonia is not clear. Certainly neutrophils 
are important in systemic immunity to pathogens, with S. pneumoniae being no exception 
(Wang et al. 2002). Complement-mediated neutrophil phagocytosis is the dominant host 
immune mechanism against S. pneumoniae in systemic infection and the classical pathway 
is  the  major  complement  pathway  responsible  for  clearance  of  S.  pneumoniae  from 
systemic infection (AlonsoDeVelasco et al. 1995; Brown et al. 2002).  
 
1.3.2  Alveolar Macrophages 
AMs are the resident specialised phagocytic cell in the lung and are early effectors of innate 
immune responses against S. pneumoniae. AMs are relatively long lived cells which are 
derived from blood borne monocytes although some AM replication occurs (Thomas et al. 
1976;  van  oud  Alblas  et  al.  1979).  Recently  a  brisk  turnover  of  resident  AMs  and 
replacement  of  these  cells  with  newly  recruited  monocytes  was  demonstrated  in  S. 
pneumoniae pneumonia (Taut et al. 2008). An important role for AMs in preventing S. 
pneumoniae pneumonia is suggested by the increased incidence of pneumonia in subjects 37 
 
exposed to cigarette smoke or welding fumes, which impair macrophage activity, and by 
experimental  data  showing  that  depletion  of  AMs  increases  S.  pneumoniae  replication 
within  the  lung  in  mice  (Dockrell  et  al.  2003).  In  addition,  impaired  function  of  AMs 
allows increased S. pneumoniae replication within the lung and a higher mortality in animal 
models of pneumonia (Arredouani et al. 2004; Arredouani et al. 2006; Didierlaurent et al. 
2008). Hence avoidance of AM-mediated clearance from the lung is probably critical in 
dictating whether inhalation or aspiration of a pathogen results in lung infection. 
 
AMs  are  able  to  phagocytose  S.  pneumoniae,  but  this  is  hindered  by  the  capsule  and 
effective opsonisation with complement, antibody and other opsonins is required (Jonsson 
et al. 1985). AMs are efficient at killing internalised pneumococci, however as bacterial 
numbers increase this process becomes overwhelmed (Gordon et al. 2000; Dockrell et al. 
2003). Macrophages increase nitric oxide levels following challenge with S. pneumoniae 
and NADPH oxidase has also been implicated in macrophage killing (Kerr et al. 2004; 
Marriott et al. 2004). Depletion of AMs has been shown to reduced survival to several lung 
pathogens highlighting their importance for pulmonary immunity (Broug-Holub et al. 1997; 
Kooguchi et al. 1998; Cheung et al. 2000; Traeger et al. 2009). AMs are an important 
source of proinflammatory cytokines (such as TNFα) which acts as a chemoattractant for 
neutrophils and are also able to phagocytose apoptotic PMNs and hence mediate resolution 
of the inflammation (Fig 1.3) (Knapp et al. 2003). Depletion of AMs leads to reduced 
clearance of apoptotic neutrophils and lead to increased levels of the anti-inflammatory  
IL-10 and AM depleted mice showed reduced survival compared to control mice (Knapp et 
al. 2003).  38 
 
AMs express various receptors which may be involved in the recognition, phagocytosis and 
the innate activation which is induced following S. pneumoniae infection. These include but 
are not limited to FcR (fragment, crystallizable receptor); complement receptor 1 and 3 
(CR1 and CR3); scavenger receptors (SR) such as SR-A and macrophage receptor with 
collagenous structure (MARCO); Dendritic Cell-Specific Intercellular adhesion molecule-
3-Grabbing Non-integrin (DC-SIGN); toll-like receptors 2 and 4 (TLR2 and TLR4); and 
dectin-1 (Taylor et al. 2005). MARCO
-/- mice show impaired pulmonary clearance of S. 
pneumoniae,  increased  inflammation  and  reduced  survival  (Arredouani  et  al.  2004). 
Furthermore the association of macrophages with S. pneumoniae is significantly impaired 
in  MARCO
-/-  deficient  macrophages,  suggesting  this  receptor  is  important  in  innate 
immune responses against pneumococcus (Arredouani et al. 2004). SR-A I/II deficiency 
has also been shown to cause impaired in vivo phagocytosis of S. pneumoniae, reduced lung 
clearance and increased pneumonic inflammation as well as reduced survival (Arredouani 
et al. 2006). However the relative contribution of each of these receptors to the function of 
AMs and the pathogenesis of pneumococcal disease  remains unclear. Furthermore how 
pneumococcal  virulence  factors  including  CPS  modulate  their  function  is  not  fully 
understood.   
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Fig 1.3 Role of AMs and PMNs in S. pneumoniae lung infection 
1. AMs are the resident phagocytic cell in the lung, killing S. pneumoniae (green ovals) and 
releasing  important  pro-  and  anti-inflammatory  cytokines  to  modulate  the  immune 
response. 2. PMNs are recruited to the site of infection by chemokines including IL-8 and 
C5a. 3. As the infection progresses the epithelium becomes leaky, and the alveolus fills 
with  oedema  and  fibrin.  4.  Monocytes  do  not  respond  until  late  in  S.  pneumoniae 
pneumonia.  5.  Pneumolysin  and  hydrogen  peroxide  contribute  directly  to  pulmonary 
damage, killing epithelial cells, macrophages and arresting ciliary beating. Proteinases are 
secreted  by  AMs  and  epithelium  and  include  elastase,  matrix  metalloproteinases,  α1-
proteinase inhibitor and α2-macroglobulin and act to kill bacteria.  40 
 
Recently data suggests that induction of apoptosis in AMs by bacterial infection may be a 
host mediated strategy (Zychlinsky et al. 1997; Dockrell et al. 2001; Ali et al. 2003). AM 
apoptosis  induced  by  S.  pneumoniae  shows  features  of  mitochondrial  apoptosis  and 
interestingly there seems to be no effect of death receptors including Fas ligands or the 
TNFα receptor on this process (Dockrell et al. 2001). Apoptotic AMs are phagocytosed by 
non-apoptotic  AMs,  and  this  is  associated  with  decreased  neutrophil  recruitment  and 
reduced TNFα levels, potentially defining a mechanism by which apoptosis may regulate 
lung inflammation (Marriott et al. 2006; Marriott et al. 2008). 
 
Systemic clear of S. pneumoniae is dependent on an intact reticuloendothelial system and S. 
pneumoniae are found within the liver and spleen in sepsis (Brown et al. 1981; Brown et al. 
1981;  Brown  et  al.  1983).  The  macrophages  found  within  the  spleen  are  important  in 
systemic immunity to S. pneumoniae, and marginal zone macrophages express a SIGN R1 
receptor which binds and internalises CPS (Mitchell et al. 1983; Evans 1985; Kang et al. 
2004).  
 
1.3.3  Dendritic Cells 
Dendritic cells (DCs) are the most important antigen-presenting cell, whose function is to 
ingest and present antigen to T lymphocytes. Tissue DCs engulf antigens at infection sites, 
become activated as part of the innate immune response, migrate to lymphoid tissue and 
differentiate  into  highly  effective  antigen-presenting  cells  (Janeway  et  al.  2002).  Hence 
DCs  act  as  a  critical  bridge  between  innate  and  adaptive  immunity,  initiating  adaptive 
immune  responses  (Banchereau  et  al.  2000).  Mature  DCs  are  distinguished  by  co-41 
 
stimulatory  molecules  which  act  in  synergy  with  antigen  in  the  activation  of  T 
lymphocytes,  and  there  are  also  changes  in  surface  expression
  of  MHC,  adhesion 
molecules, and cytokine production
 in mature antigen presenting cells (Reis e Sousa 2001). 
The capsule polysaccharide significantly impairs S. pneumoniae phagocytosis by DCs, and 
the serotype 1 capsule polysaccharide has been shown to activate CD4+ T cells through 
presentation  of  the  polysaccharide  by  MHC  class  II-positive  tubules  of  murine  DCs 
(Stephen et al. 2007; Noske et al. 2009). It is likely that S. pneumoniae induces apoptosis in 
DCs, which seems to occur through both a rapid caspase-independent but pneumolysin-
dependent as well as a delayed pneumolysin-independent mechanism, and this may be a 
survival  strategy  for  the  bacteria  since  apoptotic  DCs  do  present  function  as  efficient 
antigen presenting cells (Colino et al. 2003; Kleindienst et al. 2003).  
 
1.3.4  T lymphocytes 
T lymphocytes are thymus matured cells composed of different subsets known and helper 
(TH) CD4
+, cytotoxic (TC) CD8
+, regulatory, memory and gamma-delta T cells. TH immune 
responses are divided into three classes referred to as TH1, TH2 and TH17. TH1 responses 
typically promote cell-mediated killing of pathogens, and are primarily made in response to 
bacteria  which  stimulate  macrophages  or  NK  cells  and  viruses.  TH1  T  cells  produce 
lymphotoxin, TNF-β and IFN-γ which acts to activate macrophages. This induces increased 
microbial killing in phagolysosomes, release of inflammatory cytokines and promotes TH1 
cell differentiation. In contrast the TH2 response is directed against extracellular pathogens, 
allergens and toxins and tends to induce a cytokine response composed of IL-4 and IL-13. 
These  cytokines  stimulate  B  cells  to  produce  antibody  and  mast  cells  to  release 42 
 
inflammatory mediators. The cytokine milieu determines whether a naive T cell develops 
into  a  TH1  or  TH2  cell.  The  mutual  antagonism  of  the  cytokine  products  of  each  TH 
response  further  supports  this  T  cell  differentiation.  TH17  lymphocytes  produce  IL-17, 
inducing stromal cells to produce inflammatory cytokines including IL-6, IL-8 and IL-22. 
 
T cells have been implicated in the host immune response to S. pneumoniae since patients 
with MHC I and (due to mutations in TAP-1 or TAP-2) II deficiencies who have ‘bare 
lymphocyte’ syndrome show increased incidence of S. pneumoniae pneumonia (Klein et al. 
1993; Donato et al. 1995; Carneiro-Sampaio et al. 2007). A TH1 response to pneumococcus 
is protective in human S. pneumoniae infection (Kemp et al. 2002). Furthermore CD4
+ 
deficient mice are more susceptible to infection and show increased bacterial counts in both 
the lung and in blood (Kadioglu et al. 2000). 
 
Recently the role of CD4
+ T lymphocytes in S. pneumoniae disease has been examined 
further.  There  is  a  rapid  influx  of  CD4
+  T  cells  into  infected  areas  of  lung  observed 
(Kadioglu et al. 2004). However this response is abrogated in the absence of pneumolysin 
and studies performed in vitro have confirmed that the CD4
+ chemotaxis is dependent on 
pneumolysin (Kadioglu et al. 2000; Kadioglu et al. 2004). Furthermore these cells appear to 
be  required  for  efficient  nasopharyngeal  clearance  of  S.  pneumoniae  and  intranasal 
immunization does not protect CD4
+ deficient mice, indicating a role for these cells in 
nasopharyngeal immunity (Malley et al. 2005; van Rossum et al. 2005). TH17 CD4
+ cells 
have  been  shown  to  mediate  the  recruitment  to  the  nasopharynx  of  monocytes  and 
macrophages as well as neutrophils in response to S. pneumoniae, in a mechanism which is 43 
 
independent of IFNγ and IL-4 may depend upon TLR2 (Lu et al. 2008; Zhang et al. 2009). 
TH17 CD4
+ cells may also have a role in inducing the production of anti-microbial peptides 
by epithelial cells in response to S. pneumoniae (Liang et al. 2006).  
 
Classically  TC  cells  are  involved  in  host  immunity  against  intracellular  pathogens  and 
viruses,  and  act  to  induce  the  death  of  host  cells  which  have  become  infected  by 
programming  apoptosis in target cells. This occurs through release from the TC cell of 
preformed granules which contain membrane disrupting proteins such as perforin, serine 
proteases, cathepsin and stored effector molecules including Fas ligand. CD8
+ TC cells have 
been implicated in lung immunity to S. pneumoniae (Angrill et al. 2001) and these cells are 
essential for antibody-mediated pulmonary protection against S. pneumoniae, but do not 
seem to be required for systemic immunity (Tian et al. 2007). CD8
+ T cells may mediated 
an antibody dependent effect through their production of IFNγ, which has been shown to be 
an  important  chemokine  for  immunity  to  S.  pneumoniae,  Klebsiella  pneumoniae  and 
Cryptococcus neoformans (Rubins et al. 1997; Moore et al. 2002; Lindell et al. 2005). 
Interestingly CD8
+ T cells may in fact suppress antibody responses to CPS, suggesting T 
lymphocytes are important regulators of the response to CPS (Jeurissen et al. 2002). 
 
In addition NK T cells are a lymphocyte population which express both T cell receptors and 
NK cell markers and act in innate immune responses producing IFNγ and IL-4 (Taniguchi 
et al. 2000; Kronenberg et al. 2002). Mice lacking NK cells have been shown to have 
increased S. pneumoniae load in the lungs and reduced survival compared to control mice 
(Kawakami et al. 2003). These NK T cells have been linked to a MCP-1 dependent early 44 
 
pulmonary immune mechanism which promotes PMN recruitment (Kawakami et al. 2003). 
 
1.3.5  B lymphocytes and antibody 
B lymphocytes are cells which play a key role in humoral responses by producing antibody 
and developing into memory B cells. Follicular B cells systemically re-circulate and mount 
antibody responses against thymus dependent protein antigens, whereas marginal zone and 
CD5
- B cells generate thymus independent antibody responses (Mond et al. 1995). Marginal 
zone, CD5+ and CD5- B cells collaborate to provide immunity to S. pneumoniae (Haas et 
al. 2005). In addition there seems to be a distinct B cell populations which produce IgM 
(CD19
+CD27
+IgM
+IgD
+  memory  B  cells)  and  another  which  produces  IgG 
(CD19
+CD27
+IgM
-IgD
- switched memory B cells) to both pneumococcal polysaccharide 
and protein antigens (Moens et al. 2008).  
 
Patients  with  SCID  have  increased  incidence  of  IPD  after  passive  transfer  of  maternal 
antibodies ceases to provide protection against  S. pneumoniae (Carneiro-Sampaio et  al. 
2007). Further evidence of the importance of antibodies in host immunity to S. pneumoniae 
is provided by individuals with X-linked agammaglobulinaemia and specific IgG2, IgA and 
selective anti-polysaccharide antibody deficiencies as well as those with hyper IgM type-2 
and  IgE  syndrome,  who  all  show  increased  susceptibility  to  S.  pneumoniae  infections 
(French et al. 1995; Hammarstrom et al. 2000; Conley et al. 2002; Winkelstein et al. 2003; 
Quartier et al. 2004; Grimbacher et al. 2005).   
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Antibody responses specific for protein and polysaccharide antigens are induced by distinct 
mechanisms (Mond et al. 1995). CPS antigen stimulates B cells independently of MHC 
class II T lymphocytes by inducing crossing linking of the B cell receptors, and antibody 
titres  do  not  rise  beyond  the  level  induced  after  primary  immunization.  TH  cells  are 
involved  in  regulation  of  this  response,  which  is  thought  to  be  mediated  through  an 
essential  interaction  between  the  transiently  expressed  CD40  ligand  on  TH  cells  which 
activates  B  cells  through  cell  surface  expressed  CD40  (Jeurissen  et  al.  2002).  CPS 
stimulates  terminally  differentiated  B  cells  and  therefore  does  not  induce  responses  in 
young children, and elicits antibodies that are isotype restricted to IgM and IgG2 and to a 
lesser extent IgG1 in humans (Casal et al. 2003). In contrast, antibodies against sub-capsular 
proteins are T cell dependent, requiring B cells to be activated by a CD4
+ T cell which is 
also specific for the antigen which the responding B cell has recognised and presented 
(linked recognition). B cells stimulated in this way can proliferate, differentiate into plasma 
cells and can generate memory B cells. A wide range of cell wall and membrane associated 
pneumococcal proteins can generate a protective antibody responses (Kalin et al. 1987; 
Berry et al. 1989; Crain et al. 1990; Talkington et al. 1996; Brooks-Walter et al. 1999; 
Ferreira  et  al.  2006;  Moens  et  al.  2008).  It  is  hoped  that  antibodies  generated  against 
essential  pneumococcal  proteins  could  provide  immunity  against  multiple  serotypes  in 
vaccines. However, proteins such as CbpA have a varied structure between strains, and 
hence antibodies generated against proteins on one S. pneumoniae strain may not confer 
complete protection against another strain. Furthermore it remains unclear what the relative 
contribution  of  antibodies  against  non-capsular  pneumococcal  antigens  is  for  natural 
immunity to S. pneumoniae, compared to the contribution of anti-capsular antibody. 
 46 
 
Current  vaccines  against  S.  pneumoniae  use  the  polysaccharide  capsule  to  induce  a 
protective antibody response. Unconjugated polysaccharide vaccines (such as Pneumovax) 
fail to induce a sustained memory response from the host immune system, and the immune 
response to Pneumovax is thymus independent. This response is typically predominated by 
IgM and repeated immunisation does not induce a higher level of anti-capsular antibody in 
the host (Schneerson et al. 1980). In contrast, conjugate vaccines such as Prevenar stimulate 
thymus dependent response, resulting in germinal centre formation and the induction of 
immunological memory (Borriello et al. 1997; Garside et al. 1998). Many prominent B and 
T  cell
  membrane  proteins  play  a  significant  role  in  the  formation
  and  stabilization  of 
antigen-specific B-cell-T-cell conjugates (Clark et al. 1991; Sharpe 1995). CD40 to CD40L
 
and  B7  to  CD28  interactions  co-stimulate  cell  activation  and  proliferation  (Clark  et  al. 
1991; Sharpe 1995). Data has shown that the major co-stimulatory pathway involving
 the 
ligation  of  CD28  on  T  cells  with  B7  molecules
  on  activated  B  cells  is  critical  for  the 
induction of immunologic
 memory to capsule polysaccharide and for isotype switching to 
IgG in the response to conjugate vaccines (Guttormsen et al. 1999). 
 
An antibody response from the host is not limited to IPD, and nasopharyngeal colonisation 
induces a serum  IgG and secretory  IgA response against PspA of the inoculated strain 
(McCool  et  al.  2002).  However  antibody  does  not  seem  to  promote  clearance  of  
S. pneumoniae from the nasopharynx, as antibody levels of PspA in both serum and nasal 
lavages positively correlate with disease severity in mice, and immunodeficient mice that 
respond  poorly  to  protein  antigens  or  which  are  unable  to  produce  antibody  clear 
colonisation as well as wild-type mice (McCool et al. 2004). However, antibody plays an 
important role in systemic immunity to S. pneumoniae and this is thought to occur through 47 
 
the opsonic action of antibody (Robbins et al. 1995; Lefeber et al. 2003; Martinez et al. 
2006). However it is worth noting that IgG and IgM antibody can activate the complement 
system through the classical pathway, and some of the effect of antibody may be mediated 
by complement (Heidleberger et al. 1942; Brown et al. 1982; Brown et al. 1983).  
 
Natural IgM antibodies are germ-line coded and not affinity maturated antibodies, which 
have a genetically limited antigen repertoire and only few mutations expand this range. 
However, a certain acquired genetic variability of the innate immunoglobulin receptors is 
achieved by combinatorial association of germ-line immunoglobulin genes (Vollmers et al. 
2006). Additional mutations, deletions and additions in recombination events guarantee a 
variability which is sufficient to cover a wide antigen range on pathogenic organisms and 
gives a adequate protection by these antibodies (Constantinescu et al. 1997; Rothenberg 
2000; Vollmers et al. 2006). Peritoneal cavity CD5
+ B cells are believed to produce natural 
IgM antibodies, and these cells are precursors of CD11b/CD18
- splenic IgM
 Ab-secreting 
cells (van Rooijen 1989; Kawahara et al. 2003). The repertoires of natural IgM antibodies 
may be driven by selection by self-antigens or by exposure to microorganisms (van Rooijen 
1989; Berland et al. 2002). Natural IgM has an important role in innate immune defence 
mechanisms and are involved in early  recognition of pathogens  and  cancer cells  (Ben-
Aissa-Fennira  et  al.  1998;  Boes  2000;  Ulvestad  et  al.  2001;  Brandlein  et  al.  2003). 
Furthermore,  natural  IgM  has  been  shown  to  contribute  to  early  immunity  against 
encapsulated bacteria, leading to clearance of bacteria from the blood to the spleen and 
provide specific protections against S. pneumoniae (Brown et al. 2002; Baxendale et al. 
2008). 48 
 
1.3.6  Inflammation 
Both  humoral  and  cellular  immune  responses  are  regulated  by  cytokines,  which  are 
produced by many cell types including AMs. However cytokines are a double edged sword 
and a balance needs to be maintained between pro- and anti-inflammatory cytokines. This 
is  particularly  important  for  the  lung,  where  gas  exchange  is  severely  impaired  by 
inflammation and excessive inflammation would be detrimental to the host. TNFα, IL-1, 
IL-6 and IL-8 levels rise quickly in areas of lung infected with S. pneumoniae (Dehoux et 
al.  1994;  van  der  Poll  et  al.  1996;  van  der  Poll  et  al.  1997).  In  addition  AMs  from 
individuals infected with S. pneumoniae produce G-CSF which is likely to contribute to 
PMN  release  from  bone  marrow  (Tazi  et  al.  1991).  Mice  treated  with  an  anti-TNFα 
antibody when infected with S. pneumoniae have increased bacterial CFU isolated from the 
lungs and rapidly develop fatal disease (van der Poll et al. 1997). IL-6 has also been shown 
to be protective in lung infection in mouse models using a similar model (van der Poll et al. 
1997).  However  the  relationship  between  cytokine  profiles  and  clinical  outcome  in 
pneumonia patients remains unclear, with some studies finding no relationship between 
TNFα levels and outcome and others showing increased TNFα levels correlate with less 
severe disease (Marik et al. 1993; Moussa et al. 1994; Puren et al. 1995) 
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1.3.6.1 Receptors that initiate inflammation 
The inflammatory immune response is an essential component of the host immune response 
to pathogens, and there are various receptors through which this response is mediated. One 
class  of  receptor  which  is  important  in  regulating  inflammatory  responses  to  bacterial 
pathogens but not phagocytosis is the Toll like receptor family. TLRs play a crucial role in 
the  host  immunity  to  invading  microbes  by  recognizing  pathogen-associated  molecular 
patterns  (Takeda  et  al.  2003).  They  are  members  of  the  interleukin-1  receptor  (IL-1R) 
superfamily and are characterized by the presence of a leucine-rich repeat domain in their 
extracellular  regions  and  a  Toll/IL1  receptor  (TIR)  domain  in  the  intracellular  regions 
(Takeda  et  al.  2003).  Most  TLRs  share  a  common  signalling  pathway  via  the  adaptor 
molecule,  myeloid  differentiation  primary-response  protein  88  (MyD88)  (Takeda  et  al. 
2003). Once stimulated TLRs recruit MyD88 and the death domain of MyD88 then binds 
the death domain of IL1R-associated kinase (IRAK). The signal is then propagated via TNF 
receptor-associated factor-6 (TRAF6), leading to the activation of NFκB and MAP kinases, 
and the transcription of immunologically relevant genes (Takeda et al. 2003; Akira et al. 
2004). A second TIR containing adaptor protein, TIR-associated protein (TIRAP)/MyD88-
adaptor-like (Mal), is involved in the MyD88-dependent pathways of TLR1/2, TLR2/6 and 
TLR4, but not other TLRs (Horng et al. 2002; Yamamoto et al. 2002). The most important
 
TLR-expressing cell types are thought to be DCs, macrophages, and B cells (Iwasaki et al. 
2004). S. pneumoniae has been shown to induce NFκB activation through
 TLR2 and 9, and 
the  ability  to  activate  TLR2  may  involve  recognition  of  the  cell  wall  components 
peptidoglycan
 and lipoteichoic acid (Yoshimura et al. 1999; Moore et al. 2003; Mogensen 
et al. 2006). However, this data needs to be re-evaluated in the light of recent data showing 
that TLR2 stimulation by Staphylococcus aureus is mediated entirely through lipoproteins, 50 
 
demonstrating that previous work illustrating the effect of lipoteichoic  acid was due to 
contamination  of  the  cell  wall  preparations  with  lipoproteins  (Hashimoto  et  al.  2006; 
Hashimoto et al. 2006; Schmaler et al. 2009). There is also some evidence
 that pneumolysin 
is able to stimulate cells through TLR4, although
 some investigators finding no evidence of 
TLR4 activation (Yoshimura et al. 1999; Malley et al. 2003; Branger et al. 2004; Mogensen 
et al. 2006).  
 
Another subset of pattern recognition receptors is the nucleotide-binding oligomerization 
domain (NOD) proteins, and these receptors are involved in the intracellular recognition of 
pathogens. NOD1 recognizes peptidoglycans containing meso-diaminopimelate acid found 
mainly in Gram-negative bacteria (Girardin et al. 2003), and is expressed by most cells. In 
contrast,  NOD2  mediates  responsiveness  to  muramyldipeptide  MurNAc-L-Ala-D-isoGln 
which is conserved in peptidoglycans of most bacteria and the  expression of NOD2 is 
restricited to leukocytes, DCs and epithelial cells (Ogura et al. 2001; Inohara et al. 2003). 
NOD2  activates  the  NFκB  signaling  pathway  as  well  as  the  p38  and  ERK1/2  MAPK 
pathways, and NOD1 has been shown to activate the JNK pathway (Girardin et al. 2001; 
Kobayashi et al. 2005). It has been shown that S. pneumoniae is recognized by NOD2 and 
signal transducing molecules including IRAK, IRAK2, TRAF6 and NIK are involved in 
NFκB activation by NOD proteins in cells stimulated with pneumococci (Opitz et al. 2004). 
 
In  contrast,  the  inflammasome  is  a  multiprotein  complex  which  is  responsible  for  the 
activation of caspases 1 and 5, which results in the production and release of the pro-
inflammatory  cytokines  IL-1β  and  IL-18  (Martinon  et  al.  2002).  The  central  proteins 51 
 
involved in inflammasomes are NOD-like receptors with pyrin domains (NALPs) although 
little  is  known  about  their  precise  function.  The  stimuli  which  induce  assembly  and 
activation of the inflammasome, although it is thought that the inflammasome is activated 
through the recognition of pathogen-associated molecular patterns by leucine rich repeats 
found on NALP proteins. Intracellular pathogens including Shigella and Salmonella have 
been shown to induce apoptosis in infected macrophages, which occurs through caspase 1 
(Monack et al. 2001; Obregon et al. 2003). 
 
Another  important  cell  surface-receptor  involved  in  the  regulation  of  the  inflammatory 
response is the C5a receptor (CD88). The C5aR is expressed on the surface of immune cells 
including  macrophages,  neutrophils  and  T  cells.  C5aR  primarily  couples  to  Gαi2  
(Skokowa et al. 2005) which is a pertussis toxin-sensitive G protein, although ectopically 
expressed C5aR and C5aR in some cells including monocytes can also couple to Gα16 
(Kalant et al. 2003), a pertussis toxin-insensitive G protein. Through these G proteins the 
C5aR is able to activate the Ras/Raf/MAP kinase signalling pathway (Gerard et al. 1994). 
The C5aR has been shown to mediate chemotaxis, superoxide generation and the release of 
histamine, interleukins, leukotrienes and enzymes from granules from granulocytes as well 
as upregulation of adhesion molecules (Goetzl et al. 1974; Hartman et al. 1981; Morita et 
al. 1989; Elsner et al. 1994). C5 has been demonstrated to have a significant effect on PMN 
recruitment to the lung of mice infected with S. pneumoniae as well as other pathogens  
(Snyderman et al. 1971; Toews et al. 1984; Winkelstein 1984; Rubins et al. 1995). C5a also 
improves efficiency of PMN phagocytosis.  
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It is likely that all of these receptors contribute to inflammation in pneumococcal disease, 
although  the  effect  of  the  capsule  on  cell  activation  through  these  pathways  remains 
unclear. 
 
1.3.6.2 The NFκB transcription factor pathway 
Inflammation  involves  a  sequential  release  of  mediators,  leukocyte  recruitment  to  the 
inflammatory site and activation of recruited leukocytes. This response is self-limiting and 
both  the  induction  and  resolution  of  inflammatory  responses  seem  to  be  regulated  by 
transcription factors including the NFκB transcription factor pathway. NFκB activation is 
tightly  regulated  by  signals  that  degrade  IκB,  which  classically  occurs  through 
phosphorylation by the IκB kinase (IKK) complex followed by degradation by the 26S 
proteosome (Karin et al. 2000). The IKK complex is composed of catalytic subunits known 
as IKKα and IKKβ as well as a regulatory subunit IKKγ (Nishikori 2005). The key NFκB 
family member in classical NFκB activation is RelA, which is found in a wide variety of 
cells including macrophages (Moine et al. 2000; Roux et al. 2004). The classical pathway is 
typically activated by a ligand binding to TNF receptors, TCRs, BCRs, or the TLR-IL1 
receptor superfamily, leading to increased transcription of genes encoding for chemokines, 
cytokines  including  TNFα,  IL-8  and  RANTES  as  well  as  adhesion  molecules, 
cyclooxygenase 2 and iNOS (Vane et al. 1994; Hobbs et al. 1999; Karin et al. 2000; Tak et 
al. 2001; Yamamoto et al. 2001) (Fig 1.4). Classical pathway activation tends to result in 
enhanced inflammatory responses and promotes cell survival. In contrast, the alternative 
pathway is activated through certain TNF receptor family members including CD40, CD30, 
B  cell  activating  factor  belonging  to  the  TNF  family  receptor  and  the  lymphotocin  β 53 
 
receptor  (Nishikori  2005).  The  alternative  pathway  NFκB2  and  p100  subunits  are 
phosphorylated  at  two  C-terminal  sites  by  the  IKKα  homodimer  and  then  ubiquinated, 
which  leads  to  targeting  of  the  inhibitory  C-terminus  for  proteosomal  degradation 
(Nishikori 2005). Activation of the alternative pathway typically regulates development of 
lymphoid organs and adaptive immune mechanisms (Fig 1.4). Only the NFκB subunits 
RelA and p50 have been identified in extracts of lungs exposed to bacteria, suggesting that 
pulmonary  NFκB  signalling  to  pneumococcus  would  be  mediated  through  the  classical 
pathway (Mizgerd et al. 2002; Jones et al. 2005). Furthermore patients with deficiencies in 
IRAK4 (IL-1 receptor associated kinase) and NEMO-dependent NFκB activation have a 
marked  increased  in  incidence  of  IPD  (Ku  et  al.  2005).  Furthermore  common 
polymorphisms  in  the  IκB  genes  NFKBIA  and  NFKBIE    genes  are  associated  with 
increased  frequency  of  S.  pneumoniae  infection  (Chapman  et  al.  2007).  AMs  have  an 
essential  role  in  NFκB  activation  in  the  lungs  (Mizgerd  et  al.  2002).  RelA  deficiency 
decreases  cytokine  expression,  PMN  migration  and  S.  pneumoniae  killing  in  the  lung 
following intratracheal infection (Quinton et al. 2007). IκBα is degraded in both mouse 
lungs and human
 bronchial epithelial cells exposed to S. pneumoniae, and inhibition
 of IκB 
kinase complex blocks cytokine release from epithelial cells, suggesting that epithelial cells 
are an alternative pro-inflammatory cytokine source to AMs in S. pneumoniae pneumonia 
(Schmeck et al. 2004).  
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Fig 1.4 Activation of NFκB by the alternative and classical pathways 
Signalling through TNFR, IL-1R or TLRs activates the classical NFκB pathway involving 
predominantly the α and β subunits of the IKK complex. Nuclear translocation and DNA-
binding  of  p50-RelA  occurs  through  phosphorylation  of  IκBα  and  ubiquitin-dependent 
proteasomal  degradation.  Membrane-bound  LTα1β2  heterodimers,  CD40,  and  BAFF 
activate via their respective receptors the kinases NIK and IKK. Phosphorylation of p100 
results in the processing of the precursor to the p52 subunit and nuclear accumulation of 
p52-RelB heterodimers. There is significant cross talk as signalling through the LTβR also 
results in the induction of RelA complexes and LPS can also trigger the processing of p100 
to p52.  
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1.3.6.3 The MAPK pathways 
Since pneumococcal components can activate Toll like receptors (TLRs) it is also likely 
that  macrophage  responses  to  S.  pneumoniae  are  affected  by  mitogen  activated  protein 
kinases (MAPKs). MAPKs affect several macrophage properties including pro- and anti-
inflammatory cytokine production, apoptosis, cell migration and particle uptake which are 
all  important  in  pulmonary  immune  responses  to  S.  pneumoniae  (Hazzalin  et  al.  2002; 
Blander et al. 2004; Yates et al. 2005; Shin et al. 2008). MAPK cascade pathways are 
composed of a MAPK, MAPK kinase (MAPKK) and a MAPKK kinase (Guha et al. 2001; 
Jeffrey  et  al.  2007).  To  date  5  distinct  groups  of  MAPKs  have  been  characterised: 
extracellular  signal-related  kinases  1  and  2  (ERK  1/2);  c-Jun  animo-terminal  kinases 
(JNKs); p38 isoforms α, β, γ and δ; ERKs 3 and 4; and ERK 5 (Roux et al. 2004) (Fig 1.5). 
MAPK pathways can be activated through TLRs and NOD, which are important in immune 
responses to pneumococcus (Wellmer et al. 2002; Barton et al. 2003; Koedel et al. 2004; 
Opitz et al. 2004). However, the role of the precise pathways involved and the effect of 
specific virulence factors on signalling pathways remains unclear. In addition is it unknown 
if and consequently how CPS modulates these responses, since studies were carried out 
using only encapsulated S. pneumoniae without comparison to unencapsulated strains. 
 
1.3.6.4 The ERK pathway 
Many studies have shown that LPS can activates the ERK 1/2 pathway in monocytes and 
macrophages.  The  ERK  1/2  kinase  domains  have  a  Threonine-Glutamic  acid-Tyrosine 
(TEY) motif which is activated by phosphorylation (Guha et al. 2001). Dominant-negative 
repressors of Ras and c-Raf inhibit LPS induction of the TNFα promoter in RAW 264.7 56 
 
macrophages, suggesting that activation of tyrosine kinases leads to activation of the MEK- 
ERK 1/2 pathway in a  Raf-1-dependent mechanism (Geppert et al. 1994; Arbibe et al. 
2000). Inhibition of MEK reduces production of inflammatory cytokines including IL-1, 
IL-8,  TNFα  following  LPS  stimulation  of  monocytes  (Scherle  et  al.  1998).  Upon 
stimulation,  ERK  1/2  accumulates  in  the  nucleus  but  activated  ERK  1/2  phosphorylate 
numerous substrates including membrane proteins, nuclear substrates (SRC-1, NF-AT, Elk-
1,  c-Myc,  c-Fos,  STAT3  and  Pax6),  cytoskeletal  proteins  and  MAPK-activated  protein 
kinases (Chen et al. 2001) (Fig 1.5). ERK pathways have been shown to induce iNOS and 
TNF production during LPS and IFNγ stimulation of murine macrophages (Ajizian et al. 
1999). Recently a novel pneumococcal virulence factor EstA was shown to stimulate RAW 
264.7 macrophages via the ERK pathway which led to iNOS production (Kang et al. 2009).  
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Fig 1.5 The MAPK signalling pathways 
The  three  main  MAPK  signalling  pathways  ERK,  JNK  and  p38  mediate  immune  cell 
functional responses through multiple receptors. MAPK cascade pathways are composed of 
a MAPK, MAPK kinase (MAPKK) and a MAPKK kinase (Guha et al. 2001; Jeffrey et al. 
2007). ERK 1/2 accumulates in the nucleus but activated ERK 1/2 phosphorylate numerous 
substrates including membrane proteins, nuclear substrates (SRC-1, NF-AT, Elk-1, c-Myc, 
c-Fos, STAT3 and Pax6), cytoskeletal proteins and MAPK-activated protein kinases. p38 
activates transcription factors including activating transcription factor-2, Elk-1, Gadd153, 
myocyte enhancer factor 2C and Sap1a as well as phosphorylating downstream kinases. 
Red arrows indicate feedback or cross talk within the pathways. Taken from Jeffrey et al, 
Nature Reviews Drug Discovery, 2007.   
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1.3.6.5 The p38 pathway 
p38 was identified in LPS-stimulated macrophages and this pathway includes isoforms of 
p38/stress activated protein kinase-2/reactive kinase (Han et al. 1994; Zhang et al. 2000). 
Cdc42, PAK and Rac1 are upstream signalling molecules which activate the p38 pathway. 
MAPK kinases involved in activation of the p38 cascade include MKK3 and MKK6 and 
possibly MKK4 (Derijard et al. 1995; Raingeaud et al. 1996). Furthermore disruption of the 
mkk3 gene causes a selective defect in p38 activation and TNFα induction of cytokine gene 
expression  (Wysk  et  al.  1999).  p38  activates  transcription  factors  including  activating 
transcription factor-2, Elk-1, Gadd153, myocyte enhancer factor 2C and Sap1a as well as 
phosphorylating downstream kinases which regulate gene expression by phosphorylating 
transcription factors such as cAMP response element binding and activating transcription 
factor 1 (Rolli et al. 1999; Guha et al. 2001) (Fig 1.4). p38 may impact on the NFκB 
transcription  factor  pathway  through  phosphorylation  of  the  p65  subunit  after  IL-1β  or 
thrombin stimulation or bacterial infection (Madrid et al. 2001; Schmeck et al. 2004). S. 
pneumoniae infection has been shown to lead to p38 pathway activation in epithelial cells, 
which  resulted  in  NFκB  and  RNA  polymerase  II  recruitment  to  the  cox2  promotor 
(N'Guessan et al. 2006). 
 
1.3.6.6 The JNK pathway 
This pathway is activated in RAW 264.7 macrophages through innate immune mechanisms 
and contains the c-Jun N-terminal kinase (JNK) (Hambleton et al. 1996; Karin 1998). There 
are 2 isoforms of JNK which phosphorylate the N-terminus of c-Jun. Upstream protein 
kinases  including  p21-activated  kinase,  germinal  center  kinase  and  hPAK1  activate  the 59 
 
JNK  pathway  (Bagrodia  et  al.  1995;  Brown  et  al.  1996;  Hirai  et  al.  1997).  MEKK1, 
MEKK4  and  MUK/DLK/ZPK  also  activate  the  JNK  pathway  in  response  to  various 
inflammatory stimuli (Xia et al. 1998; Davis 1999; Tournier et al. 1999). In addition MKK4 
and MKK7 are direct activators of JNK (Guha et al. 2001). Many of the downstream targets 
of JNK are transcription factors which regulate genes encoding inflammatory mediators, 
including activating transcription factor-2, Elk-1 and c-Jun (Karin et al. 1997) (Fig 1.5). 
JNK  has  been  shown  to  be  essential  for  the  transcriptional  activation  of  inflammatory
 
cytokine  genes  in  response  to  GBS  but  not  S.  pneumoniae,  and
  in  turn  JNK  activates 
activator protein-1 and NFκB, which are critical for activation
 of the TNF promoter (Kenzel 
et  al.  2006).  However,  other  studies  show  S.  pneumoniae  induces  IL-8  expression  by 
human epithelial cells which depends on JNK activation and recruitment of phosphorylated 
c-Jun to the il8 promoter (N'Guessan et al. 2006; Schmeck et al. 2006). 
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1.4 COMPLEMENT 
1.4.1 Overview 
The complement system is an example of a biochemical proteinase cascade, and although it 
is  a  component  of  innate  immunity  it  also  links  to  the  adaptive  immune  system.  The 
proteins and glycoproteins that comprise the complement system are synthesized by tissue 
macrophages,  monocytes  and  epithelial  cells  of  the  genitourinary,  gastrointestinal  and 
respiratory tracts. These proteins circulate in the blood as inactive zymogens which are 
activated  by  proteases,  although  some  components  of  the  complement  system  are  cell 
surface  bound.  Complement  proteins  are  also  present  in  bronchoalveolar  lavage  fluid 
(BALF) but at levels approximating 10% those found in serum (Kerr et al. 2005). There are 
3  pathways  known  as  the  classical,  mannose-binding  lectin  (MBL)  and  alternative 
pathways  that  activate  the  cascade  (Walport  2001).  All  complement  pathways  result  in 
deposition of C3 convertase on the pathogen cell surface, cleavage of C3 into C3a and C3b 
and subsequent C5 convertase formation and cleavage (Fig 1.6).  
 
The classical pathway is activated when C1q binds directly to pathogenic surfaces, binds 
the Fc receptor of antibody complexed with antigen, or non antibody proteins like CRP and 
SAP (Hughes-Jones et al. 1979; Volanakis et al. 1981; Poon et al. 1985; Bristow et al. 
1986). In addition a novel C-type lectin, SIGN-R1, was shown to bind CPS, capture C1q 
and activate the classical pathway (Kang et al. 2006). C1q binding leads to change in the 
conformation of the associated (C1r:C1s)2 complex (Bauer et al. 1981), with cleavage of 
C1r and then C1s (Schumaker et al. 1987). This in turn leads to C4 cleavage, followed by  61 
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Fig 1.6 Schematic of the classical, MBL and alternative complement pathways 
Factors which stimulate each pathway are shown in addition to the cascade sequence of 
each  complement  pathway.  The  MBL  pathway  interacts  with  the  classical  pathway  to 
produce C1qC1rC1s and both pathways then proceed by the same route. The alternative 
pathway is shown to be separate from the classical pathway and only shares the late stages 
of the cascade with the classical cascade. The amplification loop of the alternative pathway 
is  shown  with  a  dashed  arrow.  All  three  pathways  result  in  formation  of  the  MAC. 
Anaphylaxins  are  highlighted  with  circles  and  opsonins  with  rectangles.  Adapted  from 
(Loeffler 2004).  62 
 
C2,  resulting  in  formation  of  C4b2b  on  the  target  surface.  The  C4b2b  acts  as  the  C3 
convertase  of  the  classical  pathway,  and  is  covalently  bound  to  the  pathogen  surface  
(Walport  2001).  C4b  is  also  an  opsonin  for  phagocytosis.  The  classical  pathway  is 
regulated by C4b binding protein (C4BP) which dissociates C4b2b by dissociating the C2 
from the complex (Hourcade et al. 1989). The MBL pathway is similar to the classical 
pathway,  but  mannose-binding  lectin  (MBL)  replaces  C1q  and  binds  directly  to  sugar 
residues on the cell surface, specifically mannose residues (Hajela et al. 2002). When the 
MBL complex is bound to the pathogen surface MASP-2 is activated to cleave C4 and C2, 
and this initiates the subsequent steps of the classical pathway (Hajela et al. 2002). 
 
In contrast, spontaneous C3 hydrolysis on the surface of pathogens initiates the alternative 
pathway. Hydrolysed C3 binds to factor B which is then cleaved by factor D into factor Bb, 
resulting in the formation of the alternative pathway C3 convertase, C3bBb (Walport 2001). 
The C3bBb complex deposits multiple C3b molecules on the pathogen surface, leading to 
opsonisation of the bacterium and MAC component activation (Walport 2001). On host 
cells C3bBb is regulated by FH, CR1 and DAF, which displace factor Bb from the complex 
and inactivate the C3 convertase (Hourcade et al. 2002). FH competes with factor B to 
displace Bb and binds  preferentially to C3b which is already bound to cells due to its 
affinity for sialic acid residues (Fujita et al. 1999). The alternative pathway also increases 
the C3 convertase bound on the pathogen cell surface through an amplification loop (Fig 
1.6) 
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The C3b formed by either the classical or alternative pathway and C5 convertase act to 
cleave C5 producing C5a and C5b (Vogt et al. 1978). C5a is a potent chemoattractant for 
neutrophils, monocytes and macrophages and enhances phagocytosis (Goldstein et al. 1974; 
Mollnes et al. 2002; Hawlisch et al. 2004). C5b initiates assembly of the later components 
of the complement cascade into the membrane attack complex (MAC). C5b first binds C6, 
and the complex then binds C7. The binding of C7 results in a conformation change in this 
protein thereby exposing a hydrophobic site, and the C5b67 complex inserts into the lipid 
bilayer of the cell membrane. C8 binds to the complex and also inserts into the membrane, 
and this is followed by the binding of multiple C9 molecules. Eventually 10-18 molecules 
of C9 polymerise to form a pore in the cell membrane, which allows free passage of solutes 
and  water  across  the  lipid  bilayer  of  the  bacterial  cell,  resulting  in  bacterial  cell  lysis 
(Walport 2001).  
 
1.4.2 Conformational changes in C3 on activation 
The central step in the complement cascade system is cleavage of C3 (186kDa) into C3b 
(177kDa) and C3a (9kDa). As this occurs C3b is split by Factor I and a co-factor in two 
positions to form iC3b (inactive C3b) and C3f. iC3b is cleaved further forming C3c and 
C3dg,  and  other  proteases  produce  fragments  including  C3d  and  C3g  (Fig  1.7).  C3b 
formation is a tightly regulated step, as it is able to stimulate uptake of opsonised particles 
by phagocytes via complement receptor (CR) 1, 3, 4 and CRIg as well as upregulating B-
cell  response  10,000  fold  through  co-stimulatory  and  B-cell  receptors  (Dempsey  et  al. 
1996; Carroll 2004; Helmy et al. 2006). The C3 β-ring provides a stable platform for the  64 
 
 
         
  
 
Fig 1.7 C3 degradation pathway 
C3 is cleaved by an intracellular processing enzyme into βC3 and αC3. C3 convertase then 
cleaves αC3 into C3b, which is cleaved at two sites into iC3b by Factor I and a co-factor. 
Molecular weights shown are for human proteins. Taken from Kang et al, Cell 2006. 
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functionally important domains of the α-chain that undergo conformational rearrangements 
(Fig 1.8). Conversion of C3 into C3b involves proteolytic removal of a small anaphylatoxin 
domain inducing marked structural rearrangements in the protein, resulting in the exposure 
and activation of the thioester moiety that binds via a thioester bond to target surfaces. The 
C3 residues involved in the formation of a thioester bond are protected in C3 so that the 
reaction site is not exposed, but due to conformational changes that occur in conversion to 
C3b these residues become exposed and highly reactive towards hydroxyl nucleophiles 
(Janssen et al. 2007). Furthermore, the conversion of C3 also exposes binding sites of factor  
 
 
A B C D
 
Fig 1.8 Schematic showing the conformational changes in the C3 activation pathway 
(A) Unactivated C3,  (B) C3b with C3a, (C) iC3b with C3f and (D) C3dg with C3c. These 
conformational changes determine the binding affinities towards soluble proteins (factor B, 
properdin  and  FH)  and  cell-surface  receptors  (eg  CR1-4,  CRIg,  DAF  and  MCP)  that 
underlie the biological activity of C3. 
Taken from Janssen, Nature 2006. 66 
 
B and properdin which stabilizes the resulting C3bBb convertase (Janssen et al. 2006). 
Binding of factor B to C3b (and subsequent cleavage of factor B by factor D) yields the 
short-lived C3bBb complex
 (Fishelson et al. 1984), which converts C3 into C3b and C3a, 
thereby amplifying the complement response and forming the C3b2Bb complex that cleaves 
C5 to initiate terminal complement components. Regulators of complement (FH, CR1 and 
DAF) dissociate the C3bBb complex through steric hindrance at their binding sites, and 
hence act as co-factors in the proteolysis of C3b into iC3b (Janssen et al. 2006).  
 
1.4.3 Complement interaction with S. pneumoniae 
Both clinical disease and animal models have indicated the importance of the complement 
in  the  host  immune  response  to  S.  pneumoniae  and  the  role  of  specific  complement 
pathways in IPD. Patients with C2 deficiency show an increased incidence of IPD and 
serum  from  these  patients  has  a  reduced  ability  to  opsonise  S.  pneumoniae  with  C3 
resulting in decreased phagocytosis (Yuste et al. 2008). There is a CPS fixation pathway 
which activates the classical pathway and this pathway has been shown to be the most 
important in mouse S. pneumoniae infection models (Brown et al. 2002; Kang et al. 2006).  
 
The  role  of  the  MBL  pathway  is  contentious,  with  MBL  deficient  patients  showing 
increased  IPD  incidence  (although  it  remains  unclear  if  this  is  a  serotype  specific 
phenomenon) but the MBL pathway has no effect on S. pneumoniae infection in mouse 
models (Brown et al. 2002; Roy et al. 2002). The classical pathway may be activated by 
antibody, SAP or CRP to targets on S. pneumoniae (Fig 1.9). SAP has been shown to bind  
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to  structures  on  microbial  surfaces  including  LPS,  phosphorylcholine  and  mannose  or 
galactose glycan residues and aids complement mediated immunity against S. pneumoniae 
(Hind et al. 1984; Schwalbe et al. 1992; de Haas 1999; Yuste et al. 2007). CRP also binds 
phosphorylcholine and activates the classical pathway through C1q, and furthermore binds 
capsule polysaccharide (Szalai et al. 1995).  Both SAP and CRP exert their effects on the 
complement system by providing a C1q binding site, which then activates the classical 
complement pathway (Ying et al. 1993; Volanakis 2001). However, the direct binding of 
C1q  to  bacteria  may  also  activate  the  classical  pathway  independently  of  antibody  or 
pentaxrins (Clas et al. 1981; Alberti et al. 1993; Butko et al. 1999). The alternative pathway 
also contributes to host defence against S. pneumoniae with mice lacking factor D showing 
slowed  kinetics  in  C3  opsonisation  of  pneumococcus  and  factor  B  deficient  mice 
developing more rapidly progressing disease (Xu et al. 2001; Brown et al. 2002). The main 
role of the alternative pathway is thought to be amplification of C3b/iC3b deposited on the 
bacterial  cell  surface  once  complement  activation  has  been  initiated  by  the  classical  or 
MBL pathway (Walport 2001; Brown et al. 2002). 
 
S. pneumoniae has various proteins that interact with complement and inhibit complement 
mediated immunity. These include CbpA, PspA, pneumolysin, phpA and phtD, and the 
effects of these proteins on complement are described below.  
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(a) CbpA 
Choline binding protein (CbpA or PspC) is a predominant protein isolated in the choline 
binding  proteins  of  S.  pneumoniae  (Rosenow  et  al.  1997),  and  is  highly  polymorphic 
between pneumococcal strains. CbpA is a 75 kDa multifunctional surface protein which is 
able to bind to secretory IgA, C3 and FH (Hammerschmidt et al. 1997; Smith et al. 2000; 
Dave et al. 2001). The differing CbpA structure has been shown to affect the binding of 
FH, which is a potent regulator of the alternative pathway (Quin et al. 2006). Theoretically 
CbpA could reduce alternative pathway activity by increasing the rate of C3 degradation to 
iC3b,  causing  dissociation  of  factor  B  (Bf)  from  the  C3  convertase  reducing  C3b 
deposition,  or  inhibiting  C3bBb  formation  by  preferentially  binding  C3b.  Furthermore, 
CbpA binds thioester-disrupted C3 which is not recognized by neutrophils as it is bound 
incorrectly  (Cheng  et  al.  2000),  thereby  interfering  with  complement  opsonisation  of  
S. pneumoniae. However, although the affinity of CbpA for FH has been demonstrated, the 
effects of this interaction on immunity against S. pneumoniae are relatively poorly defined 
and different investigators have found conflicting results (Janulczyk et al. 2000; Dave et al. 
2001; Iannelli et al. 2002). PspC increases iC3b and decreases C3b/iC3b deposition on D39 
S. pneumoniae, however other results seem to indicate loss of PspC has little effect on total 
C3 deposition on pneumococcus (Lu et al. 2006; Li et al. 2007; Quin et al. 2007).  
 
(b) PspA 
Pneumococcal surface protein A (PspA) was the first surface  exposed protein that was 
found  to  bind  choline  residues  and  varies  in  structure  from  CbpA  in  the  amino  acid 
sequence  of  the  α-helical  motifs  (Holtje  et  al.  1975;  Brooks-Walter  et  al.  1999; 69 
 
Hollingshead et al. 2000). PspA has been shown to have a role in resistance to complement  
deposition and is found on almost all S. pneumoniae (Hollingshead et al. 2000; Ren et al. 
2003). PspA is highly expressed by S. pneumoniae during infection and affects complement 
deposition  through  the  alternative  pathway,  although  the  precise  mechanism  for  this  is 
unknown (Ogunniyi et al. 2002; Yuste et al. 2005). PspA varies in size between strains 
from 67-99 kDa and has a high polar electrostatic charge, which stabilizes the charge of the 
polysaccharide capsule (Jedrzejas et al. 2000). This electronegative charge on PspA might 
inhibit complement deposition and activation, with mutants that lack PspA cleared faster 
from the blood in systemic infection (McDaniel et al. 1987; Tettelin et al. 2001; Ren et al. 
2003). Mice deficient in C3 or factor B are unable to clear mutants lacking PspA, whereas 
C5 deficient mice can clear the mutant strain (Tu et al. 1999). In addition, C3 serum levels 
are  significantly  reduced  within  30  minutes  of  infection  with  a  strain  possessing  PspA 
compared  to  a  mutant  strain  lacking  PspA  (Tu  et  al.  1999).  Furthermore  mutant  
S. pneumoniae strains lacking both PspA and pneumolysin cannot spread from the lung into 
the blood in complement sufficient mice (Yuste et al. 2005). This paper suggests that C3 
deposition  is  inhibited  by  PspA  modulating  the  alternative  pathway  and  pneumolysin 
inhibition  of  the  classical  pathway,  which  assists  the  establishment  of  S.  pneumoniae 
septicaemia (Yuste et al. 2005). 
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(c) Pneumolysin 
Pneumolysin is able to activate the classical pathway of the complement system in the 
absence of specific antibody (Paton et al. 1984; Mitchell et al. 1991). It was previously 
thought  that  pneumolysin  was  released  into  the  serum  by  S.  pneumoniae  and  activated 
complement by binding the Fc portion of IgG which lead to complement depletion in the 
serum (Mitchell et al. 1991). However Price and Camilli recently showed that pneumolysin 
is actually localised to the cell wall, and consequently its role complement interactions with 
S. pneumoniae needs to be  reconsidered (Price  et al. 2009). However,  the complement 
activating property of pneumolysin has been shown to be associated with bacterial growth 
in both the lung and blood within 24 hours of intratracheal inoculation (Jounblat et al. 
2003).  
 
(d) Others 
Pneumococcal histidine triad (Pht) proteins are a family of proteins which share extensive 
peptide sequence identity (Adamou et al. 2001). Currently the role of this protein family in 
pneumococcal virulence is poorly understood, however data seems to suggest that PhtB 
may cleave C3, based on fragments of these protein showing C3 degradation activity in 
human serum (Hostetter 1999; Zhang et al. 2001). Recently it was shown that removal of 
all  four  family  members  seems  to  be  needed  to  reduce  complement  deposition  on  
S. pneumoniae, and this may occur through recruitment of FH by these proteins (Ogunniyi 
et al. 2009). No doubt in the future more surface proteins will be identified that affect 
complement activity. 71 
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Fig 1.9 Interaction of S. pneumoniae with complement 
Mechanisms of complement deposition on S. pneumoniae mediated by the host are shown 
on the left and S. pneumoniae mechanisms of resistance to complement deposition on the 
right. Yellow ovals represent C1q, blue triangle represent SAP and green rectangles CRP. 
Antibodies are shown as either specific IgG (triangular Fab) or natural Ig (rectangular Fab). 
The macrophage receptor SIGN-R1 (blue pentagon) is known to mediate phagocytosis of S. 
pneumoniae through the classical pathway. Pneumolysin was thought to be released into 
the  serum  and  act  to  deplete  complement,  however  needs  amending  given  recent  data 
indicating that it is cell wall attached. 72 
 
1.5 THE POLYSACCHARIDE CAPSULE 
S.  pneumoniae  expresses  a  polysaccharide  capsule  (CPS)  which  is  required  for  full 
pathogenicity (Austrian 1981), and it has been demonstrated that unencapsulated mutants 
are highly attenuated in infection models (MacLeod et al. 1950; Brown et al. 1982; Watson 
et al. 1990; Morona et al. 2004). The polysaccharide capsule forms a highly hydrated 100-
400nm thick shell, and is normally partially covalently attached to the bacterial cell wall. 
There are currently 91 known capsular serotypes, with the structure of the polysaccharides 
varying  between  the  different  capsular  serotypes  (Park  et  al.  2007).  Most  are  complex 
structures that contain multiple sugars, linkages and frequently side chains, although the 
serotype 3 and 37 are composed of only one or two sugars and are relatively simple in 
structure.  
 
1.5.1 Capsule Structure 
Capsule  polysaccharides  are  high  molecular  mass  structures  composed  of  different 
monosaccharides  occurring  in  various  combinations.  The  primary  structure  of  the 
polysaccharides  depends  upon  the  nature  and  number  of  constituent  monosaccharides, 
sequence and ring size of the monosaccharides, type and configuration of the glycosidic 
linkages and nonsugar substituents, and repeat an unknown number of times to produce the 
CPS  (Jiang  et  al.  2001).  The  capsule  polysaccharides  are  generally  anionic  due  to  the 
presence  of  uronic  acid,  phosphate  and  pyruvate,  with  the  exception  of  the  capsular 
polysaccharides of serotypes 7F, 7A, 14, 33F and 37 which have no net charge (Kamerling 
et al. 2000).  In addition, the polysaccharide from serotype 1 has been found to have a 
zwitterionic charge, having an equal number of positively and negatively charged groups. 73 
 
Some commonly occurring monosaccharides found in the capsule polysaccharides include 
α/β-D-glucose,  α/β-D-galactose,  α/β-L-rhamnose  and  N-acetyl-α/β-D-glucosamine 
(Kamerling et al. 2000). In general, monosaccharides are found as pyranose rings (a six-
membered ring consisting of 5 carbon atoms and an oxygen atom), excluding D-galactose 
which  can  be  found  in  capsule  polysaccharides  in  both  pyranose  and  furanose  rings 
(consisting of 1 carbon and an oxygen atom), and D-ribose which only occurs as a furanose 
ring.  Phosphate  groups  are  common  in  capsular  polysaccharides,  and  several  capsular 
serotypes  contain  phosphodiester  bridges  between  an  aldose  derivative  and  a 
monosaccharide, including serotype 6A and 6B. However phosphate groups can also be 
found as a backbone substituent. Some serotypes have only small differences in structure 
between them, with differences occurring in the position of a glycosidic linkage or a single 
monosaccharide  (Kamerling  et  al.  2000).  For  example,  the  polysaccharide  structures  of 
serotype 6A and 6B differ only a single glycosidic linkage: in serotype 6A, the α-L-Rha 
residue is linked to the C-3 of the D-ribitol residue, whereas in 6B it is linked to the C-4 of 
the D-ribitol residue (Larm et al. 1976). Furthermore, the serotype 7A and 7F capsular 
polysaccharides have been found to contain a similar arrangement of monosaccharides, and 
the structural difference between these two polysaccharides is comprised of the presence or 
absence of a β-D-galactose terminal side-chain (Moreau et al. 1988; Backman-Marklund et 
al. 1990) (Fig 1.10 and 1.11).   74 
 
Serotype    Primary Structure of CPS 
1      →3)-AAT-α-D-Galp-(1→4)-α-D-GalpA-(1→3)-α-D-GalpA-(1→ 
2      →4)-β-D-Glcp-(1→3)-α-L-Rhap-(1→3)-α-L-Rhap-(1→3)-β-L-Rhap-(1→ 
                            2 
                                                           ↑ 
                                                            1 
            α-D-GlcpA-(1→6)-α-D-Glcp 
3      →3)-β-D-GlcpA-(1→4)-β-D-Glcp-(1→ 
4      →3)-β-D-ManpNAc-(1→3)-α-L-FucpNAc-(1→3)-α-D-GalpNAc-(1→4)-α-D-Galp2,3(S)Pyr-(1→   
6A      →2)-α-D-Galp-(1→3)-α-D-Glcp-(1→3)-α-L-Rhap-(1→3)-D-Rib-ol-(5→P→ 
6B      →2)-α-D-Galp-(1→3)-α-D-Glcp-(1→3)-α-L-Rhap-(1→4)-D-Rib-ol-(5→P→   
7F      →6)-α-D-Galp-(1→3)-β-L-Rhap2Ac-(1→4)-β-D-Glcp-(1→3)-β-D-GalpNAc-(1→ 
                         2                 4 
                           ↑                 ↑ 
                         1                 1 
                 β-D-Galp             α-D-GalpNAc-(1→2)-α-L-Rhap 
 
Fig 1.10 Primary Structure of repeating units of serotypes 1, 2, 3, 4 6A, 6B and 7F CPS 
Gal, galactose; Glc, glucose; GalA, galacturonic acid; GalNAc, N-acetylgalctosamine; Rha, rhamnose; ManNAc, N-acetylmannosamine; 
FucNAc, N-acetylfucosamine; Ac, acetate; Rib, ribose; P, phosphate; p, pyranose  Adapted from Kamerling in Streptococcus pneumoniae, 
Tomasz 2000  75 
 
   Serotype    Primary Structure of CPS 
 
9V    →α-D-GlcpA-(1→3)- α-D-Galp-(1→3)-β-D-ManpNAc-(1→4)-β-D-Glcp- (1→4)- α-D-GlcpNAc-(1→ 
                                :               :              : 
                             2Ac (17%)                                            4Ac (6%)                                                     2Ac (3%)                         
        3Ac (25%)                                       6Ac (55%)                                                   3Ac (4%) 
14    →6)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-β-D-Glcp-(1→ 
                                    4 
                                    ↑ 
                                    1 
                           β-D-Galp 
23F              Gro-(2→P 
                                                                        ↓   
                                                                        3 
                        →4)-β-D-Glcp-(1→4)-β-D-Galp-(1→4)- β-L-Rhap-(1→ 
                                                                        2 
                                                                        ↑   
                                                                        1   
                                                          α-L-Rhap 
 
Fig 1.11 Primary Structure of repeating units of serotypes 9V, 14 and 23F CPS 
Gal, galactose; Glc, glucose; Gro, glycerol; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalctosamine; Rha, rhamnose; ManNAc, N-
acetylmannosamine; Ac, acetate; Rib, ribose; P, phosphate; p, pyranose. Dots indicate where alternative side chains may occur in serotype 
9V. Adapted from Kamerling in Streptococcus pneumoniae, Tomasz 2000  76 
 
1.5.2 Capsular Genetics 
The  pneumococcal  capsule  is  encoded  by  a  single  genetic  locus  (cps)  which  has  a 
cassette-like organization and appears to be organized as a single transcriptional unit. 
The type-specific biosynthetic genes are flanked by genes dexB and aliA which are 
highly homologous amongst different capsular serotypes, (Garcia et al. 1997; Bentley et 
al. 2006) and do not play a role in capsule synthesis. 7 of the 18 capsule polysaccharide 
component  monosaccharides  are  available  to  S.  pneumoniae  through  housekeeping 
metabolic pathways and the remaining 11 are encoded by genes in the cps locus, which 
is  composed  of  type-specific  genes  involved  in  the  biosynthesis  of  specific 
polysaccharides (Bentley et al. 2006). In addition to encoding for monosaccharides, the 
cps  locus  also  encodes  for  polysaccharide  polymerases,  flippases  and  transferases 
(Yother 2004). Enzymes specific for the synthesis and polymerisation of CPS are found 
in the central region of the cps locus. Only one set of type-specific genes is present in 
any given strain of S. pneumoniae, and there is little homology between type-specific 
genes from different capsular serotypes (Fig 1.12). Only a few genes (cpsA, cpsB, cpsC, 
cpsD, and in most cases cpsE,) located at the 5’ end of the cps locus are conserved 
between clusters, and these are involved in the processing, regulation and export of CPS 
and may be involved in attachment of polysaccharide to the bacterial cell wall (Fig 
1.12) (Yother 2004; Bentley et al. 2006). Only cpsA is more than 90% identical in all 
gene clusters (Garcia  et  al. 2000). A functional promoter sequence (cpsp)  has been 
located  30  nucleotides  upstream  of  the  first  codon  in  the  cpsA  gene  and  the 
transcriptional start point of the cps operon has also been identified (Munoz et al. 1997).  
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dexB aliA IS cps2A B C D E T F G H I M J K L N O
dexB IS1380 IS A B C D I J K L wxy M wzx mnaA fnl1 2 3 4 aliA
cps2
cps4
dexB
cap3
aliA
dexB A B C D E N O P wzy wzx L M N O aliA
cps6B
cap3A B C IS
dexB IS A B C D E F G aliA M L N O H I J K IS1167 IS
cps9V
dexB A B C D E F G aliA H I J
cps14
L IS
dexB A B C D E T I U V
cps23F
J W M L N O aliA X Y Z  
Fig 1.12 Organization of the cps loci from selected S. pneumoniae serotypes  
ORFs within the DNA sequence are indicated by large boxed arrows showing common 
genes  (dark  blue),    transferase  genes  (light  blue),  polysaccharide  polymerase  genes 
(pink),  the  synthase  (glycosyltransferase)  gene  (green),  activated  sugar  biosynthesis 
genes (grey) and IS sequences (white).  Narrow boxes represent ORFs which are not 
required for CPS biosynthesis. Organisations based on published data for serotypes 2 
(Iannelli et al. 1999), 3 (Arrecubieta et al. 1996), 4 (Jiang et al. 2001), 6B (Jiang et al. 
2001), 9V (van Selm et al. 2002), 14 (Kolkman et al. 1997) and 23F (Morona et al. 
1999). Figure adapted from Paton et al, 2005 and Yother, 2004.  78 
 
There are two genes which are not located within the cps locus are likely to be essential 
for formation of the CPS in all S. pneumoniae strains. Both PGM and GalU are required 
for  the  synthesis  of  UDP-glucose,  which  is  a  precursor  for  the  biosynthesis  of  all 
pneumococcal CPS. A phosphoglucomutase (PGM) encoded by the pgm gene catalyses 
the  conversion  of  Glu-1-P  to  Glu-6-P  (Hardy  et  al.  2001).  The  other  gene  (galU) 
encodes  a  uridine  diphosphate  glucose  pyrophosphorylase  which  catalyses  the 
reversible formation of UDP-Glu from uridine 3-phosphate and Glu-1-P (Frey 1996). 
UDP-Glu is required for the synthesis of UDP-glucuronic acid and is also required for 
the interconversion of galactose and glucose. S. pneumoniae mutants with disruptions to 
either  the  galU  or  pgm  gene  produced  no  CPS  and  also  exhibited  growth  defects 
(Mollerach et al. 1998; Cieslewicz et al. 2001). 
 
1.5.3  Capsular Polysaccharide Biosynthesis 
The  biosynthesis  of  CPS  is  complex,  with  constituent  monosaccharides  being 
synthesised or taken up and converted to a nucleotide derivative before being linked on 
a membrane-bound lipid carrier (likely to be C55 undecaprenyl) (Cartee et al. 2005). In 
general pneumococcal CPS are synthesized by the Wzx/Wzy-dependent pathway, the 
genes for which are located invariably at the 5’ end of the cps locus (cpsA, cpsB, cpsC, 
cpsD)  (Bentley  et  al.  2006).  The  CPS  is  synthesized  by  transfer  of  an  initial 
monosaccharide phosphate from a nucleotide diphosphate sugar to the undecaprenyl 
lipid carrier. Usually glucose-1-phosphate (Glc-1-P) is transferred from UDP-glucose 
onto a lipid acceptor (Kolkman et al. 1998; Yother 2004). However when the capsule 
contains galactose and not glucose, the initial step involves transfer of galactose-1-P 
(Gal-1-P) from UDP-galactose onto the lipid carrier (Yother 2004). This is followed by 
a sequential transfer of additional monosaccharides to produce the lipid-linked repeat 79 
 
unit. This process is catalysed by glycosyl-transferases which are encoded within the 
serotype-specific regions of the cps locus (Kolkman et al. 1997). The lipid linked repeat 
unit is then transferred to the outer face of the cytoplasmic membrane by ‘flippases’ 
which contain approximately 12 membrane spanning domains and are homologous to 
the  Wzx  repeat  unit  transporter.  Polymerisation  occurs  through  the  action  of  Wzy 
polymerase homologues to form mature CPS, which is then attached to peptidoglycan 
which anchors the CPS to the cell wall (Sorensen et al. 1990; Bentley et al. 2006) (Fig 
1.13).  However,  it  is  unclear  which  enzyme  is  responsible  for  the  polysaccharide 
transfer to the cell and at which precise point it occurs, however this process appears to 
be independent of CPS size (Bender et al. 2003).  
 
In both serotype 37 and 3, the common sequences located at the 5’ end of all other cps 
loci are either not present (serotype 37) or are mutated and not transcribed (serotype 3) 
(Paton et al. 2007). Serotype 3 and 37 are synthesized via the synthase pathway, in 
which  CPS  synthesis  is  catalyzed  by  a  single,  membrane  bound  glycosyltransferase 
(synthase)  (Arrecubieta  et  al.  1996).  This  synthase  is  a  member  of  the 
glycosyltransferase  family  2,  and  the  enzymes  in  this  family  have  binding  sites  for 
nucleotide  sugars  and  CPS,  which  allows  transport  of  the  polymer  across  the 
cytoplasmic  membrane  during  synthesis  (Campbell  et  al.  1997).  For  the  serotype  3 
polysaccharide  initiation  begins  on  a  glycerophosphate  lipid  acceptor  (Cartee  et  al. 
2001) and is followed by addition of Glc and GlcUA (Cartee et al. 2000). Since the 
synthase  does  not  have  transmembrane  domains  such  as  those  found  in  the  Wzx 
transporter, the polysaccharide ejection mechanism is thought to result from premature 
translocation  in  the  absence  of  UDP-Glc  and  UDP-GlcUA  which  leads  to  the  CPS 
binding site failing to recognize the polymer (Forsee et al. 2000). 80 
 
 
CpsE
P---lipid
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CYTOPLASM MEMBRANE
 
Fig 1.13 The Wzx/Wzy dependent pathway for biosynthesis of serotype 14 CPS 
Functions  for  the  glycosyltranferases  CpsE,  CpsG,  CpsI  and  CpsJ  have  been 
experimentally determined in serotype 14. PGM and GalU are the cellular enzymes and 
are  not  capsule  specific.  PGM,  GalU,  CpsG,  CpsI  and  CpsJ  are  located  in  the 
cytoplasm,  whereas  CpsJ,  Wzx  transporter  homologues  and  Wzy  polymerases  are 
membrane associated. Following the transfer of the chain, the lipid P-P is hydrolysed to 
lipid-P and recycled to the cytoplasmic face of the membrane.  
Adapted from Yother, in The Pneumococcus, 2004 
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1.5.4  Regulation of capsule polysaccharide production 
The  ability  of  S.  pneumoniae  to  regulate  production  of  CPS  at  the  transcriptional, 
translational  or  post-translational  level  is  likely  to  be  important  for  S.  pneumoniae 
survival in different host environments. However, currently no transcriptional control 
elements have been identified in association with the cps promoter (Munoz et al. 1997), 
although  there  is  evidence  to  suggest  that  the  cps  locus  level  of  expression  differs 
between  opaque  and  transparent  phase  variants  (Weiser  et  al.  2001).  Additionally, 
approximately fourfold higher levels of cps mRNA, are found in S. pneumoniae isolated 
from the blood of infected mice compared to bacteria grown in vitro (Ogunniyi et al. 
2002).  
 
The cpsA, cpsB, cpsC, cpsD common genes found at the 5’ end of the cps locus encode 
proteins which are involved in the modulation of CPS production. Whilst the precise 
role of CpsA is not known, cpsA deletion mutants produce less CPS (Morona et al. 
2004). Interestingly a cpsA homologue in group B streptococci does seem to function as 
a transcriptional  activator (Cieslewicz  et  al. 2001). CpsB, CpsC and CpsD  act  in a 
phophoregulatory pathway that regulates CPS production and chain length. CpsB (a 
manganese  dependent  phophotyrosine-protein  phosphatase)  and  CpsC  (a  membrane 
protein) function together to regulate capsule assembly, export and attachment to the 
cell  wall  by  tyrosine  phosphorylation  of  CpsD.  CpsC,  CpsD  and  ATP  interact  to 
promote biosynthesis of CPS. This is followed by autophoshorylation of CpsD which 
slows capsule polysaccharide  synthesis through  changes in protein interactions. The 
CPS  polymer  is  then  transferred  to  the  putative  polysaccharide  cell-wall  ligase  and 
finally CpsB dephoshorylates CpsD allowing for further polysaccharide synthesis to be 
promoted (Morona et al. 2000; Morona et al. 2004; Kadioglu et al. 2008) (Fig 1.14). 82 
 
Deletion of cpsC or cpsD results in only a low level of CPS which is composed of short-
chain polymers (Morona et al. 2000; Bender et al. 2003). Deletion of cpsB leads to 
increased  phosphorylation  of  CpsD  and  increased  capsule  production  (Bender  et  al. 
2003). 
 
The transcription of the cps locus is also affected by RegM, a protein involved in the 
regulation of sugar-metabolism. This suggests that a carbon source could also affect 
capsular expression (Giammarinaro et al. 2002). Recently it was shown that serotypes 
producing polysaccharides that are less metabolically costly (ie with a low number of 
carbons and correspondingly low number of high-energy bonds or ATP-equivalents) 
tend to be more heavily encapsulated and therefore more likely to avoid phagocytic 
clearance and persist in carriage (Weinberger et al. 2009).  
 
1.5.5  Capsular Switching 
Capsular switching is clinically important in S. pneumoniae disease as this phenomenon 
may undermine the efficacy of current capsular polysaccharide conjugate vaccines. The 
introduction of the conjugate vaccine in children has caused a rapid and large decrease 
in the prevalence of vaccine serotypes in IPD and carriage. However, this has been 
associated  with  a  rise  in  the  prevalence  of  non-vaccine  serotypes  in  both  IPD  and 
carriage (Long 2005; Beall et al. 2006; Munoz-Almagro et al. 2008). The cassette-like 
arrangement of the cps genes between genes which are highly conserved amongst all 
strains allows the naturally transformable S. pneumoniae to change serotype through 
recombinational  exchange.  Studies  of  antibiotic-resistant  isolates  show  that  serotype 
switching between different capsular serotypes occurs naturally within populations of  83 
 
S.  pneumoniae  (McGee  et  al.  2001;  Sandgren  et  al.  2004;  Hanage  et  al.  2005; 
Brueggemann et al. 2007). The major multiresistant Spanish serotype 23F clone has 
undergone capsular switching on at least 4 occasions, transforming into serotype 19F 
(Coffey et al. 1998). Serotype 19A variants of the same multiresistant serotype 23F 
have also emerged through recombinational exchanges at the cps locus on more than 
one occasion (Coffey et al. 1998). Recombinations between serotype 9V and 14 loci can 
occur upstream  of dexB and downstream of aliA or  within  the  conserved  TDP-Rha 
synthesis genes (Coffey et al. 1998).   
 
Furthermore, capsular switching can be utilized to engineer strains of S. pneumoniae 
which are genetically isogenic except at the cps locus. The use of a Janus cassette has 
increased  the  identification  of  extremely  low-frequency  transformants,  enabling  this 
technique to be used to create multiple strains with the same genetic background but 
expressing different cps loci (Trzcinski et al. 2003). Furthermore there seems to be no 
detectable cost of this particular transformation of a strain and by the performance of 
backcross  steps  ensures  a  low  likelihood  of  recombination  replacements  involving 
exogenous DNA taking place outside the dexB-cps-aliA locus (Fig 1.14) (Trzcinski et 
al. 2003). These strains are potentially a powerful experimental tool, since differences 
between these mutants must be due to the either the type or amount of CPS which is 
expressed.  This  enables  studies  on  the  effect  of  capsular  serotype  without  the 
confounding  of  non-capsular  genetic  variation  and  without  mutant  strains  suffering 
metabolic costs of the transformation. 
 
 84 
 
 
1.
2.
3.
4.
5.
 
 
Fig 1.14 Construction of the Janus cassette in the R96 S. pneumoniae cps locus 
dexB and aliA genes of R6 and aphIII (Km
r, Kanamycin resistant) and rpsL
+ (Sm
s, 
Streptomycin  sensitive)  genes  of  Janus  (size  of  the  ORF  is  in  parentheses)  are 
represented  by  pentagons.  Oligonucleotides  used  to  amplify  cassette  elements 
capitalised. Restriction sites of enzymes creating sticky ends before ligation steps are 
shown  by  dotted  lines.  The  2  top  lines  show  elements  of  CP1296  and  R6  used  to 
construct the dexB-Janus-aliA cassette. The ligation product was used as a template to 
amplify the TTM05-06 fragment (3) and this was then used to transform R6S (4) to 
create  R6J  (5)  using  selection  for  resistance  to  kanamycin.  Sizes  of  PCR  products 
generated are given in brackets next to the product names. Adapted from Trizcinski et 
al, 2003. 
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1.5.6  Phase variation 
S.  pneumoniae  undergoes  spontaneous  phase  variation  between  two  distinct  colony 
forms,  which  are  distinguishable  based  on  colony  morphology  when  viewed  using 
oblique,  transmitted  light.  Rates  of  phase  variation  between  opaque  and  transparent 
phenotypes vary between 10
-3 to 10
-6 per generation depending on the isolate (Weiser et 
al. 1994). Transparent phenotypes are more adherent to epithelial cells and type II lung 
cells  in  vitro  (Cundell  et  al.  1995),  and  are  more  efficient  at  nasopharyngeal 
colonization in animal models of carriage (Weiser et al. 1994). Opaque colonies appear 
dome-shaped, undergo spontaneous lysis less rapidly and are more frequently isolated 
from IPD (Serrano et al. 2006). Depending on the strain, opaque phase variants express 
a 1.2 to 5.6 fold greater amount of CPS compared to the transparent variant (Kim et al. 
1998). However, outside of CPS expression there are also differences in other strain 
characteristics and structures which are summarized in Table 1.1. 
 
Table 1.1 Summary of the characteristics and structure associated with the phase 
variation of S. pneumoniae  Taken from Weiser 1998 
 
Characteristic/Structure  Opaque Phenotype  Transparent Phenotype 
 
Autolysis 
 
↓ 
 
↑ 
LytA Expression  ↓  ↑ 
PspA Expression  ↑  ↓ 
CbpA Expression  ↓  ↑ 
Teichoic Acid Content  ↓  ↑ 
Nasopharyngeal  colonization  (infant 
rat) 
↓  ↑ 
IP virulence (adult mice)            ↑               ↓ 
 86 
 
Phenotypic variation also occurs in GBS, in which populations coexist with different 
capsule thicknesses, allowing for phase shifting towards a less encapsulated form which 
adheres well to epithelial cells or a phase of  abundant encapsulation which adheres 
poorly (Rubens et al. 1987; Philips et al. 1992; Cieslewicz et al. 2005). N. meningitidis 
also  varies  the  level  of  CPS  with  changes  in  pH  and  nutrient-limiting  conditions, 
however these changes are reversible and due to changes in the number of cytidine 
residues within the 5’ region of the α-2,8-polysiayltransferase gene, an enzyme found 
on the inner membrane which is responsible for capsule formation (Hammerschmidt et 
al.  1996).  In  S.  pneumoniae  a  genetic  locus  able  to  transform  a  transparent  strain 
recipient to an opaque phenotype identified two genes, glpD and glpF which may be 
involved  in  regulation  of  phase  variation  although  the  precise  mechanism  remains 
unclear (Weiser 1998). Both these genes have homology to the glycerol regulon genes 
in other bacteria and are followed by a sequence with homology to other repetitive 
pneumococcal intergenic elements (BOX A and C) upstream of an ORF which may 
encode  a  126  amino  acid  protein.  There  is  also  a  second  longer  ORF  which  is 
transcribed in the opposite orientation, and neither ORF has any significant homology to 
current entries in sequence databases (Weiser 1998). Interestingly this second ORF has 
an associated area of 19 tandem thymidine residues located upstream, and these have 
been shown to create ‘molecular switches’ associated with phase variation (Weiser et al. 
1989). Hence a stem-loop forming element  which is known as BOX A-C has been 
implicated in the control of opaque phase variation.  However the stimuli and signals 
which stimulate phase switching and the exact mechanism by which this occurs remains 
poorly understood.  
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1.5.7  Role of polysaccharide capsules in other species 
The presence of a polysaccharide capsule surrounding the cell wall is not unique to S. 
pneumoniae, and many pathogenic Gram positive and negative bacteria species possess 
a  capsule.  Bacterial  surfaces  contain  various  structures  which  induce  host  immune 
responses,  and in  general  bacterial capsules that  completely  surround bacteria mask 
underlying cell surface structures which would otherwise be potent activators of the 
complement  system.  Generally  the  capsules  which  surround  bacteria  have  surfaces 
which  are  poor  activators  of  complement,  thereby  masking  potent  complement 
activators and replacing the bacterial cell surface with a poor target for complement. For 
example, the K1, K10 and K16 capsules of Klebsiella pneumoniae have been shown to 
prevent the complement system activating by masking surface structures (Salo et al. 
1995), with the further consequence of reduced opsonophagocytosis. Certain bacterial 
capsules,  such  as  the  K66  K.  pneumoniae  strain,  are  co-expressed  with  strong 
complement activating structures of the bacterial outer membrane (Tomas et al. 1991). 
In this particular strain, the capsule masks the C3b (which is deposited on the O antigen 
LPS chain) from phagocytes, thereby reducing opsonophagocytosis.  
 
The  K.  pneumoniae  serotype  K1  capsule  has  been  shown  to  have  an effect  against 
antibody, and acts as a barrier against O-specific antibodies (Cryz et al. 1986). The 
serotype K2 polysaccharide capsule acts as a partial barrier, and this effect of the K. 
pneumoniae capsule against antibody seems to be serotype specific (Meno et al. 1990; 
Held et al. 2000). In addition, masking by capsular polysaccharides may induce a weak 
or absent immune response to the bacteria, which may even induce tolerance to foreign 
antigens in the host. GBS that produce higher levels of type-III polysaccharide are more 
virulent that strains which produce lower levels (Rubens et al. 1987; Philips et al. 1992), 88 
 
and  this  polysaccharide  has  been  shown  to  mask  cell  wall  complement-activating 
structures (Hulse et al. 1993; Tamura et al. 1994) and prevent C3 deposition (Marques 
et al. 1992). In addition several Gram positive bacteria prevent the antibody activation 
of  complement  (Corbeil  2000).  IgA  antibody  directed  against  the  group  C  N. 
meningitidis capsule also acts to prevent IgG mediated complement killing (Jarvis et al. 
1991). 
 
The  sialic  acid  found  in  the  N.  meningitidis  capsule  acts  to  inhibit  the  alternative 
complement pathway by binding factor H, which mimics the effect of sialylation on cell 
membranes  in  reducing  the  amount  of  C3b/iC3b  deposited  (Ram  et  al.  1998). 
Furthermore it is thought that sialylation of the group B streptococcus polysaccharide 
capsule increases FH binding and thereby reduces C3 deposition (Wessels et al. 1989; 
Vimr et al. 2002; Lewis et al. 2004). Sialylation of the LPS in non-typable Haemophilus 
influenzae also inhibits C3 deposition although this does require FH binding (Figueira et 
al. 2007).  
 
Polysaccharide capsules may also prevent the activation of terminal complement MAC 
in Gram negative bacteria (Gram positive bacteria are resistant to MAC lysis due to the 
presence  of  a  rigid  and  thick  peptidoglycan  layer).  In  K.  pneumoniae  and  Serratia 
marcescens this is thought to occur by preventing MAC binding or forcing the MAC to 
bind  too  far  from  the  bacterial  cell  surface  to  be  effective  (Alberti  et  al.  1996). 
Additionally in these strains the MAC associates to O-antigen side chains on LPS by 
weak  ionic  interactions,  so  that  it  is  shed  and  therefore  not  effective  in  lysing  the 
bacterium. 89 
 
Extracellular pathogens possess polysaccharide capsules which inhibit phagocytosis by 
preventing  phagocyte  recognition  and/or  ingestion  of  bacteria.  For  example,  the  N-
acetylneuraminic  acid  capsule  of  Neisseria  meningitidis  and  K1  E.  coli  strains 
surrounds  the  bacteria,  weakly  activates  complement  providing  a  poorly  opsonised 
external surface in the absence of specific antibodies and make ligands inaccessible to 
phagocytes (Kim et al. 1992; Read et al. 1996; Virji et al. 1996). Furthermore some 
airway pathogens possess capsules which may down-regulate IL-6 and IL-8 cytokine 
expression which decreases plasma cell maturation and thereby amount of antibody, 
hence  slowing  the  migration  of  phagocytes  towards  infection  sites.  This  has  been 
demonstrated  in  Actinobacillus  actinomycetemcomitans  serotype  b  and  some  K. 
pneumoniae serotypes  (Yoshida et al. 2001; Ohguchi et al. 2003).  
 
Polysaccharide capsules are also present on some fungi, and Cryptococcus neoformans 
is  a  haploid  yeast  which  is  surrounded  by  a  capsule  composed  primarily  of 
glucuronoxylomannan (Cherniak et al. 1980). The C. neoformans capsule is essential 
for cryptococcosis in mice and unencapsulated strains are easily phagocytosed by both 
neutrophils and macrophages (Bulmer et al. 1967; Bulmer et al. 1968; Kozel 1977). 
Inhibition of phagocytosis is mediated directly by glucuronoxylomannan component of 
the capsule, which also enables adherence to type II alveolar epithelial cells via the 
CD14  receptor  (Kozel  et  al.  1976;  Barbosa  et  al.  2007).  Furthermore  the 
glucuronoxylomannan interferes with neutrophil migration, suppresses T cell immunity 
and up-regulates cytokine production (Murphy et al. 1982; Retini et al. 1996; Lipovsky 
et al. 2000; Ellerbroek et al. 2004). In contrast to other polysaccharide capsules, the 
cryptococcal capsule is a potent activator of the complement system, with encapsulated 
yeast cells binding 10
7-10
8 C3 fragments, mostly in iC3b form (Young et al. 1993). 90 
 
Complement activation occurs solely through the alternative pathway which produces 
an asynchronous focal initiation because of random deposition of fluid-phase C3b onto 
the capsule, which is followed by amplification leading to complete capsule coverage 
with C3 (Kozel et al. 1991). This acts as a diversion technique for avoiding complement 
deposition on the yeast cell surface. 
 
In summary, the capsules of other microbial pathogens have been shown to have a 
variety of effects on complement and phagocytosis that will aid immune evasion.  
 
1.5.8  Role of the S. pneumoniae capsule 
The  capsule  has  been  shown  to  be  vital  for  virulence  of  S.  pneumoniae,  and 
unencapsulated strains are not recoverable from animal models of disease. Furthermore 
transparent  strains,  which  express  a  thinner  polysaccharide  capsule,  show  enhanced 
colonization  compared  to  opaque  strains,  and  capsule  is  required  for  sustained 
colonization  of  the  nasopharynx,  though  strains  with  less  polysaccharide  retain  the 
ability to colonize (Weiser et al. 1994; Kim et al. 1998; Magee et al. 2001). Recent 
studies  have  utilized  unencapsulated  mutants  transformed  from  virulent  strains  of  
S. pneumoniae to confirm that the capsule is required for virulence (Hardy et al. 2001; 
Magee et al. 2001). Furthermore opaque phase variants are more virulent in systemic 
disease than their transparent phase counterparts (Kim et al. 1998). It has previously 
been demonstrated that different S. pneumoniae capsular serotypes vary in their ability 
to cause invasive disease (Hausdorff et al. 2000), and this may be due to differences in 
the  chemical  structure  of  the  capsular  polysaccharides  of  which  the  capsule  is 
comprised. Interestingly despite differences in the range serotypes which cause animal 91 
 
models of pneumococcal disease, there is still a limit to the number of serotypes which 
do so. Furthermore virulence of  S. pneumoniae in these models correlates with serotype 
(Briles et al. 1992; Wu et al. 1997).  
 
The capsule is believed to protect the bacteria through its effect against complement and 
phagocytosis. This is thought to occur by blocking access to C3b which is localized on 
the  cell  wall  beneath  the  polysaccharide  capsule,  with  studies  showing  alternative 
pathway activation by the S. pneumoniae wall leading to increased deposition of C3b on 
the cell wall (Abeyta et al. 2003). However earlier studies found similar levels of C3b 
deposited on the cell wall fragments obtained from encapsulated and unencapsulated 
through  activation  of  the  alternative  complement  pathway  (Winkelstein  et  al.  1976; 
Winkelstein et al. 1980; Brown et al. 1983). Therefore the capsule may act to both limit 
C3 access as well as the amount of complement which is deposited on the bacteria. 
However  CPS  may  also  act  as  a  target  for  complement  mediators,  providing  a 
mechanism for complement mediated immunity. Recently a classical pathway fixation 
pathway was reported in which capsule polysaccharide is targeted by SIGN-R1 (Kang et 
al. 2006) further outlining the importance of the classical pathway in host immunity to 
S. pneumoniae (Brown et al. 2002). Furthermore both SAP and CRP may target the 
capsule  polysaccharides  as  well  as  phosphocholine  on  cell  membranes,  DNA  and 
chromatin (Volanakis et al. 1971; Volanakis et al. 1979; Hind et al. 1984; Loveless et al. 
1992; Li et al. 1994). Overall the precise role of the capsule in preventing complement 
deposition remains confused and unclear.  
 
There is good evidence that capsular effects on immune function vary with serotype. 
Complement  deposition  and  activation  varies  between  clinical  isolates  of  different 92 
 
serotypes, and there are also differences in phagocytosis between serotypes (Wood et al. 
1949; Fine 1975; Giebink et al. 1977; Winkelstein et al. 1977; Braconier et al. 1982; 
Gordon et al. 1986; Hostetter 1986; Melin et al. 2009). Abeyta and Yother demonstrated 
that the switching of a serotype 2 locus with a serotype 3 locus resulted in a level of C3 
deposition on the mutant strain that was between that of the wild-type D39 and WU3 
strains, which was reflected in differences in the levels of antibody binding (Abeyta et 
al.  2003).  The  capsular  switching  technique  was  used  by  Kelly  and  Yother,  who 
converted strains of serotype 2, 5 and 6B to serotype 3. In a mixed result, replacement 
of  the  serotype  2  capsule  did  not  affect  virulence  in  a  mouse  model,  whereas 
replacement  of  serotype  5  and  6B  had  profound  effects  on  the  virulence  of  the  
S.  pneumoniae  strain  (Kelly  et  al.  1994).  This  indicates  the  capsule’s  key  role  in 
determining  complement  access  to  the  cell  surface  of  S.  pneumoniae,  however 
complement deposition seem to be affected by both capsular serotype and other non-
capsular genetic variation. Non-capsular genetic variation may account for differences 
in  expression  and  structure  of  numerous  virulence  factors,  including  CbpA, 
neuraminidase, autolysin, pneumococcal surface protein A (pspA), hyaluronidase and 
pneumococcal adhesins. The S. pneumoniae capsule surrounds many of these virulence 
factors and possibly affects interactions between these pneumococcal proteins and host 
immune mechanisms. Therefore variation in the structure of multiple virulence factors 
combined  with  differences  in  the  effect  of  different  capsule  polysaccharides  may 
account for differences in complement deposition between strains of different serotypes 
as well as between strains of the same capsular serotype. 
 
Phagocytosis of S. pneumoniae plays an important role in clearing pneumococcus from 
the lungs during pneumonia, and the capsule is believed to inhibit phagocytosis (Wood 93 
 
et al. 1946; MacLeod et al. 1947). Previous studies have shown that the polysaccharide 
capsule  from  several  serotypes  inhibits  phagocytosis  and  that  serotypes  expressing 
thicker polysaccharide capsules are more resistant to phagocytosis (Wood et al. 1949; 
MacLeod et al. 1950). However these experiments were performed using strains which 
are now known to have significant non-capsular genetic variation or using dead bacteria 
(Wood  et  al.  1949;  Lanie  et  al.  2007).  More  recent  experiments  have  shown  that 
unencapsulated mutants have are more susceptible to phagocytosis and there is limited 
data showing increased levels of complement deposition on their surface (Winkelstein 
1981; Rubens et al. 1987; Abeyta et al. 2003; Quin et al. 2007). Complement is required 
for efficient opsonisation, and it remains unclear if the capsule’s effect on phagocytosis 
is a down-stream consequence of its ability to inhibit complement deposition. Indeed 
recent data showing increased phagocytosis of an unopsonised unencapsulated serotype 
6B  strain  suggests  there  can  be  a  capsular  effect  on  non-opsonic  phagocytosis 
(Weinberger  et  al.  2009).  Furthermore  the  capsule  has  an  inhibitory  effect  on 
macrophage  phagocytosis  and  an  unencapsulated  TIGR4  strain  has  been  shown  to 
induce increased apoptosis in monocyte derived macrophages (Jonsson et al. 1985; Ali 
et al. 2003). Recently is has been suggested that the structure of the polysaccharide 
predicts prevalence of a given serotype, with common carriage strains of S. pneumoniae 
showing  increased  capsule  thickness  and  resistance  to  non-opsonic  phagocytosis  by 
neutrophils (Weinberger et al. 2009). This may be important as effects of capsule on 
phagocytosis  are  likely  to  reduce  complement  mediated  uptake  (Yuste  et  al.  2008). 
However,  other  data  has  shown  that  the  capsule  prevents  S.  pneumoniae  killing  by 
neutrophil extracellular traps and assists nasopharyngeal colonization through charge-
dependent  interactions  with  nasal  mucous  rather  than  inhibition  of  phagocytosis  or 
complement-mediated immunity (Nelson et al. 2007; Wartha et al. 2007).  
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Despite the studies described above, the mechanisms by which the capsule prevents 
complement deposition on S. pneumoniae, which complement pathways are involved 
and  the  differences  in  the  pattern  of  complement  deposition  on  encapsulated  and 
unencapsulated  are  poorly  understood.    Whether  the  effects  of  the  capsule  on  
S.  pneumoniae  phagocytosis  are  solely  attributable  to  inhibition  of  bacterial 
opsonisation with complement or are also consequences of the effects of the capsule on 
other mechanisms of phagocytosis is also poorly defined. As there are few data on 
which  effects  of  the  capsule  are  relevant  during  invasive  infection,  the  relative 
importance  during  systemic  infection  of  capsule  inhibition  of  complement-mediated 
immunity to S. pneumoniae compared to other effects of the capsule on interactions 
with the host remains unclear. 
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1.6  SUMMARY AND HYPOTHESIS 
S. pneumoniae is the commonest cause of pneumonia in the UK and is also a common 
cause  of  other  respiratory  infections  including  bronchitis  and  empyema.  A  vital 
component of systemic immunity to S. pneumoniae is complement, and patients with 
complement deficiencies and animal models of infection using complement deficient 
mice show increased disease severity. The pneumococcal capsule is the main virulence 
factor of S. pneumoniae virulence however surprisingly little is known about the precise 
effect of the capsule on interactions with host immunity. Previous studies have provided 
conflicting data about the role of the capsule in preventing complement deposition on 
the bacterial cell surface. The S. pneumoniae capsule is thought to be anti-phagocytic 
and it is also unclear as to whether this is an inherent property of the polysaccharides or 
a downstream consequence of any anti-complement or antibody effect.  
 
Hence the effect of the capsule on innate immune mechanisms remains undefined. In 
addition the effect of the S. pneumoniae capsule during early lung infection. AMs are 
the  resident  specialised  phagocytic  cell  in  the  lung  and  an  important  modulator  of 
inflammatory  responses,  and  are  likely  to  be  the  first  immune  cell  encountered  by  
S. pneumoniae in the lung. The capsule may affect interactions with AMs however this 
remains unclear from existing data. Furthermore it since complement levels in BAL 
fluid are about 10% of that found in serum it is unclear as to whether complement 
mediates  an  effective  pulmonary  immune  mechanism  and  whether  the  capsule 
modulates this response in pulmonary disease.  
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As the capsule is the  current target used in vaccination against S. pneumoniae it is 
important to clarify the effect of the capsule on host immunity. There is only limited 
evidence for the efficacy of conjugate vaccines against pneumococcal pneumonia and 
innate immune responses may have a significant effect on adaptive immune responses 
to  vaccines.  Hence  any  difference  in  the  effect  of  capsule  between  different  S. 
pneumoniae serotypes on innate immune mechanisms may affect the efficacy of the 
conjugate vaccine.  
 
Different  serotypes  and  clones  of  S.  pneumoniae  have  differing  abilities  to  cause 
invasive disease but as yet no mechanism has been described which fully accounts for 
this  phenomenon.  The  ability  of  different  capsular  polysaccharides  to  affect 
complement  deposition  is  unknown  as  previous  studies  showing  differences  in 
complement  deposition  between  serotypes  have  been  confounded  by  non-capsular 
genetic variation. In addition the relative contribution of variation in capsular serotype 
and other non-capsular  pneumococcal structures to  complement mediated  immunity, 
phagocytosis and virulence remains unclear.  
 
This thesis will therefore address the following hypothesis: 
The S. pneumoniae capsule aids virulence by preventing complement dependent 
and independent interactions with phagocytes.  
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The specific aims of this thesis are to: 
(i)  Clarify the effect of the capsule on complement deposition on S. pneumoniae 
and 
investigate potential mechanisms by which the capsule can reduce complement 
activity against S. pneumoniae. 
(ii)  Characterise the effects of the capsule on interactions with PMNs, and determine 
if these are complement dependent or independent.  
(iii)  Investigate the effects of the capsule on interactions with macrophages and the 
capsule’s role in early lung infection 
(iv)   Determine if capsular serotype affects complement mediated immunity.  
(v)  Determine  if  non-capsular  genetic  variation  affects  complement  mediated 
immunity. 98 
 
CHAPTER 2  
MATERIALS AND METHODS 
 
2.1 BACTERIAL STRAINS 
 
2.1.1 Bacteria 
The  parental  (WT)  strains  of  Streptococcus  pneumoniae  and  their  respective 
unencapsulated mutants that were used in these experiments are: 
·  TIGR4: a highly virulent capsular serotype 4 isolated from the blood of a 30 
year old male patient in Kongsvinger, Norway. It was given as a gift from Prof J 
Weiser, University of Pennsylvania. 
·  TIGR4cps: TIGR4 strain containing a Janus cassette in place of the capsule gene 
locus, conferring resistance to Kanamycin (Trzcinski et al. 2003). Also given as 
a gift from Prof J Weiser, University of Pennsylvania. 
·  D39: An important, invasive serotype 2 strain
 that was used in experiments by 
Avery and co-workers to demonstrate
 that DNA is the genetic material (Paton et 
al. 1993). 
·  D39-D :  the  D39  WT  strain  with  an  insertion  duplication  mutation  using 
pVA891 in part of the capsule locus (cps  2D) (Paton et al. 1993). 
·  Serotype  3:  Strain  0100993  was  obtained  from  a  human  clinical  pneumonia 
isolate, originally from SmithKline Beecham. This strain was given as a gift 
from Dr D Holden, Imperial College. 
 
2.1.2 TIGR4 Capsular Switch Strains 
S. pneumoniae TIGR4 genetic background strains which have been genetically modified 
at the capsule gene locus but which are otherwise isogenic, were given as a gift from 99 
 
Prof  J  Weiser,  University  of  Pennsylvania.  The  TIGR4  capsule  genetic  locus  was 
replaced with a Janus cassette, and this cassette was then replaced with the capsule 
genetic  locus  from  a  different  serotype  by  researchers  in  Prof  Weiser’s  laboratory 
(Trzcinski  et  al.  2003).  Furthermore  these  strains  were  separated  into  opaque  and 
transparent phenotypes and checked regularly throughout the work of this thesis, and 
the Quelling Reaction performed to check capsular serotype. These strains are fully 
listed in Table 2.1. 
 
2.1.3 Clinical Isolate Strains 
Strains isolated from blood or cerebrospinal fluid (CSF) of children under the age of 5 
in Finland in 2002 (Hanage et al. 2005) was given as gifts from Dr Hanage and Dr 
Spratt.  These  strains  comprised  of  5  different  capsular  serotypes,  and  within  each 
serotype there were 4 different strains based on MLST, with some of the strains having 
a  known  invasive  potential.  These  strains  are  listed  in  full  in  Table  2.2,  and  when 
phenotyped were all found to be in opaque phase.  
 
The strains provided by Dr Henriques-Normark were isolated from patients in Sweden 
and are of different MLST backgrounds covering a range of serotypes, but all these 
strains were of a known invasive potential, and are listed in Table 2.3.   
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Table  2.1  TIGR4  and  D39  background  strains,  provided  by  Prof  Jeffrey  Weiser, 
University of Pennsylvania, USA or Prof James Paton, University of Adelaide.  
 
 
Name    Background  Capsule Serotype  Phase    Antibiotic 
             Strain         Variation  Resistance 
_____________________________________________________________________ 
 
TIGR4   TIGR4   Serotype 4 (WT)  -    Streptomycin-R 
TIGR4cps  TIGR4   Unencapsulated  -    Streptomycin-S 
                  Kanamycin-R 
D39    D39    Serotype 2 (WT)  -    - 
D39-D   D39    Unencapsulated  -    Erythromycin-R 
_____________________________________________________________________ 
P1637   TIGR4   Serotype 6A    Opaque  Streptomycin-R 
P1638   TIGR4   Serotype 6A    Transparent  Streptomycin-R 
P1688   TIGR4   Serotype 7F    Opaque  Streptomycin-R 
P1689   TIGR4   Serotype 7F    Transparent  Streptomycin-R 
P1691   TIGR4   Serotype 23F    Opaque  Streptomycin-R 
P1692   TIGR4   Serotype 23F    Transparent  Streptomycin-R 
P1702   TIGR4   Serotype 4    Opaque  Streptomycin-R 
P1701   TIGR4   Serotype 4    Transparent  Streptomycin-R 
_____________________________________________________________________ 
 
 
-R, Resistant 
-S, Sensitive 
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Table 2.2 Clinical isolate strains taken from blood and CSF of children under 5 years 
old  in  Finland  2002  MLST  performed  by  Dr  William  Hanage,  Imperial  College, 
London. 
 
 
Serotype  Strain    Strain Name    Lab Name  Odds Ratio for 
 Type                Invasiveness 
 
 
   4    205    M127      M127      - 
   4    259    M313      M313      -
______________________________________________________________________ 
  6A        518    IOKOR801-2      6Aa        - 
  6A        490    IOKOR1373-9    6Ab        - 
  6A      488    IOKOR1277-3    6Ac      0.48 
  6A      1068    IO13048      6Ad        - 
_____________________________________________________________________ 
  6B      138    M7-6B       6Ba      2.45 
  6B      273    JJ270-6B      6Bb        - 
  6B       90    M225-6B      6Bc        - 
  6B       176    M49-6B      6Bd      0.97 
_____________________________________________________________________ 
  14      124    M117-14      14a      2.57 
  14      162    M65-14      14b      1.37 
  14      156    M134-14      14c      10.1 
  14      307    PJ581/14      14d        - 
_____________________________________________________________________ 
  23F      36    OXC-1417-23F    23Fa      0.67 
  23F      515    IOKOR706-5      23Fb       -   
  23F      37    IOPR1592      23Fc      0.48 
  23F      277    JJ279-23      23Fd       -  
_____________________________________________________________________ 
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Table  2.3  Clinical  isolate  S.  pneumoniae  strains  given  by  Dr  Birgitta  Henriques-
Normark. MLST performed in Karolinska Institute, Sweden.  
 
 
 
Serotype  Strain Type (ST)  BHN Number       Odds Ratio for 
                       Invasiveness 
   
  1      306    BHN 30      9.6 
  1      228    BHN 32      9.6 
  1      217    BHN 166      9.6 
  4      1222    BHN 42      12.1 
  4      205    BHN 43      12.1 
 6B       138    BHN 49      0.6 
 6B      176    BHN 50      0.6 
 9V      162    BHN 62      1.5 
 9V      162    BHN 63      1.5 
 9V      156    BHN 69      1.5 
 14      124    BHN 84      4.4 
 19F      425    BHN 97      0.6 
 19F      162    BHN 100      0.6 
 19F      236    BHN 388      0.6 
 19F      556    BHN 95      0.6 
_____________________________________________________________________ 
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2.2 MEDIA AND GROWTH CONDITIONS 
 
2.2.1 Bacterial Culture 
Bacteria were cultured at 37 °C in 5% CO2 on 5% blood Columbia agar (Oxoid) plates, 
made using defibrinated horse blood (TCS Biosciences). Working stocks were made by 
transferring  one  colony  of  S.  pneumoniae  to  Todd-Hewitt  broth  (Oxoid)  with  0.5% 
yeast extract (Oxoid) (THY) and grown to an optical density (OD) between 0.3 and 0.4 
(corresponding to a colony forming unit count of 10
8 CFU/ml). 10% glycerol was added 
and bacteria were stored in single use aliquots at -80 °C. The exact numbers of bacterial 
cell  per  ml  was  determined  by  plating  tenfold  serial  dilutions  of  an  aliquot  onto 
Columbia blood agar, culturing overnight and counting the number of colonies to give a 
value for the colony forming units (CFU) per ml.  
 
2.2.2 Synthetic Medium 
Cden  medium  was  used  for  growth  of  S.  pneumoniae  in  conditions  which  required 
synthetic medium (Tomasz et al. 1964) (a full recipe is listed in Appendix I).  
 
2.2.3 Growth Curves 
2 x 10
7 CFU S. pneumoniae were inoculated into 6mls of THY Broth and incubated at 
37°C for 2 hours. Under sterile conditions, 1ml of culture broth was transferred into a 
sterile  cuvette  in  triplicate  for  each  strain  tested.  The  OD  was  then  measured  in  a 
spectrophotometer at 580nm every hour to produce a growth curve in medium. 
 
For growth in blood or serum, 50mls of blood was taken from a human volunteer and 
15ml was heparinised and the remaining 35mls used to produce serum. 2 x 10
6 CFU S. 
pneumoniae were inoculated into 1ml of blood or serum and then incubated at 37°C for 104 
 
4, 6 or 8 hours. At each time point, serial dilutions were made and plated onto blood 
agar plates which were incubated overnight at 37°C to allow a calculation of the CFU 
bacteria per ml of blood or serum for each strain tested. 
 
2.2.4 Opaque and Transparent Phenotyping 
Broth cultures of S. pneumoniae were streaked onto Tryptone Soy (Oxoid) plates onto 
which 5000 units of bovine catalase (Sigma) had been spread. Cultures were grown 
overnight in a 5% CO2 incubator, after which colony morphology was assessed under 
transmitted illumination and magnification as previously described (Weiser et al. 2001). 
 
2.2.5 FAM-SE Labelling  
S. pneumoniae was cultured overnight on 5% blood Columbia agar at 37°C in 5% CO2. 
A  single  loop  of  this  culture  was  inoculated  into  0.5%  THY  and  grown  to  an  OD 
between  0.7  and  0.8  (a  mid  log  phase  OD600).  15ml  bacteria  were  harvested  by 
centrifugation and washed once with 5ml 0.1M sterile NaHCO3, resuspended in 1ml 
bicarbonate buffer and 50 l FAM-SE solution (Cambridge Bioscience) (10mg/ml in 
DMSO) and incubated for 1 hour at 37 °C in 5% CO2 without shaking. The cells were 
then  washed  6  times  in  opsonophagocytosis  buffer  (Hanks  balanced  salt  solution 
(HBSS) (GIBCO) o with 0.2% bovine serum albumin), until no free dye could be seen 
in the supernatant. Aliquots of FAM-SE labelled cells were made, 10% glycerol was 
added and the bacteria stored at -80 °C, protected from light.  
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2.3 SERUM AND ANIMALS 
 
2.3.1 Serum Collection 
Human serum was obtained from healthy volunteers, pooled and stored at -70 °C as 
single use aliquots. Before use human serum was thawed on ice and diluted using PBS 
[137mM  NaCl,  2.7mM KCL, 8.1mM Na2HPO4, 1.5mMKH2PO4, pH 7.2-7.4] to the 
required concentration. Mouse blood was obtained by terminal cardiac puncture, clotted 
to  produce  serum  and  stored  in  the  same  manner  as  human  serum.    Furthermore, 
commercially obtained serum was purchased which had been depleted of either C1q, 
factor B, C9 or C3 (Calbiochem). This serum was also thawed on ice, divided into 
single use aliquots and stored at -70°C.  
 
2.3.2 Complement Inactivated Serum 
Serum was treated at 65°C for 20 minutes to inactivate complement but retain antibody 
activity. The complement activity of the serum was measured using the method listed 
below in 2.3.3 and the antibody activity confirmed by ELISA for capsular specific IgG 
and IgM (data not shown). 
 
2.3.3 Complement Activity 
The activity of the classical and alternative complement pathways sera was assessed 
using  complement  activity  kits  (The  Binding  Site).  Briefly,  following  the 
manufacturer’s instructions, calibrators and controls were resuspended, diluted and 5µl 
of each added to appropriate wells along with samples. The plate was left overnight at 
4°C and then incubated at 37°C  for 2 hours. The lysis zone around  each well was 
measured using a x10 magnifier with graticule (Agar Scientific) and activity of each 106 
 
sample was calculated from the resulting calibration curve (see Fig 2.1) (Yuste et al. 
2008).  
 
2.3.4 Capsule Serotype Specific Antibody Measurement  
IgG and IgM levels were ascertained in serum using the WHO protocol (Wernette et al. 
2003).  96  well  flat-bottomed  plates  were  plated  overnight  with  dilutions  of  capsule 
polysaccharide  extracts  and  washed  with  TBS  [20mM  Tris,  150mM  NaCl,  pH  7.6] 
Tween 0.1%. 89-SF serum was used as a reference serum and diluted in buffer with cell 
wall polysaccharide (CWPS) and serum samples were diluted in buffer with CWPS and 
22F  polysaccharide  (to  avoid  non-specific  binding).  Following  incubation  for  30 
minutes  at  room  temperature,  50µl  serum  dilutions  were  added  to  each  well  and 
followed by a 2 hour incubation at room temperature. Plates were washed with TBS 
Tween 0.1% and 100µl 1:20,000 anti-human IgG or IgM (Sigma) was added per well.  
This was allowed to incubate for 2 hours at room temperature, plates were washed again 
and then 100 l 1mg/ml p-Nitrophenyl Phosphate (pNNP) in 1M DEA/0.5mM MgCl2 
was added to each well. Plates were transferred to the dark and the substrate allowed to 
develop until approximately OD 1.0. Plates were read using a reader at 450nm and 
620nm signals and the final optical density calculated by subtracting the blank well 
readings from each signal and then subtracting  the 450nm reading from the 620nm 
reading.  
 
2.3.5 Serum IgG depletion using IdeS 
IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) is a cysteine 
proteinase which cleaves IgG with a unique degree of specificity in the hinge region 
(von Pawel 2002, Wenig 2004). Purified IdeS was given as a kind gift from Dr Lars 
Björck. 1% IdeS or BSA (as a negative control) was incubated with 25% human serum  107 
 
 
 
  Serum    Alternative Pathway     Classical Pathway  
          Activity        Activity   
 
 Normal           -          100% 
 Heat Treated          0%            0% 
 C1q Depleted        85%           0% 
 C1q Depleted + C1q       86%         100% 
 Factor B Depleted        0%          100% 
_____________________________________________________________________ 
  
Fig 2.1 Complement activity of serum used in this thesis 
(A) Alternative complement activity in control wells (1-4), heat treated serum (5, 6), 
C1q depleted serum (9, 10), C1q depleted serum with C1q protein added (11, 12) and 
Factor B depleted serum (13, 14). (B) Classical pathway complement activity in control 
wells (1-4), normal serum (5, 6) heat treated serum (7, 8), C1q depleted serum (9, 10), 
C1q depleted serum with C1q protein added (11, 12) and Factor B depleted serum (13, 
14). (C). Final percentage complement pathway activity of different sera tested. 
A 
B 
C 
 1           2            3            4            5            6 
 1            2            3            4            5            6 
 9           10          11         12          13         14 
 9           10          11         12          13         14 
 7                                                                      8 
 7                                                                      8 108 
 
for 45 minutes at 37°C to cleave the heavy chains of IgG. This serum was then used in 
complement and IgG binding assays as well as opsonophagocytosis assays. 
 
2.3.6 Animals 
CD1  mice  were  purchased  from  Charles  River  and  used  in  pneumonia  model 
experiments. WT, C1qa
-/-, Bf
-/- and C3
+/- C57BL/6 mice were obtained from Marina 
Botto (Imperial College). All mice were sex matched in  experiments and used at 6 
weeks of age. 
 
2.4 ANTIBODIES  
 
Antibodies  used  in  the  work  presented  in  this  thesis  were  used  under  optimised 
conditions for temperature, duration of incubation and antibody dilution. A variety of 
primary antibodies directly conjugated were utilised, as well as unconjugated primary 
antibodies which required a conjugated secondary antibody. A full list of antibodies 
used for this thesis is detailed in table 2.4 and 2.5. 
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Table 2.4 Antibodies used in the complement factor work in this thesis 
Target           Monoclonal/            Host        Conjugation  Company  Dilution   Incubation  
         Polyclonal          Species                Duration 
 
 
Human Complement C3     Polyclonal      Goat    FITC     Cappel  1:300    30 mins 
Human Complement C3     Polyclonal    Goat    HRP            MP Biomed  1:4000   1 hour 
Human Complement C1q     Polyclonal     Goat    FITC            Calbiochem  1:300    30 mins 
Human IgG (γ chain specific)   Monoclonal    Goat    PE      Sigma  1:300    40 mins 
Human IgM (  chain specific)  Monoclonal    Goat    FITC      Sigma  1:300    40 mins 
Murine IgM (µ chain specific)  Monoclonal    Goat    PE      Sigma  1:300    30 mins   
_______________________________________________________________________________________________________________ 
 
Human Factor H         Polyclonal       Goat    -    Calbiochem  1:300    40 mins 
Human Serum Amylase Protein   Polyclonal    Rabbit          -    Calbiochem  1:300    40 mins 
Human C-Reactive Protein       Polyclonal    Rabbit   -    Calbiochem  1:300    40 mins 
_______________________________________________________________________________________________________________ 
 
Goat/Sheep IgG       Monoclonal    Donkey  FITC    Serotec  1:300    30 mins 
Rabbit IgG        Monoclonal     Goat    FITC      Sigma  1:300    40 mins 
Goat IgG         Polyclonal    Rabbit        Immunogold          BB Int  1:200    3 hours 
_______________________________________________________________________________________________________________ 110 
 
Table 2.5 Antibodies, stains and toxins used in macrophage cell work in this thesis 
Target                  Monoclonal/            Host        Conjugation       Company          Dilution   Incubation  
                  Polyclonal          Species                Duration 
 
 
Murine F4/80        Monoclonal    Rat    PE        Bioreactives   1:100    1 hour    
_______________________________________________________________________________________________________________ 
 
Human/Mouse NFκB RelA (p65)  Polyclonal    Rabbit          -         Santa Cruz   1:100    Overnight (4°C) 
IκB-α          Monoclonal    Rabbit   -               NEB     1:3000   Overnight (4°C)              
phosphorylated
 p38 MAPK             Monoclonal    Rabbit   -               NEB     1:3000   Overnight (4°C)              
phosphorylated ERK1/2    Monoclonal    Rabbit   -               NEB     1:3000   Overnight (4°C)              
β-actin         Monoclonal    Mouse   -    Abcam   1:5000   Overnight (4°C)             
_______________________________________________________________________________________________________________ 
 
Rabbit IgG        Monoclonal    Goat    AF-633         Invitrogen  1:500    1 hour 
Rabbit IgG        Polyclonal    Pig         HRP         Santa Cruz   1:3000   1 hour 
Mouse IgG        Polyclonal    Rabbit   HRP            Abcam    1:3000   1 hour 
_______________________________________________________________________________________________________________ 
     
DAPI              -                             -          Invitrogen  1 g/ml   5 mins 
_______________________________________________________________________________________________________________ 
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2.5 CELLS 
 
2.5.1 RAW 264.7 Cell Culture 
RAW  264.7  (ATCC)  cells  are  derived  from  a  murine  macrophage  leukaemia  cell  line. 
Propagation of cells was conducted in T75 or T175 Nunc flasks at 37
οC, 5% carbon dioxide 
using RPMI 1640 (Invitrogen) with 10% FBS supplement as medium until cells formed a 
confluent layer. Cells were washed with HBSS without calcium and magnesium, and then 
trypsinised  using  with  0.025%  trypsin  with  EDTA  solution  (BioWhittaker).  Cells  were 
viewed under microscope and agitated until the majority of cells were dislodged. An equal 
volume of media was added to neutralise the trypsin, and the suspension was then washed 
using HBSS without calcium and magnesium. The pellet was resuspended in 5mls and 2 x 
10
5 cells/ml, passaged into a T75 Nunc flask and incubated as above. 
 
2.5.2 Neutrophil Extraction from Human Volunteers 
Neutrophils  were  extracted  from  blood  donations  from  human  volunteers  (Segal  et  al. 
1980). 100mls of freshly collected blood was heparinised (300U/50mls) and floated onto 
Lymphoprep (Axis Shield), followed by centrifugation at 2,000 rpm for 30 mins without 
brakes to ensure separation into three distinct layers: the upper PBMC layer, a middle layer 
containing remaining Lymphoprep and neutrophils and the lower sedimented erythrocytes. 
The monocyte interface was removed and the middle and lower layer pooled to create a 
final volume of 40mls. 10mls of 10% Dextran (MW 200,000-300,000) (MP Biomedical) in 
normal saline was added and sedimentation of erythrocytes was allowed to occur for an 
hour by leaving undisturbed at room temperature. The upper neutrophil containing band 
was extracted into a fresh container, centrifuged at 2,000 rpm for 10 minutes and remaining 112 
 
erythrocytes were removed by hypotonic lysis. Neutrophils were counted and assessed for 
viability using Trypan Blue exclusion and used within 4 hours. In addition 100µl of the cell 
preparation was diluted 1:100 with PBS, cytospun, stained using Diff-quick (Merck) and 
400 cells morphologically assessed under microscopy. Neutrophil extractions were found to 
be over 95% pure using this method. 
 
2.6 CAPSULE POLYSACCHARIDE METHODS 
 
2.6.1 All-Stains Assay for Acidic Polysaccharides 
S. pneumoniae strains were grown overnight on 5% blood Columbia agar plates, inoculated 
into 15mls Cden medium and grown to OD 0.4. Following 10 mins centrifugation at 4,800 
rpm  bacteria  were  resuspended  in  500µl  ddH20  and  1ml  chloroform  was  added.  After 
shaking, 400µl of the aqueous layer was added to 2mls All Stains Solution [10mg All 
Stains  (Sigma)  in  50mls  50%  formamid  and  30µl  acetic  acid].  The  optical  density  of 
samples was measured at a wavelength of 640nm, with various strains being processed in 
triplicate separately for analysis. 
 
2.6.2 The Quellung Reaction 
S. pneumoniae strains were grown overnight on blood agar plates 37 °C in 5% CO2 on 5% 
blood Columbia agar. One loop of each bacterial strain was inoculated into 15mls THY 
Broth and grown at 37°C in 5% CO2 until mid-log phase (OD 0.4). One loop of bacterial 
culture solution was spread on a glass slide; one loop of capsular type specific rabbit anti-
serum (Staten’s Serum Institute) was mixed and allowed to react for 1 minute. A further 113 
 
loop of filter sterilised India ink (Winsor and Newton) was added to the mixture, which was 
placed under a cover-slip and viewed under oil immersion x100 magnification. 
 
2.7 COMPLEMENT FACTOR AND MEDIATORS METHODS 
 
2.7.1 Complement Factor Binding Assays 
5 x 10
6 S. pneumoniae bacteria were added to each eppendorf, centrifuged at 13,000 rpm 
for 5 minutes and supernatant aspirated without disturbing the pellet. 10 l PBS, or 25% 
human serum, was added to each pellet and incubated at 37°C for 20 minutes. Samples 
were  then  washed  twice  using  0.1%  PBS  Tween-20  and  50 l  of  appropriate  primary 
antibody added (at a dilution of 1:300 with 0.1% PBS Tween). An incubation of 30 minutes 
on ice was followed by a further two washes with 0.1% PBS Tween-20. Samples were then 
fixed  with  100µl  3%  PFA  and  200µl  PBS  if  a  directly  conjugated  antibody  was  used 
initially. Samples requiring a secondary antibody were instead subjected to a 30 minute 
incubation on ice with 50µl conjugated secondary antibody (also at a 1:300 dilution in 0.1% 
PBS Tween-20), followed by the same washing and fixation process. Samples were then 
analysed by flow cytometry using FacsCalibur, selecting 25,000 cells for analysis.  
 
2.7.2 Antibody (IgG and IgM) Binding Assays 
Total IgG and IgM binding to S. pneumoniae was assessed by adapting the protocol for 
complement binding assays detailed above. An antibody mixture comprised of 1:300 goat 
anti-human  IgM  FITC  conjugated  and  1:300  goat  anti-human  IgG  phycoerythrin 
conjugated in PBS Tween 0.1% was incubated on ice for 30 minutes, with positive controls 
stained singly with each antibody. Analysis by flow cytometry included using the singly 114 
 
probed IgM and IgG bacteria to ensure that there was no bleeding through of either signal 
on the double probed samples. 
 
 
2.7.3 Immunoblot for Complement Component 3 
S. pneumoniae strains were serially diluted from 1 x 10
8 to 1 x 10
6 CFU, and to each 
bacterial  dilution  100µl  10%  human  serum  was  added.  Bacteria  were  incubated  for  20 
minutes  at  37°C,  centrifuged  for  15  mins  at  13,000  rpm  and  the  supernatant  carefully 
transferred to a clean eppendorf. The supernatant was then diluted 1:10 with PBS (giving a 
final serum dilution of 1%) and 50µl of this solution was added to 10µl laemelli buffer 
[3.125mM TRIS HCl, pH 6.8, 10% SDS, 20% Glycerol, 50nM DTT, bromophenol blue, 
4.375ml H2O] and incubated for 5 mins at 100°C. 15µl of each sample was loaded onto a 
12% acrylamide gel in running buffer [0.25M TRIS Base, 1.92M Glycine, 1% SDS] and 
run at 100V to separate proteins. Protein bands were then transferred onto a nitro cellulose 
membrane  for  1  hour  at  20V  using  transfer  buffer  [50mM  Tris,  150mM  NaCl,  0.1% 
Tween-20, pH 7.4] and the membrane blocked overnight with TBS-Tween and 5% milk. 
Following 3 washes with TBS-Tween, membranes were probed for 1 hour with agitation 
using 1:4000 anti-human C3 antibody conjugated with HRP in a final volume of 5mls TBS-
Tween 5% milk. After a further 3 washes with TBS-Tween the membrane was developed 
with ECL Reagent (Amersham) and exposed onto photographic film (Kodak) for between 1 
and 10 minutes. 
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2.8 ELECTRON MICROSCOPY METHODS 
 
2.8.1 Section Preparation 
S.  pneumoniae  strains  were  grown  overnight  on  10%  blood  Columbia  agar  plates, 
inoculated into 30mls THY medium and grown to OD 0.4. Cultures were equally divided in 
two, and centrifuged at 4,800 rpm for 15 minutes. Pellets were resuspended in 2mls of PBS 
or 20% human serum and incubated for 30mins at 37°C. Samples were washed twice in 
PBS and fixed with 1ml 1% PFA for 1 hour at 4°C. The samples were then pelleted again 
and resuspended in 1.5% low gelling temp agarose (Sigma) in 0.1M phosphate buffer and 
left  overnight  at  room  temperature.  The  agarose  plugs  were  cut  into  1mm
2  blocks  and 
incubated in a solution of 2% formaldehyde (Sigma), 2.5% glutaldehyde (Sigma), 0.075% 
ruthenium  red  (Agar  Sci),  0.075M  lysine  acetate  (Sigma)  in  cacodylate  buffer  [0.1M 
cacodylate trihydrate, pH 7.4, 3% sucrose, 0.1% CaCl] on ice for 20 minutes. Samples were 
washed  twice  with  0.075%  Ruthenium  Red  in  cacodylate  buffer  and  incubated  in  2% 
formaldehyde, 2.5% glutaldehyde, 0.075% ruthenium red in cacodylate buffer for 3 hours 
on ice. Following a further two washes samples were fixed with 1% osmium in cacodylate 
buffer containing 0.075% ruthenium red for 1 hour on ice. Samples were washed several 
times  with  cacodylate  buffer  0.075%  ruthenium  red  and  then  dehydrated  using  ethanol 
(Sigma) (10%, 20%, 50%, 70%, 90%, 100%) for 30 minutes at each concentration in the 
series on ice. Dehydrated blocks were then incubated in a solution of 1 part LR White 
Resin (Agar Sci) to 1 part ethanol for 2 hours on ice, and then overnight in 2 parts LR 
White to 1 part ethanol. Samples were incubated in 100% LR White Resin for 3 days at 
4°C with the resin changed every 12 hours. Finally blocks were baked in gelatin capsules in 116 
 
LR White Resin at 65°C for 24 hours, cut into very fine sections and mounted on copper or 
nickel grids.  
 
2.8.2 Capsule Thickness Measurement 
Sections were stained with 1% uranyl acetate for 3 minutes, washed 10 times in distilled 
water  and  then  stained  with  lead  citrate  [0.19M,  Reynold’s  Lead  Citrate  Stain]  for  3 
minutes and again washed 10 times in distilled water. Following air drying sections were 
viewed using a Jeol 1010 transmission electron microscope (100kV). Images were obtained 
for at least 10 randomly chosen bacteria for each strain investigated and analysed using 
Image  J  software  (http://rsb.info.nih.gov/ij).  The  cross-sectional  area  of  the  whole 
bacterium including and excluding the capsule were obtained and, by assuming circularity, 
used to calculate the bacterial radius with or without the capsule and hence the average 
width of the capsule layer. Data is expressed as a mean value for each strain investigated. 
 
2.8.3 C3b/iC3b Immunogold Staining 
Sections  were  inverted  onto  50 l  10%  rabbit  serum  (Sigma)  and  incubated  at  room 
temperature for 30 minutes. The sections were then washed twice with PBS and inverted 
onto either 1/100 goat anti human C3 in PBS or PBS alone overnight at 4°C. Sections were 
washed 5 times in PBS and then inverted onto 50 l immunogold conjugated rabbit anti-
goat IgG for 3 hours at room temperature. Finally grids were washed 3 times in PBS, 5 
times in distilled water and air dryed. Sections were stained with lead nitrate as in section 
2.8.2 and visualised using a Jeol 1010 transmission electron microscope (100kV). Data was 
obtained for at least 10 randomly chosen bacteria for each strain investigated and expressed 
as medians with IQRs. 117 
 
2.9 IN VITRO CELLULAR METHODS 
 
2.9.1 Neutrophil Opsonophagocytosis Assay 
Human serum was diluted in Hanks Buffered Salt Solution (HBSS) with divalent cations 
and 10 l added per well in a 96 well plate. HBSS with divalent cations and heat-treated 
serum were used as controls. Bacteria were diluted in HBSS with divalent cations (GIBCO) 
to  optimised  multiplicity  of  infections  (MOI),  with  10 l  of  FAM-SE  labelled  S. 
pneumoniae  added  per  well  and  incubated  for  30  mins  at  37°C  and  150  rpm.  PMNs 
extracted from human volunteers were washed once in HBSS without divalent cations and 
once in HBSS with divalent cations whereas neutrophils extracted from human blood were 
washed  in  HBSS  with  divalent  cations.  Neutrophils  were  counted  using  Trypan  Blue 
exclusion, and 5 x 10
5 cells added per well. The opsonised S. pneumoniae were incubated 
with neutrophils for 30 mins, 37°C, 150rpm and the cells fixed with 50 l 3% PFA. Cells 
were analysed for fluorescence using flow cytometry (FacsCalibur), selecting 15,000 cells 
for analysis. For experiments using cytochalasin D, neutrophils were incubated with 1 M 
cytochalasin D (Sigma) for 30 mins at room temperature before incubation with FAM-SE 
bacteria. Trypan blue quenching was performed by adding 1mg/ml Trypan Blue (Sigma) 
before samples were analysed by flow cytometry.  
 
 
2.9.2 RAW 264.7 Cell Opsonophagocytosis Assay 
RAW 264.7 cells were trypsinised, counted and adjusted to a concentration of 5 x 10
5 
cells/ml. 400µl of the cell suspension was added to each well of 24 well plates and allowed 
to adhere for 1 hour. FAM-SE labelled S. pneumoniae were incubated for 30’ at 37°C in 118 
 
PBS, 20% HK Serum or 20 % normal serum, washed and resuspended in RAW 264.7 
culture medium. Culture wells were aspirated and 400 l of 5 x 10
6 opsonised bacteria was 
added to each well, giving an MOI of 10 bacteria per RAW 264.7 cell. RAW 264.7 cells 
were incubated at 37°C with 5% CO2 for 15 minutes, 1 hour, and 2 hours or 4 hours, after 
which  time  the  supernatant  was  removed.  Wells  were  washed  three  times  with  HBSS 
without divalent cations (GIBCO). Cells were trypsinised using 300 l 0.025% trypsin with 
EDTA solution (BioWhittaker) and 50 l FBS added to each well to neutralise the trypsin. 
Finally  150 l  3%  PFA  was  added  to  each  well  and  samples  were  analysed  by  flow 
cytometry using FacsCalibur (Becton Dickinson).  
 
 
2.9.3 TNFα Time Course 
2 x 10
5 RAW 264.7 cells were seeded into each well of 24 well plates (Nunc) and allowed 
to adhere for 1 hour. FAM-SE labelled S. pneumoniae were incubated for 30 minutes at 
37°C in PBS, 20% HK Serum or 20 % normal serum, washed and resuspended in RAW 
264.7  culture  medium.  Wells  were  aspirated;  400 l  of  culture  medium  containing 
opsonised bacteria was added to each well, giving an MOI of 10 bacteria per RAW 264.7 
cell. 1ng/ml LPS (lipopolysaccharide) (InvivoGen) was used as a positive control. Cells 
were  incubated  at  37°C  with  5%  CO2  for  3,  6,  and  12  or  24  hours,  after  which  the 
supernatant was aspirated, centrifuged at 13,000 rpm for 15 minutes to remove bacteria in 
suspension and stored at -20°C until processing. Samples were analysed using the TNFα 
ELISA outlined in 2.11.1.  
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2.9.4 NFkB Translocation Assay 
RAW 264.7 cells were trypsinised, counted and adjusted to a concentration of 5 x 10
5 
cells/ml. 400µl of the cell suspension was added to each well of 24 well plate (Nunc) 
containing  a pre-sterilised, 13mm diameter  glass cover-slip (Invitrogen) and allowed to 
adhere for 3 hours. Dilutions of S. pneumoniae were made in RAW 264.7 culture medium 
with 25% human serum added to ensure MOI of 1, 10 and 100. These were incubated for 
30 minutes at 37°C, centrifuged at 13,000 rpm for 10 mins and resuspended in the original 
volume of culture medium. 400 l opsonised S. pneumoniae or 1ng/ml Ultrapure LPS from 
Escherichia coli O111:B4 (InvivoGen) were added to aspirated RAW 264.7 cell wells and 
incubated at 37°C for 1 hour. Following the incubation, the supernatant was aspirated; the 
cover-slips were covered with 3% PFA and left for 15 mins in the dark, washed three times 
with  HBSS  with  divalent  cations  (Invitrogen)  and  resuspended  in  400µl  HBSS  with 
divalent cations and stored at 4°C in the dark until staining. 
 
Cover-slips were stained by floating face down on 50 l of solution at room temperature 
with the following method, unless otherwise stated, and washed 3 times in TBS between 
staining solutions. Cover-slips were washed three times in TBS followed by 50 l 0.2% 
Triton-X100 (Sigma) for 10 minutes. This was followed by a 30 minute block using 10% 
goat  serum  (Sigma)  and  then  1:100  Rabbit  anti-NFκB  antibody  in  10%  goat  serum 
overnight  at  4°C.  Cover-slips  were  then  floated  face  down  on  1:500  Alexa  Fluor  633 
conjugated goat anti-rabbit IgG in 10% goat serum for 1 hour. Cover-slips were mounted 
using Vectashield containing DAPI (Vector Labs) and analysed using confocal microscopy. 
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2.9.5 Confocal Microscopy Image Acquisition 
Images were acquired using a Leica SP2 confocal microscope, with 5 frames taken for each 
stain analysis. Each fluorochrome was captured using a sequential acquisition with a pin 
hole of 1 Airy, scan speed of 400Hz and 4 frame averaging used. Fluorochromes used were 
DAPI (excitation 405 nm, emission 400–450
 nm), AF555 (excitation 543 nm, emission 
560–580 nm), AF633 (excitation 633 nm, emission 650–700 nm), FITC (excitation 488nm, 
emission 515-545nm) and PE (excitation 488nm, emission 560-580nm). A sub-saturating 
fluorescence  intensity  with  optimal  signal  to  noise  ratio  was  achieved  by  adjusting  the 
photomultiplier tube offset and gain.  Each field was selected based on identification of a 
near confluent cell layer by identifying nuclear (DAPI) staining (Noursadeghi et al. 2008) . 
 
Image
  analysis  was  performed  with  Metamorph  v7.17  (Molecular  Devices)
  to  quantify 
nuclear:cytoplasmic  ratios  NF-κB  RelA  staining  and
  proportion  of  cells  demonstrating 
positive co-localization of
 DAPI/RelA (AF655) staining (correlation coefficient >0.5)
 as 
markers of NF-κB nuclear translocation (Noursadeghi et al. 2009).  
 
2.9.6 Innate Activation Westerns 
1 x 10
6 RAW 264.7 cells were added to each well of 6 well plate (Nunc) and allowed to 
adhere for 1hr at 37°C. Dilutions of S. pneumoniae were made in RAW 264.7 culture 
medium with 25% human serum added to ensure MOI of 10, incubated for 30 minutes at 
37°C, centrifuged at 13,000 rpm for 10 mins and resuspended in the original volume of 
culture medium. 400 l opsonised S. pneumoniae or 1ng/ml LPS were added to aspirated 
RAW 264.7 cell wells and incubated at 37°C for 15, 30, 60 or 120 minutes. Supernatant 
was aspirated and cell lysates were collected in into
 SDS sample buffer [62.5 mM Tris-HCl 121 
 
(pH 6.8), 10% glycerol,
 2% SDS, 0.01% bromphenol blue, and 5% 2-ME], sonicated, and
 
heated (100°C for 5 min) before PAGE (4–12% gradient
 gels) and transfer onto Amersham 
Hi-bond membranes (GE Healthcare).
 Membranes were blocked for 1 hour in 5% milk 
powder  in  TBS  with
  0.05%  Tween  20  (Sigma-Aldrich)  and  then  immunoblotted 
sequentially
  with  primary  antibody  overnight  (4°C),  and  HRP-conjugated    secondary 
antibody
  for  1  hour  (room  temperature),  all  prepared  in  TBS/Tween  20  with
  1%  milk 
powder. Membranes were washed with TBS/Tween-20 after
 each step. Immunostains were 
developed  with  Amersham  ECL  reagent
  (GE  Healthcare)  and  visualized  on  Amersham 
Hyperfilm ECL (GE
 Healthcare), according to manufacturer’s instructions. Antibodies used 
in these westerns are listed in Table 2.5. 
 
2.10 IN VIVO METHODS 
 
2.10.1 Pneumonia Infection Model 
5 x 10
5 colony forming units of FAM-SE labelled S. pneumoniae in filtered sterilised PBS 
was inoculated intranasally (IN) into mice anaesthetised using a halothane chamber. During 
inoculation the mouth was held closed to ensure that all inspiration was through the nose to 
promote optimum uptake of inoculums into the lungs. After 4 hours mice were culled with 
an overdose of pentobarbitone and the diaphragm carefully cut to allow lung expansion. 
The  neck  was  dissected  to  reveal  the  trachea  and  a  cannula  inserted  through  a  small 
opening  made  with  a  scalpel.  1ml  filter  sterilised  PBS  was  flushed  three  times  before 
collection of the bronchoalveolar lavage fluid (BALF).  
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50 l aliquots of BALF were immediately frozen at -80C and cytokine levels analysed later 
(see 2.9). BALF was also plated undiluted and at 1/10 and 1/100 dilutions on 5% blood 
Columbia agar plates with 5mg/ml gentamycin (Sigma), which were incubated overnight at 
37°C and S. pneumoniae colonies counted to determine free bacterial counts. Furthermore, 
alveolar  macrophages  were  stained  with  anti-mouse  F4/80  phycoerythrin  conjugate 
antibody  and  this  population  isolated  using  flow  cytometry  (FacsCalibur),  and  the 
association of FAM-SE stained bacteria was determined in this cell population.  
 
2.10.2 Intraperitoneal (IP) Model 
Mice were inoculated by intraperitoneal injection with 2000 CFU S. pneumoniae in a 100 l 
volume. Organs were harvested 24 hours after inoculation and blood collected by terminal 
cardiac  puncture  under  pentobarbitone  anaesthesia.  Serial  dilutions  of  either  blood  or 
splenic homogenates were plated onto blood agar to allow calculation of bacterial CFU 
within the spleen and blood of each mouse. 
 
2.10.3 Competitive Index (CI) Method 
Mixtures of the two S. pneumoniae
 strains being compared were inoculated in a 1:1 ratio, 
with the inoculum diluted and plated onto plain and antibiotic medium to determine the 
ratio of the strains using antibiotic sensitivities to discriminate between strains.  Mice were 
inoculated by intraperitoneal injection with a total of 5
 x 10
4 CFU, organs harvested (blood 
and spleen) extracted as previously described after 24 hours. Dilutions of blood and splenic 
homogenates were plated onto plain and antibiotic medium to determine the ratios of
 the 
two strains using antibiotic sensitivities. The relative
 virulence of the strains was calculated 
as a competitive index
 (CI), defined as the ratio of the test strain (unencapsulated strain) to 123 
 
the reference strain (WT encapsulated strain) recovered from the mice divided by the ratio
 
of the test strain to the reference strain in the inoculum (Brown et al. 2001).
 A CI of <1.0 
indicates that the test strain is reduced in
 virulence compared with the reference strain, with 
the lower the
 CI the greater the reduction in virulence. 
 
2.11 CYTOKINE METHODS 
 
2.11.1 TNFα ELISA 
ELISAs were performed using a murine TNFα kit (RnD Systems) Briefly ELISA plates 
were coated overnight at room temperature with 50 l 144 g/ml capture antibody (goat anti-
mouse TNFα) in PBS. Following aspiration and three washes with wash buffer [0.05% 
Tween-20 in PBS], 300 l 1% BSA in filter sterilised PBS was added to each well and 
allowed to incubate for 1 hour at room temperature. Three further washes were performed 
using wash buffer and samples were diluted to appropriate concentrations predetermined in 
pilot  experiments in  reagent  diluent  [1%  BSA  in  filter  sterilised  PBS]. 50 l  sample  or 
standard was added per well and incubated for 2 hours at room temperature. Three more 
washes  with  wash  buffer  were  performed  and  50 l  27 g/ml  detection  antibody 
(biotinylated  goat  anti-mouse  TNFα)  (in  reagent  diluents)  was  added  to  each  well, 
incubated for 2 hours and 3 further washes performed. Finally 50 l 1:200 Streptavidin-
HRP conjugated antibody was added to each well, incubated for 20 minutes in the dark at 
room temperature and the reaction stopped by adding 25 l 0.19M H2SO4. Samples were 
analysed using a plate reader at 550nm wavelength.  
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2.12 STATISTICS 
 
Statistical analysis was performed using Prism Version 4.0. Results expressed as means 
were  compared  between  strains  using  one  way  ANOVAs  with  post-hoc  tests.  Results 
presented as medians (IQRs) were compared using the Kruskal Wallis test with Dunn’s 
multiple comparison test (multiple groups) or the Mann Whitney U test (for two groups). 
Data are representative of results obtained with repeated assays with at least three replicas 
per experimental condition. 125 
 
CHAPTER 3  
ROLE OF CAPSULE IN COMPLEMENT DEPOSITION AND NEUTROPHIL 
INTERACTIONS 
 
3.1  INTRODUCTION 
Although unencapsulated S. pneumoniae strains are never isolated from invasive disease, 
clearly  outlining  the  importance  of  the  capsule  in  pneumococcal  virulence,  there  is  a 
surprising lack of detail known about exactly how the capsule assists the development of 
infection.  Previous studies have shown that that deposition of the complement opsonins 
C3b/iC3b is increased on an otherwise isogenic unencapsulated serotype 2 strain (Quin et 
al. 2007) and capsular serotype affects the site and nature of complement deposition on  
S. pneumoniae (Winkelstein 1981; Abeyta et al. 2003). The key importance of complement 
for host immunity to S. pneumoniae (Brown et al. 2002; Jonsson et al. 2005; Yuste et al. 
2005;  Yuste  et  al.  2008)  suggests  the  effects  of  the  capsule  on  complement-mediated 
immunity may be crucial for its role in virulence. However, the mechanisms by which 
complement deposition on S. pneumoniae is prevented by the capsule, which complement 
pathways  are  involved  and  the  variation  in  the  complement  deposition  pattern  on 
encapsulated  and  unencapsulated  S.  pneumoniae  strains  are  poorly  understood.  
Furthermore,  previous  data  has  shown  that  phagocytosis  of  S.  pneumoniae  is  mainly 
complement dependent (Wright et al. 1903; Brown et al. 2002; Yuste et al. 2005). Hence 
the capsule may modulate its effect on phagocytosis solely through its ability to prevent 
complement deposition or alternatively the capsule could inhibit phagocytosis receptors as 
well.  Overall,  there  are  few  data  on  which  effects  of  the  capsule  are  relevant  during 
infection,  and  the  relative  importance  during  systemic  infection  of  inhibition  of 126 
 
complement-mediated immunity to S. pneumoniae compared to other effects of the capsule 
during systemic infection remains unclear. 
 
In  this  chapter  I  have  used  unencapsulated  mutants  from  serotype  2  (D39-D )  and  4 
(TIGRcps) S. pneumoniae strains which are otherwise isogenic to the encapsulated parental 
(wild-type)  strain  to  investigate  the  effect  of  capsule  on  complement  activity  and  on 
interactions with neutrophils. In addition, using genetically modified mice I have assessed 
whether the effects of the capsule on complement pathway activity contributes towards how 
the capsule increases S. pneumoniae virulence during invasive infection. 
 127 
 
3.2 RESULTS 
3.2.1 Confirmation of capsule depletion in unencapsulated mutants 
Unencapsulated mutants from parental strains D39 (serotype 2) and TIGR4 (serotype 4)  
S.  pneumoniae  strains  were  confirmed  to  have  the  correct  mutation  and  be  otherwise 
isogenic to the encapsulated parental (wild-type) strain in the  laboratories which made the 
mutants (Trzcinski et al. 2003; Morona et al. 2004; Nelson et al. 2007).  Quellung reactions 
were performed on all strains to confirm the serotype of the parental strain and lack of 
capsule in the unencapsulated mutants (data not shown). In order to confirm the capsule 
locus  mutations  in  the  unencapsulated  D39  and  TIGR4  S.  pneumoniae  stains  caused  a 
change in expression of polysaccharide capsule, a colorimetric assay for the determination 
of  mucopolysaccharides  was  used  (Edstrom  1969).  Both  the  unencapsulated  strains  of 
TIGR4 and D39 show very low levels of staining for polysaccharides compared to their 
encapsulated  parental  strains  (Fig  3.1,  Ρ  <  0.001).  We  measured  the  thickness  of  the 
capsule  after the S. pneumoniae strains were fixed and viewed by  electron microscopy 
using  a  lysine  acetate  and  ruthenium  red  protocol  to  preserve  polysaccharides 
((Hammerschmidt et al. 2005). A serotype 3 strain was used as a positive control, since this 
serotype is known to have a relatively thick polysaccharide capsule (Hammerschmidt et al. 
2005). In confirmation of the results obtained by the colorimetric Stains-All assay (Fig 3.1) 
both  the  TIGR4cps  and  D39-D   strains  were  found  to  have  minimal  capsule 
polysaccharide  expression,  with  an  average  thickness  of  12  ±  4nm  and  24  ±  9nm 
respectively (Fig 3.2). The TIGR4 parental strain was found to have a thicker capsule (185 
± 19nm) than the D39 wild-type strain ( 104 ± 11nm).  
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Fig 3.1 Biochemical capsule assessment in TIGR4 and D39 strains 
All  Stains  Assay  semi-quantitative  assessment  of  the  amount  of  bacterium-associated 
capsule polysaccharide in serotype 3 WT, and TIGR4 and D39 encapsulated (slashed bars) 
and unencapsulated (open bars) strains (Unpaired student’s t-test * Ρ < 0.001).  
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Fig 3.2 EM capsule measurement in TIGR4 and D39 strains 
(A).  Electron  microscopy  images  (100,000X)  of  TIGR4,  TIGR4cps,  D39  and  D39-D  
strains when prepared using the LRR fixation method. (B). Capsule thickness as calculated 
by measuring the area inside the cell wall and the total bacterial area and deriving the radius 
of  the  capsule  using  area  =  Πr
2.  **  Ρ  <  0.001  (Kruskal-Wallis  with  Dunn’s  multiple 
comparison). The TIGR4 capsule is significantly thicker than the D39 (Ρ < 0.001) and both 
are thinner than that of the serotype 3 strain (Ρ < 0.001). 130 
 
3.2.2 Growth of unencapsulated mutants compared to parental strains 
Previous research has indicated that the first four capsule genes are important in growth of 
the  D39  S.  pneumoniae  strain  in  vitro  (Battig  et  al.  2007).  In  contrast  to  the  results 
published by Battig et al, there was no detectable growth deficit in our D39-D  strain 
growth in THY broth (Fig 3.3 A and B) compared to the encapsulated wild-type D39. 
There was also no growth deficit exhibited by the TIGR4cps strain in comparison to the 
wild-type  TIGR4.  In  addition  to  growth  in  culture  medium,  bacterial  growth  in 
physiological fluids was determined using human blood or serum. There was no difference 
in growth in human blood between the unencapsulated or wild-type strains in either the 
TIGR4  or  D39  background,  with  all  four  strains  growing  to  approximately  1.90  x  10
9 
cfu/ml after 8 hours (Fig 3.3 C).  Bacterial growth in serum also showed no growth deficit 
between  the  encapsulated  and  unencapsulated  strains  (Fig  3.3  D).  Since  growth  was 
determined in blood and serum from the same donors, it was possible to compare growth 
between both fluids as there is no interdonor variability. S. pneumoniae growth in serum 
was significantly greater than in human blood at both the 4 and 6 hour time point (ANOVA 
Ρ < 0.001),  perhaps reflecting the effect of immune cells in blood which were not present 
in human serum. However, all four strains grew to approximately the same level (2.08 x 10
9 
cfu/ml) after 8 hours in both blood and serum. Overall, these results indicate that there is no 
growth deficit in the unencapsulated mutant in relevant media used throughout this thesis.  131 
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Fig 3.3  Growth of parental and unencapsulated strains 
(A),  (B).  Growth  curves  of  the  TIGR4  and  D39  strains  (square  symbols  ￿)  and  the 
TIGR4cps and D39-D  (triangle symbols ￿) strains respectively in THY respectively. (C), 
(D). Bacterial growth in human blood and serum for TIGR4 WT (open bars), TIGR4cps 
(black bars), D39 WT (spotted bars) and D39-D  (slashed bars). There is no statistically 
significant difference between the unencapsulated and encapsulated strains. 132 
 
3.2.3 C3b/iC3b deposition on encapsulated and unencapsulated TIGR4 and D39 in 
human serum 
Using an established flow cytometry assay (Brown et al. 2002; Yuste et al. 2006; Yuste et 
al. 2007; Yuste et al. 2008), the deposition of C3b/iC3b on S. pneumoniae TIGR4 and D39 
encapsulated  and unencapsulated bacteria was measured in increasing  concentrations of 
human serum pooled from 3 healthy volunteers. Bacteria incubated in PBS alone were used 
to determine the background fluorescence for each S. pneumoniae strain used, and this was 
repeated in each experiment carried out throughout this thesis.  Experiments were repeated 
using two or more different stock sources for each strain to ensure consistent results. For all 
of the S. pneumoniae strains examined, there was a dose response of C3b/iC3b deposition 
in relation to human serum (Fig 3.4 and 3.5), with significantly more C3b/iC3b deposited 
on the bacteria in 100% serum than in all other serum concentrations tested. However, in 
comparison  to  the  encapsulated  wild-type  strains,  there  was  a  significant  increased  in 
C3b/iC3b deposition on both the TIGR4cps (Fig 3.4, ANOVA Ρ<0.001) and D39-D  (Fig 
3.5,  ANOVA  Ρ<0.001)  S.  pneumoniae  strains.  These  results  indicate  that  the 
polysaccharide capsule has a role in preventing complement deposition on S. pneumoniae 
and that this effect is not limited to a single capsule serotype. Interestingly, the extent to 
which the capsule in prevented complement deposition varied between the D39 and TIGR4 
strains, with a larger difference in the results of the C3b/iC3b deposition on the TIGR4 cps 
compared to the TIGR4 strain than between the D39-D  and D39 strains. This difference 
in effect may be due to the effect of capsule serotype, other genetic variation between the 
strains, or a difference in the expression of capsule polysaccharide i.e. capsule thickness 
(see Fig 3.1 and 3.2). 133 
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Fig 3.4 C3b/iC3b deposition on TIGR4 strains opsonised with human serum 
 
(A). C3b/iC3b deposition on TIGR4 (triangle symbols ￿) and TIGR4cps (square symbols 
￿ ￿ ￿ ￿) strains in different dilutions of human serum,  as measured by flow cytometry (ANOVA  
Ρ  <  0.001).  (B).  Representative  flow  cytometry  histogram  of  C3b/iC3b  deposition  on 
TIGR4 encapsulated (solid line) and TIGR4cps (dashed line) strains in 100% human serum. 
Grey represents the results for bacteria incubated in PBS alone. 134 
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Fig 3.5 C3b/iC3b deposition on D39 strains opsonised with human serum  
 
(A). C3b/iC3b deposition on D39 (triangle symbols ￿) and D39-D  (square symbols ￿ ￿ ￿ ￿) 
strains in different dilutions of human serum,  as measured by flow cytometry (ANOVA   
Ρ < 0.001). (B). Representative flow cytometry histogram of C3b/iC3b deposition on D39 
encapsulated (solid line) and D39-D  (dashed line) strains in 100% human serum. Grey 
represents the results for bacteria incubated in PBS alone. 
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In order to investigate if the increase in C3b/iC3b deposition was due to increased C3b or 
iC3b deposition on the bacterial cell surface or a combination of the two, the previous flow 
cytometry assay was repeated using an antibody specific for iC3b alone.  For both the 
TIGR4cps and the D39-D  strains there was a significantly greater proportion of iC3b 
deposited on the bacterial cell surface as a proportion of the total C3b/iC3b deposition 
compared to the relevant parental strain (Ρ < 0.01, Fig 3.6, Table 3.1), suggesting that the 
capsule specifically prevents breakdown of C3b deposited on the  S. pneumoniae surface to 
iC3b. 
 
 
Table 3.1: Relative proportion of iC3b deposited on TIGR4, TIGR4cps, D39 and D39-D  
strains, expressed as a percentage of the total FI  C3b/iC3b deposition as measured by flow 
cytometry. 
 
 
Strain   Percentage iC3b of 
total C3b/iC3b 
Standard 
Deviation 
Ρ value 
 
TIGR4 
 
25.23 
 
0.6 
 
 
TIGR4cps  44.19  10.4  < 0.01 
D39  23.98  1.1   
D39-D   31.70  2.6  < 0.01 
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Fig 3.6 C3b/iC3b and iC3b deposition on S. pneumoniae strains  
(A). C3b/iC3b (white bars) and iC3b alone (black bars) deposition on the TIGR4 and D39 
strains and the TIGR4cps and D39-D  strains in 25% human serum, as measured by flow 
cytometry  (ANOVA  Ρ  <  0.001).  (B).  Representative  flow  cytometry  histogram  of 
C3b/iC3b and iC3b deposition alone on TIGR4 encapsulated and unencapsulated strains. 137 
 
3.2.4 Immunoblot against complement component C3 in human serum incubated with 
S. pneumoniae strains 
Although the polysaccharide capsule has been shown to not prevent antibody binding to 
cell wall associated structures such as PspA and PspC (Briles et al. 1981; Lu et al. 2006; 
Khandavilli et al. 2008), it is possible that the capsule could restrict antibody access to cell 
surface bound C3b/iC3b. This effect could account for some of the reduction in C3b/iC3b 
deposition on the encapsulated strains when analyzed using flow cytometry methodology. 
To confirm that the apparent increase in C3b/iC3b was not due to an artefact created by 
greater access of anti-C3b/iC3b antibody to the bacterial cell surface in the absence of the 
capsule, an immunoblot against C3 was used to assess complement activation in serum. A 
range of doses of encapsulated wild-type or unencapsulated mutant strain were incubated in 
10% serum at 37°C for 20 minutes, before probing with an antibody that recognises C3 and 
all of its breakdown products. Serum incubated in the absence of bacteria was used as a 
control, and βC3 acts as an internal control in the immunoblot. The immunoblot showed 
that there were  greater  quantities of the C3 breakdown products iC3b  and C3d in sera 
incubated with unencapsulated bacteria for both the TIGR4 and D39 strains than in sera 
incubated with the wild-type strains (Fig 3.7). These results support the flow cytometry 
assay data and confirm that in the absence of the capsule there is greater activation of 
complement by S. pneumoniae.  
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Fig 3.7 Immunoblots for C3 in human serum incubated with S. pneumoniae 
(A),  (B)  Immunoblots  for  complement  component  3  when  10%  human  serum  was 
incubated with TIGR4 (A) and D39 (B) S. pneumoniae strains, and then further diluted to a 
final loading concentration of 1%. βC3 remains constant in serum and acts as an internal 
loading  control.  Serum  incubated  without  bacteria  was  used  as  a  negative  control. 
Densitometry results for iC3b (113K) and C3d (40K) bands for serum incubated with 1 x 
10
9 CFU S. pneumoniae are listed beneath the relevant lanes. 139 
 
3.2.5 The capsule inhibits both the classical and alternative complement pathways  
In order to determine which complement pathway was responsible for the relatively high 
level of C3b/iC3b deposition on the unencapsulated strains, the flow cytometry assays were 
repeated  using  commercial  serum  depleted  of  either  C9  (a  terminal  complement 
component), C1q (an essential classical pathway mediator) or factor B (Bf) (an essential 
alternative pathway mediator). For both the TIGR4cps (Fig 3.8) and D39-D  (Fig 3.9) 
strain removal of either classical or alternative pathway activity lead to a large decrease in 
total  C3b/iC3b  deposition  on  the  bacterial  surface,  indicating  that  CPS  protects  
S. pneumoniae against the action of both complement pathways.  
 
Further flow cytometry experiments carried out in which the S. pneumoniae strains were 
incubated  in  serum  from  C57BL/6  mice  confirmed  that  there  was  also  more  C3b/iC3b 
deposition on the TIGRcps and D39-D  strains in mouse serum (Fig 3.10 and 3.11). Since 
the mice have had no prior exposure to pneumococcus, this effect is independent of specific 
IgG  against  S.  pneumoniae  antigens.  As  expected,  there  was  negligible  C3b/iC3b 
deposition on bacteria incubated in C3
+/- C57BL/6 mouse serum, confirming the specificity 
of  the  assay  in  detecting  C3b/iC3b  deposited  on  bacteria.  As  expected,  there  was  also 
markedly reduced C3b/iC3b deposition on the bacterial surface when S. pneumoniae were 
opsonised with mouse sera obtained from mice genetically modified C1qa
-/- (lacking C1q 
and  hence  classical  pathway  activity)  or  Bf
-/-  (lacking  factor  B  and  hence  alternative 
pathway activity) C57BL/6 compared to results for serum from wild-type mice (Fig. 3.9, P 
< 0.001 ANOVA with post-hoc analysis). TIGR4cps incubated in serum from either C1qa
-/- 
or Bf
-/- C57BL/6 mice showed increased C3b/iC3b deposition compared to the parental 
TIGR4 strain. D39 S. pneumoniae showed a similar pattern of results as the TIGR4 strain 140 
 
(Fig 3.11), however in keeping with previous results there was a less marked increase in 
C3b/iC3b deposition on the D39-D  strain. 
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Fig  3.8  C3b/iC3b  binding  on  TIGR4cps  in  complement  depleted  human  serum 
(A). C3b/iC3b deposition on TIGR4cps strain when incubated in human serum depleted of 
C9 (solid bars), C1q (open bars) or factor B (slashed bars). Error bars represent SDs, * Ρ < 
0.01,  **  Ρ  <  0.001  (ANOVA  with  post-hoc  tests).  (B).  Representative  flow  cytometry 
histogram of C3b/iC3b deposition on TIGR4 unencapsulated strain in 100% human serum 
depleted of C9 (thick solid line), C1q (thin solid line) or factor B (dashed line).  141 
 
D39 -D 
A
B
F
I
 
C
3
 
D
e
p
o
s
i
t
i
o
n
25% serum             50% serum             100% serum
PBS
C9- Serum
Bf- Serum
C1q- Serum
ANOVA Ρ < 0.001
5.0x104
1.0x105
1.5x105
2.0x105
2.5x105 **
**
**
**
*
*
0
 
Fig 3.9 C3b/iC3b binding on D39-D  in complement depleted human serum 
(A). C3b/iC3b deposition on D39-D  strain when incubated in human serum depleted of 
C9 (solid bars), C1q (open bars) or factor B (slashed bars). Error bars represent SDs, * Ρ < 
0.01,  **  Ρ  <  0.001  (ANOVA  with  post-hoc  tests).  (B).  Representative  flow  cytometry 
histogram of C3b/iC3b deposition on D39 unencapsulated strain in 100% human serum 
depleted of C9 (thick solid line), C1q (thin solid line) or factor B (dashed line).   142 
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Fig 3.10 C3b/iC3b deposition on TIGR4 strains opsonised in mouse serum   
(A) C3b/iC3b deposition on TIGR4 encapsulated (open bars) and unencapsulated (solid 
bars) strains incubated in 10% serum from C57BL/6 wild-type (WT), Bf
-/-, C1qa
-/- or C3
+/- 
mice. Error bars represent SDs, * Ρ < 0.01, ** Ρ < 0.001 (ANOVA with post hoc tests). 
(B), (C), (D) Representative flow cytometry histogram of C3b/iC3b deposition on TIGR4 
strains incubated in 10% serum from C57BL/6 WT or C3
-/-  (B), C1qa
-/- (C) and Bf
-/- (D) 
mice. 
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Fig 3.11 C3b/iC3b deposition on D39 strains opsonised in mouse serum   
(A). C3b/iC3b deposition on D39 encapsulated (open bars) and D39-D  (solid bars) strains 
incubated in 10% serum from C57BL/6 wild-type (WT), Bf
-/-, C1qa
-/- or C3
+/- mice. Error 
bars  represent  SDs,  **  Ρ  <  0.001  (ANOVA  with  post  hoc  tests).  (B),  (C),  (D) 
Representative flow cytometry histogram of C3b/iC3b deposition on D39 strains incubated 
in 10% serum from  C57BL/6 WT or C3
-/-  (B), C1qa
-/- (C) and Bf
-/- (D) mice. 144 
 
3.2.6 The capsule affects binding of mediators of both the classical and alternative 
complement pathways 
Both innate and adaptive immune responses use the classical pathway to initiate C3b/iC3b 
deposition on S. pneumoniae and are activated by recognition of the bacteria by specific 
IgG, natural IgM, CRP and SAP (Szalai et al. 1996; Brown et al. 2002; Yuste et al. 2007), 
whereas  the  alternative  pathway  acts  mainly  to  amplify  C3b/iC3b  deposition  (Walport 
2001; Xu et al. 2001; Brown et al. 2002). The binding of classical pathway mediators was 
investigated using flow cytometry assays. Both the TIGR4cps and D39-D  strains showed 
increased  binding  of  the  serum  proteins  C1q  and  CRP  which  are  known  to  initiate 
complement activity, compared to the deposition of these classical complement pathway 
activators  on  encapsulated  bacteria  (Fig  3.12  A  and  C).  Additionally  there  was  also 
increased IgG and natural IgM binding on the both the TIGR4cps and the D39-D  strains 
compared to the encapsulated parental strains (Fig. 3.13 A and C, P < 0.001). Both IgG and 
IgM are able to activate the C1-complex and hence the classical complement pathway, 
suggesting  increased  classical  pathway  activation  through  both  complement  factors  and 
antibody activation. However, there was reduced binding of SAP (Fig 3.14 A), another 
protein  that  initiates  classical  pathway  activity,  to  the  unencapsulated  bacteria  for  both 
strains. Overall these results suggest that the capsule can inhibit classical pathway activity 
by preventing the binding of important classical pathway mediators to the bacterial surface. 
In addition, there was increased factor H (FH) binding on both TIGR4cps and D39-D  
compared to the parental strain, which would tend to decreased total C3 deposition on the 
bacterial surface by preventing alternative pathway activity (Fig 3.14 C). These effects of 
the capsule might be expected to decrease C3b/iC3b deposition on S. pneumoniae. 
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Fig 3.12 C1q and CRP binding to S. pneumoniae TIGR4 and D39 strains 
(A), (C) FI expressed as percentage of results obtained in encapsulated strains of C1q (A) 
and CRP (C) on unencapsulated S. pneumoniae strains when compared to deposition on 
WT  TIGR4  and  D39  in  25%  serum  as  measured  by  flow  cytometry.  Results  for 
encapsulated strains are shown as open bars and unencapsulated as closed bars. (B), (D) 
Example flow cytometry histograms of C1q (B) and CRP (D) binding to TIGR4 WT (solid 
line)  and  unencapsulated  (dashed  line)  strains  in  25%  serum.  For  all  panels  Р-values 
represent the result of unpaired t-tests.  
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Fig 3.13 IgG and natural IgM binding to S. pneumoniae TIGR4 and D39 strains 
(A), (C) FI expressed as percentage of results obtained in encapsulated strains  of IgG (A) 
and nIgM (C) in 25% human or mouse serum respectively, on unencapsulated strains when 
compared to deposition on WT TIGR4 and D39, as measured by flow cytometry. (B), (D) 
Results for encapsulated strains are shown as open bars and unencapsulated as closed bars. 
Example flow cytometry histograms of IgG (B) and nIgM (D) binding to TIGR4 WT (solid 
line) and TIGR4cps (dashed line) strains in 25% serum. For all panels Р -values represent 
unpaired t-tests.  
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Fig 3.14 SAP and FH deposition on S. pneumoniae TIGR4 and D39 strains 
(A), (C) FI expressed as percentage of results obtained in encapsulated strains of SAP (A), 
and factor H (C) on unencapsulated strains when compared to deposition on WT TIGR4 
and D39 in 25% human serum, as measured by flow cytometry. Results for encapsulated 
strains are shown as open bars and unencapsulated as closed bars. (B), (D) Example flow 
cytometry histograms of SAP (B) and factor H (D) binding to TIGR4 WT (solid line) and 
TIGR4cps (dashed line) strains in 25% serum. For all panels Р -values represent unpaired t-
tests.  148 
 
3.2.7 Immunogold EM C3b/iC3b deposition on S. pneumoniae  
Immunogold  EM  was  used  to  compare  the  distribution  of  C3b/iC3b  deposition  on 
encapsulated and unencapsulated S. pneumoniae after incubation in PBS or normal human 
serum. Bacteria incubated in PBS showed no immunogold staining with an anti C3b/iC3b 
antibody. Few gold particles were seen on the surface of the TIGR4 and D39 encapsulated 
strains which had been incubated in serum, and there were never more than 4 in close 
proximity  to  each  other  (Fig.  3.15  A  and  B).    In  contrast,  on  the  surface  of  both  the 
TIGR4cps and D39-D  strains immunogold EM for C3b/iC3b identified large numbers of 
gold particles, largely within one or more clusters containing a median of 29 (IQR 26-51) 
and 30 (IQR 15-56) gold particles for the TIGR4cps and D39-D  strains respectively (P < 
0.001, Fig. 3.15 C, D, and E).  These data support the results previously obtained with flow 
cytometry showing that in the absence of the polysaccharide capsule there is a marked 
increase  in  C3b/iC3b  deposition  on  S.  pneumoniae.  Furthermore,  the  EM  immunogold 
demonstrates this is mainly due to a focal accumulation at specific sites as opposed to a 
diffuse increase over the bacterial cell surface. 149 
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Fig 3.15 Immunogold against C3b/iC3b on TIGR4 and D39 strains 
 
(A, B, C, D). Electron microscopy images (100,000X) of TIGR4, TIGR4cps, D39 and D39-
D  strains incubated in 20% human serum and stained with immunogold against C3b/iC3b. 
(E).  Analysis  of  immunogold  particles  on  10  random  bacteria  for  TIGR4  and  D39 
encapsulated  and  unencapsulated  strains.  **  Ρ  <  0.001  (Kruskal-Wallis  with  Dunn’s 
multiple comparison).  150 
 
3.2.8 The effect of antibody on C3b/iC3b deposition 
In  order  to  characterize  the  relative  importance  of  the  increased  IgG  binding  for  the 
increased  complement  activity  against  the  unencapsulated  strains  compared  to  direct 
inhibition of complement activity, IdeS was used to cleave the Fc fragment of the IgG in 
serum. IdeS treated serum showed abrogated IgG binding to TIGR4, TIGR4cps, D39 and 
D39-D  (Fig 3.16 A, Table 3.2). Previous results had indicated that there was an increased 
C1q binding to the TIGR4cps and D39-D  strains (Fig 3.12A), which is compatible with 
the increased binding of antibody and CRP to the unencapsulated bacteria. This increase in 
C1q binding persisted when serum was treated with IdeS, showing that it was partially 
dependent on IgG (Fig 3.16 C, Table 3.2).  
 
For all strains C3b/iC3b deposition was reduced in IgG depleted or control sera (incubated 
with BSA rather than IdeS) compared to untreated sera, probably due to the breakdown of 
complement during the treatment process prior to the C3b/iC3b assays. In keeping with 
previous results, there was increased C3b/iC3b deposition on the TIGR4cps and D39-D  
strains compared to the TIGR4 and D39 strains respectively in control sera (Table 3.2). IgG 
depletion  reduced  C3b/iC3b  deposition  on  the  TIGR4cps  and  D39-D   strains, 
demonstrating that complement deposition on unencapsulated strains is partially dependent 
on IgG (Table 3.2). However, increased C3b/iC3b deposition persisted on unencapsulated 
strains compared to encapsulated strains showing the effect of the capsule has a significant 
IgG-independent component.  
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Table 3.2 Effects of IgG depletion using IdeS on mean FI +/- SDs of C3b/iC3b deposition 
and C1q binding to unencapsulated (-cps) and encapsulated (+cps) D39 and TIGR4 strains 
in  50%  human  serum.  P  values  represent  comparisons  between  the  results  for 
unencapsulated and encapsulated strains using unpaired Student’s t tests. 
 
 
 
 
 
Assay  Strain  IdeS 
treated 
 
+cps  -cps  P value 
   
D39 
 
No 
 
1575 
± 100 
 
2810 
± 200 
 
< 0.001 
IgG Binding    Yes  140 
± 18 
131 
± 16 
< 0.001 
   
TIGR4 
 
No 
 
1476 
± 180 
 
2698 
± 202 
 
< 0.001 
    Yes  123 
± 16 
135 
± 17 
< 0.001 
 
 
C3b/iC3b 
deposition 
 
 
D39 
 
No 
 
12118 
± 2200 
 
28776 
± 3900 
 
< 0.001 
Yes  9466 
± 440 
19856 
± 4400 
< 0.001 
 
TIGR4 
 
No 
 
20385 
± 2600 
 
38056 
± 3400 
 
< 0.001 
Yes  12133 
± 1900 
20978 
± 1900 
< 0.001 
 
 
 
C1q binding 
 
D39 
 
No 
 
1073 
± 110 
 
3524 
± 190 
 
< 0.001 
Yes  719 
± 150 
1357 
± 100 
< 0.001 
 
TIGR4 
 
No 
 
1041 
± 210 
 
4520 
± 200 
 
< 0.0001 
Yes  933 
± 110 
1648 
± 210 
< 0.001 152 
 
3.2.9 The effect of S. pneumoniae capsule on complement-dependent and -independent 
neutrophil phagocytosis  
In order to examine the functional consequences of the increased C3b/iC3b deposition on 
unencapsulated S. pneumoniae strains, an established flow cytometry assay of neutrophil 
phagocytosis was used (Yuste et al. 2007; Yuste et al. 2008). Neutrophils were extracted by 
Ficoll-dextran sedimentation from blood obtained from healthy volunteers, and experiments 
were replicated using neutrophils from at least 3 different donors. Fluorescently labelled S. 
pneumoniae strains were opsonised in either HBSS, 20% serum in which complement had 
been inactivated by heat treatment (Fig 2.1), or 5%, 10% and 20% normal human serum 
before mixing with neutrophils. As previously shown, the  association  of bacteria with 
neutrophils (assessed by flow cytometry) was increased in strains which were opsonised in 
normal serum compared to heat treated serum (Fig 3.16 and 3.17) (Yuste et al. 2008). 
Additionally there was a dose response to increasing concentrations of human serum in all 
strains.  Compared to the encapsulated strains there were higher levels of association with 
human neutrophils of both the TIGR4cps and D39-D  strains in all the concentrations of 
serum,  showing  the  capsule  inhibits  complement-dependent  bacterial  association  with 
neutrophils.  In addition there was an increased association of the TIGR4cps and D39-D  
strains compared to their parental strains in heat treated serum, in which complement is 
inactivated, suggesting there is also a complement-independent capsule effect.   153 
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Fig 3.16 Neutrophil phagocytosis of TIGR4 strains opsonised in human serum 
(A). Percentage of neutrophils associated with TIGR4 (open bars) or TIGR4cps (closed 
bars)  S.  pneumoniae  strains  incubated  in  different  opsonins,  as  determined  by  flow 
cytometry. Error bars represent SDs, * Ρ < 0.01, ** Ρ < 0.001 (ANOVA with post-hoc 
tests).  (B),  (C)  Representative  example  flow  cytometry  histograms  for  neutrophil 
association with TIGR4 (B) and TIGR4cps (C) strains when incubated in HBSS (dashed 
line), heat inactivated 20% serum (thin solid line) and 20% human serum (thick solid line).   154 
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Fig 3.17 Neutrophil phagocytosis of D39 strains opsonised in human serum 
(A). Percentage of neutrophils associated with D39 (open bars) or D39-D  (closed bars)  
S. pneumoniae strains incubated in different opsonins, as determined by flow cytometry. 
Error bars represent SDs, * Ρ < 0.01, ** Ρ < 0.001 (ANOVA with post-hoc tests). (B), (C) 
Representative example flow cytometry histograms for neutrophil association with D39 (B) 
and D39-D  (C) D39 strains when incubated in HBSS (dashed line), heat inactivated 20% 
serum (thin solid line) and 20% human serum (thick solid line).  155 
 
In order to determine the effect of the capsule on the proportion of S. pneumoniae bacteria 
that were cell-surface associated compared to phagocytosed by the neutrophils, the assays 
were repeated in 20% serum using Trypan Blue to quench fluorescence from bacteria on 
the  cell  surface  but  not  internalised,  and/or  1 M  cytochalasin  D  to  inhibit  actin 
polymerisation and therefore phagocytosis. For reactions treated with Trypan Blue there 
were similar increases in the association of the TIGR4cps and D39-D  strains compared to 
the TIGR4 and D39 strains as found for the untreated reactions. In contrast, there were no 
increases  in  the  association  of  the  TIGR4cps  and  D39-D 
  strains  with  neutrophils 
compared to results obtained with the TIGR4 and D39 strains when neutrophils were pre-
treated with cytochalasin (Fig 3.18 and 3.19).  These data confirm that the majority of the  
S.  pneumoniae  capsule  effect  on  association  with  neutrophils  is  through  inhibition  of 
phagocytosis rather than by reducing association of the bacteria with the neutrophil surface.   
 
To  further  examine  complement-dependent  and  –independent  effects  on  neutrophil 
association,  the  assays  were  repeated  using  the  human  serum  deficient  in  the  single 
complement  components  C3,  C1q,  Bf  and  C9.  There  were  significant  differences  in 
neutrophil  association  between  the  unencapsulated  and  encapsulated  strains  in  all  the 
conditions tested, including for bacteria incubated in C3
- serum or HBSS alone (Fig 3.20 A 
and B). Experiments using serum from wild-type, C3
+/-, C1qa
-/- or Bf
-/- C57BL/6 mice gave 
similar results to those obtained with depleted human serum (Fig 3.21 A and B). These 
results  demonstrated  that  for  both  the  TIGR4  and  D39  strains  the  capsule  inhibits 
neutrophil  association  by  classical  and  alternative  pathway  mediated  complement-
dependent mechanisms as well as by complement–independent mechanisms. 156 
 
Depletion  of  IgG  from  the  sera  reduced  neutrophil  phagocytosis  of  all  strains  in  both 
normal and C3
- sera, confirming the importance of IgG for S. pneumoniae phagocytosis 
(Table 3.3).  However, there was a persisting increase in phagocytosis of unencapsulated 
compared  to  encapsulated  strains  after  incubation  in  IdeS  treated  normal  and  C3
-  sera, 
demonstrating that the capsule has effects on phagocytosis even in the absence of IgG alone 
and in the absence of both complement and IgG respectively (Table 3.3).   
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Fig 3.18 Effect of cytochalasin D on TIGR4 strain association with neutrophils 
(A). Percentage of FL-1 positive neutrophils when incubated with TIGR4 (open bars) or 
TIGR4cps  (closed  bars)  S.  pneumoniae  strains,  as  determined  by  flow  cytometry. 
Neutrophils  were  untreated  and  bacteria  opsonised  with  HBSS  or  20%  serum,  or 
neutrophils were treated with 1 M cytochalasin D (inhibiting internalisation of bacteria) or 
the  FAM-SE  signal  was  quenched  using  Trypan  Blue  (results  representing  internalised 
bacteria). Cells treated with both cytochalasin D and Trypan B returned to background 
fluorescence.  Error bars represent SDs, * Ρ < 0.01, ** Ρ < 0.001 (ANOVA with post-hoc 
tests). (B). Representative example flow cytometry histograms for neutrophil association 
with TIGR4cps when incubated with cytochalasin treated cells (dashed line) or when the 
FAM-SE signal was quenched with Trypan Blue (thin solid line) and 20% human serum 
(thick solid line) incubation alone.   158 
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Fig 3.19 Effect of cytochalasin D on D39 strain association with neutrophils 
(A). Percentage of FL-1 positive neutrophils when incubated with D39 (open bars) or D39-
D  (closed bars) S. pneumoniae strains,  as determined by flow cytometry. Neutrophils 
were  untreated  and  bacteria  opsonised  with  HBSS  or  20%  serum,  or  neutrophils  were 
treated with 1 M cytochalasin D (inhibiting internalisation of bacteria) or the FAM-SE 
signal was quenched using Trypan Blue (results representing internalised bacteria). Cells 
treated with both cytochalasin D and Trypan B returned to background fluorescence.  Error 
bars  represent  SDs,  *  Ρ  <  0.01,  **  Ρ  <  0.001  (ANOVA  with  post-hoc  tests).  (B). 
Representative example flow cytometry histograms for neutrophil association with D39-D  
when incubated with cytochalasin treated cells (dashed line) or when the FAM-SE signal 
was quenched with Trypan Blue (thin solid line) and 20% human serum (thick solid line) 
incubation alone. 159 
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Fig 3.20 Effect of depletion of specific complement factors on phagocytosis of 
encapsulated and unencapsulated strains 
(A),  (B)  Percentage  of  neutrophils  associated  with  encapsulated  (open  bars)  or 
unencapsulated (solid bars) S. pneumoniae TIGR4 (A) or D39 (B) strains when opsonised 
in HBSS or 10% human serum depleted of C3, C1q, Bf or C9. For both panels, error bars 
represent SDs, * Ρ < 0.001 (ANOVA with post-hoc tests).  
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Fig 3.21 Phagocytosis of encapsulated and unencapsulated strains in serum from 
complement deficient mice 
(A),  (B)  Percentage  of  neutrophils  associated  with  encapsulated  (open  bars)  or 
unencapsulated (solid bars) S. pneumoniae TIGR4 (A) or D39 (B) strains when opsonised 
in HBSS or 20% C57BL/6 mouse serum from C3
+/-, C1qa
-/-, Bf
-/- or WT. For both panels, 
error bars represent SDs, * Ρ < 0.001 (ANOVA with post-hoc tests).  
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Table 3.3 Effects of IgG depletion using IdeS on mean +/- SDs percentage association of 
unencapsulated (-cps) and encapsulated (+cps) D39 and TIGR4 strains with neutrophils 
after incubation in 20% normal human serum (NHS) or 20% C3 deficient serum (C3
-).  P 
values  represent  comparisons  between  the  results  for  unencapsulated  and  encapsulated 
strains using unpaired Student’s t tests. 
 
 
Serum  Strain  IdeS 
treated 
 
+cps  -cps  P value 
 
 
NHS 
 
 
D39 
 
No 
 
39.2 
± 2.5 
 
79.0 
± 5.6 
 
< 0.0001 
Yes  28.5 
± 0.5 
61.0 
± 2.8 
< 0.0001 
 
TIGR4 
 
No 
 
32.0 
± 3.9 
 
85.9 
± 3.9 
 
< 0.0001 
Yes  28.9 
± 1.5 
70.2 
± 1.2 
< 0.0001 
 
 
 
C3
- 
 
D39 
 
No 
 
23.5 
± 0.8 
 
39.9 
± 1.3 
 
< 0.0001 
Yes  16.8 
± 1.1 
25.8 
± 1.2 
< 0.0001 
 
TIGR4 
 
No 
 
21.2 
± 3.2 
 
40.2 
± 2.7 
 
< 0.0001 
Yes  12.8 
± 0.8 
28.5 
± 1.1 
< 0.0001 
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3.2.10  Complement deficiency partially restores virulence in a mouse model of 
septicaemia 
Virulence of the unencapsulated S. pneumoniae strains was investigated in a mouse model 
of sepsis. In this model, bacteria are inoculated IP and even very low doses (down to 10
1 
CFU) of wild-type TIGR4 or D39 bacteria rapidly cause septicaemia which is usually fatal 
within  48  hours  (Brown  et  al.  2002;  Morona  et  al.  2004).  However,  in  keeping  with 
previous reports (Wood et al. 1949; Morona et al. 2004) TIGR4cps and D39-D  strains 
were not recoverable from the spleens or blood of mice 24 hours after inoculation IP with 5 
x 10
3 CFU, whereas mice inoculated with the TIGR4 or D39 strains had over 6 log10 CFU 
in spleen homogenates (Table 3.4). However, when C3
+/- mice were inoculated IP with the 
TIGR4cps and D39-D  strains, within 24 hours over 5 log10 CFU of bacteria were present 
in  spleen  homogenates  and  blood  (Table  3.4),  demonstrating  that  the  virulence  of  the 
unencapsulated bacteria  was restored with decreased C3 levels.  However, complement 
deficient mice are highly susceptible to S. pneumoniae (Wood et al. 1949; Brown et al. 
2002) and the increase in virulence of the unencapsulated strains in these mice does not 
necessarily mean that the effect of the capsule in this model is mediated through effects on 
complement-dependent immunity. Hence, to directly compare the effects of complement on 
the comparative virulence of the TIGR4cps and D39-D  strains to the TIGR4 and D39 
strains,  mixed  infection  experiments  in  wild-type  and  complement  deficient  mice  were 
performed. Wild-type, C3
+/-, C1qa
-/- and Bf
-/- mice were inoculated with a 50/50 ratio of 
TIGR4cps and TIGR4 bacteria or D39-D  and D39 bacteria, and the ratio of each strain 
amongst  bacteria  recovered  from  mouse  spleens  or  blood  24  hours  after  inoculation 
identified by plating on plain and antibiotic-containing medium and used to calculate a 
competitive index (CI).  As expected no TIGR4cps or D39-D  bacteria were recovered 163 
 
from either the spleen or the blood of wild-type C57BL/6 mice whereas greater than log10 6 
ml
-1  bacterial    CFU  of  the  TIGR4  and  D39  strains  were  found  in  the  blood  or  spleen 
homogenates,  giving  CIs  which  were  all  less  than  log10  -5.1  (Fig.  3.23  and  3.24).    In 
contrast in C3
+/- mice a significant proportion of bacteria recovered from the spleen or 
blood were the unencapsulated strain, giving a CI of log10 -3.1 (IQR -3.3 to -3.0) in blood 
and -2.2 (IQR -3.0 to -1.9) in spleens for the TIGR4cps strain and log10 -3.0 (IQR -3.1 to -
2.9) in blood and -2.1 (IQR -3.0 to -2.0) in spleen for the D39-D  strain.  Mixed infection 
experiments in C1qa
-/- and Bf
-/- mice also showed a lesser but similar order of magnitude 
increase in CI compared to wild-type mice (Fig. 3.23 and 3.24).  These data demonstrate 
that the effect of the capsule on S. pneumoniae virulence in this model is dependent on 
complement and is mediated by both the alternative and classical pathways. However, even 
in C3
+/- mice the unencapsulated strains were still markedly attenuated in virulence, with 
only approximately 1 in 1000 bacteria present in the blood and less than 1 in bacteria 100 
recovered  from  the  spleen  being  the  TIGR4cps  or  the  D39-D   strain  rather  than  the 
corresponding encapsulated strain.  Hence there is also likely to be a major complement-
independent effect of the capsule on the virulence of S. pneumoniae in the sepsis model. 164 
 
Table 3.4  Log10 bacterial CFU recovered from splenic homogenates and blood 24 hours 
after IP  inoculation of wild-type (C57B/6) or C3
+/- mice with 5000 CFU of wild type or 
unencapsulated S. pneumoniae strains. 
 
Bacterial 
strain 
Mouse strain  Mean (SD) log10  
CFU (n = 4 to 5) 
Spleen 
Mean (SD) log10  
CFU (n = 4 to 5) 
Blood 
 
TIGR4 
 
C57B/6 
 
6.55  (0.32) 
 
6.73 (0.10) 
TIGR4cps  C57B/6  0  (0)  0 (0) 
TIGR4cps  C3
+/-  5.08  (0.03)  5.03 (0.11) 
D39  C57B/6  6.84  (0.06)  6.58 (0.78) 
D39-D∆  C57B/6  0  (0)  0 (0) 
D39-D∆  C3
+/-  5.10  (0.06)  5.21 (0.13) 
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Fig 3.22 TIGR4 mixed infection experiments in complement deficient mice   
(A), (B) CIs for mixed infections with the TIGR4 and TIGR4cps strains expressed as log10 
for bacteria recovered from mouse blood (A) or spleens (B) after intraperitoneal inoculation 
with 5000 CFU in total. Mouse strain is given on the X axis, and for the results obtained for 
complement deficient mice versus those obtained for wild-type mice * Ρ=0.001 (Kruskal-
Wallis with post hoc analysis).  166 
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Fig 3.23 D39 mixed infection experiments in complement deficient mice   
(A) and (B) CIs for mixed infections with the D39 and D39-D  strains expressed as log10 
for bacteria recovered from mouse blood (A) or spleens (B) after intraperitoneal inoculation 
with 5000 CFU in total. Mouse strain is given on the X axis, and for the results obtained for 
complement deficient mice versus those obtained for wild-type mice * Ρ=0.001 (Kruskal-
Wallis with post hoc analysis).  167 
 
3.3 SUMMARY 
The experiments in this chapter have examined the consequences of loss of the capsule on 
interactions with complement and neutrophils for two S. pneumoniae strains, TIGR4 and 
D39, both of which have been used extensively for pathogenesis studies and are capable of 
causing  severe  infections  in  mice.  Flow  cytometry  has  confirmed  the  results  of  other 
investigators,  showing  that  the  capsule  inhibits  opsonisation  of  S.  pneumoniae  with 
C3b/iC3b for both strains, and immunoblots for C3 also show that this is associated with 
reduced activation of complement in sera. Data obtained with both human and mouse sera 
depleted  in  either  the  first  component  of  the  classical  pathway  C1q  or  the  alternative 
pathway protein factor B demonstrated that both pathways are required for the increase in 
C3b/iC3b deposition on unencapsulated S. pneumoniae. The EM immunogold experiments 
showed  large  clusters  of  C3  particles  at  one  site  on  the  cell  wall  suggestive  of  focal 
amplification of complement activity only in unencapsulated stains. Taken together these 
results  suggest  that  the  capsule  can  prevent  both  recognition  of  S.  pneumoniae  by  the 
classical pathway mediators IgG and CRP and amplification of C3b/iC3b deposition by the 
alternative pathway.   
 
Neutrophil  phagocytosis  is  considered  one  of  the  major  elements  of  immunity  to  
S.  pneumoniae,  and  there  were  significant  increases  in  phagocytosis  of  both  of  the 
unencapsulated  strains  compared  to  the  corresponding  encapsulated  strains  at  all 
concentrations of complement used and in the commercially available C9, C1q and factor B 
depleted sera. Experiments with cytochalasin D demonstrated that the differences between 
unencapsulated and encapsulated bacteria were largely due to increased internalisation of 
unencapsulated bacteria. However as well as complement-dependent effects of the capsule 168 
 
on phagocytosis, there were also significant impairments of the association of encapsulated 
TIGR4 and D39 with neutrophils when the bacteria were incubated in HBSS, heat treated 
or  commercially  available  C3  depleted  serum,  all  conditions  in  which  bacteria  are  not 
opsonised  with  complement.  These  results  show  that  as  well  as  inhibiting  neutrophil 
phagocytosis by reducing opsonisation of S. pneumoniae with C3b/iC3b, the capsule also 
prevents complement-independent mechanisms of phagocytosis.   
 
Interestingly depletion of IgG from the test serum resulted in reduced C3b/iC3b deposition 
on the TIGR4cps and the D39-D  strains, demonstrating that complement deposition on 
unencapsulated strains is partially dependent on  IgG.   However, there  was a persisting 
increase in C3b/iC3b deposition on unencapsulated strains compared to the encapsulated 
strains in IdeS treated serum. In addition, in IdeS treated serum although C1q binding to  
S.  pneumoniae  was  reduced,  there  were  still  significant  increases  in  C1q  binding  to 
unencapsulated compared to encapsulated strains. Furthermore, depletion of IgG from the 
sera reduced neutrophil phagocytosis of all strains in both normal and C3
- sera. However, 
there was a persisting increase in phagocytosis of unencapsulated compared to encapsulated 
strains after incubation in IdeS treated normal and C3
- sera, demonstrating that the capsule 
has effects on phagocytosis even in the absence of IgG alone and in the absence of both 
complement and IgG respectively. 
 
The importance of the effects of the capsule on complement activity during infection was 
investigated using a mouse model of sepsis and genetically modified mice with reduced C3 
levels,  or  deficient  in  C1q  (no  classical  pathway  activity)  or  factor  B  (no  alternative 
pathway activity). In wild-type mice although both the D39 and TIGR4 strains are highly 169 
 
virulent,  even  inoculation  with  large  numbers  of  unencapsulated  bacteria  did  not  cause 
disease.  In  contrast,  infection  of  C3
+/-  mice  with  unencapsulated  bacteria  resulted  in 
significant septicaemia, suggesting that complement activity is required for the effects of 
the  capsule  on  virulence.  This  was  confirmed  using  competitive  infection  experiments, 
which showed that the unencapsulated strains were avirulent in complement sufficient mice 
but regained virulence when there was partial deficiency of C3 and absence C1q or factor 
B. 
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CHAPTER 4  
ROLE OF CAPSULE IN INTERACTIONS WITH MACROPHAGES AND INNATE 
IMMUNE ACTIVATION 
 
4.1 INTRODUCTION 
A  central  component  of  early  pulmonary  immunity  is  the  alveolar  macrophage  (AM), 
resident phagocytic cells found within alveoli and the bronchial tree. AMs are the first 
immune effector cell to interact with invading pathogens (Gordon et al. 2002) and are likely 
to be vital in preventing the development of significant lung disease. Depletion of AMs 
increases  S.  pneumoniae  replication  in  the  lung  (Dockrell  et  al.  2003),  but  it  remains 
unclear how the capsule aids development of S. pneumoniae respiratory infections, and if 
any capsular effect is complement dependent or independent. Although complement factors 
are  present  in  BALF  and  increase  during  S.  pneumoniae  infection,  the  contribution  of 
complement to the interactions of S. pneumoniae with AMs during the development of 
pneumonia is also unclear. Complement levels in BALF are only approximately 10% of 
those  in  serum  (Gross  et  al.  1978),  and  macrophage  phagocytosis  of  S.  pneumoniae  is 
slower than that of neutrophils, with significant associations taking up to 2 hours rather 
than 30 minutes (Gordon et al. 2000; Arredouani et al. 2004).  
 
However both the S. pneumoniae capsule and complement could also aid host defense to 
early  S.  pneumoniae  infection  by  effects  on  the  inflammatory  response.  The  role  of 
inflammation during immunity to S. pneumoniae pneumonia is complex, with deficiencies 
of pro-inflammatory cytokines or intracellular signaling molecules resulting in poor control 
of bacterial replication (Nakasone et al. 2007; Sun et al. 2007), but down-regulation of 171 
 
inflammatory responses by macrophages improves host survival, possibly by preventing 
damage to the lung and impaired gas exchange (Knapp et al. 2003). As well as promoting 
phagocytosis, increased activation of complement by unencapsulated S. pneumoniae could 
affect inflammatory responses. The small soluble products of C3 cleavage (C3a) is pro-
inflammatory,  causing  vasodilation,  white  cell  chemotaxis,  impairment  of  neutrophil 
apoptosis, and the induction of cytokine production (Walport 2001). As well as the effects 
of  C3a,  bacteria  opsonised  by  C3b  and  iC3b  could  induce  inflammation  indirectly  by 
activating AMs, an important source of pro-inflammatory cytokines. Hence complement 
activity could aid immunity to S. pneumoniae pneumonia by increasing recruitment and 
activation  of  white  cells  directly  or  through  the  increased  release  of  pro-inflammatory 
cytokines and chemokines. 
 
In this chapter I have investigated the effect of capsule on phagocytosis of S. pneumoniae 
and a mouse macrophage cell line (RAW 264.7 cells) and alveolar macrophages in a model 
of early lung infection in vivo. In addition, I have investigated the effect of capsule in 
modulating the inflammatory response produced by macrophages through analyzing TNFα 
production both in vitro and in vivo, as well as looking a innate cell activation pathways.  172 
 
4.2 RESULTS 
4.2.1 The effect of S. pneumoniae capsule on complement-dependent and -independent 
phagocytosis by macrophages 
In  order  to  determine  if  the  S.  pneumoniae  capsule  had  an  effect  on  macrophage 
phagocytosis a flow cytometry opsonophagocytosis assay was used. Adherent RAW 264.7 
cells were incubated with FAM-SE labelled S. pneumoniae strains which were previously 
opsonised in either HBSS, 20% serum in which complement had been inactivated by heat 
treatment,  or  20%  normal  human  serum.  Within  15  minutes,  there  was  a  significant 
complement dependent association with RAW 264.7 cells for the TIGR4cps or D39-D  
strains, which was not present with either the TIGR4 or D39 strains (Fig 4.1 and 4.2). 
Interestingly,  at  this  time  point  there  were  only  small  differences  in  the  association  of 
TIGR4 and TIGR4cps strains with RAW 264.7 cells when opsonised in heat-treated serum 
or PBS, indicating that the increased association of TIGR4cps in serum at this time point 
requires  complement.  However,  at  60  minutes  there  was  a  significant  increase  in 
association between RAW cells and TIGR4cps opsonised in heat-treated serum and PBS 
compared  to  TIGR4  (Ρ<0.001,  ANOVA).  This  indicates  that  there  is  also  a  slower, 
opsonin-independent  effect  of  the  TIGR4  capsule  on  association  with  macrophages. 
Overall, similar results for phagocytosis by RAW 264.7 cells were obtained with the D39 
strains, with a large early increase in association for D39-D . There was a more significant 
effect of heat treated serum on association of D39-D  with RAW cells (Ρ<0.001, ANOVA) 
at 15 minutes than seen with the TIGR4 strains (Fig 4.2). In general, both the TIGR4 and 
D39 strains were resistant to phagocytosis by RAW 264.7 cells, with a maximum of only 
10% of cells becoming associated with S. pneumoniae within 60 minutes (Fig 4.1 and 4.2).  173 
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Fig 4.1 RAW 264.7 macrophage phagocytosis of TIGR4 S. pneumoniae strains 
(A), (B) Percentage of RAW 264.7 cells associated with TIGR4 (open bars) or TIGR4cps 
(solid bars) S. pneumoniae at 15 minutes (A) or 60 minutes (B) after opsonisation with 
HBSS, 20% heat treated (HT) or 20% human serum. For both panels, error bars represent 
SDs, and * Ρ < 0.001 (ANOVA with post-hoc tests).  174 
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Fig 4.2 RAW 264.7 macrophage phagocytosis of D39 S. pneumoniae strains 
(A), (B) Percentage of RAW 264.7 cells associated with D39 (open bars) or D39-D  (solid 
bars) S. pneumoniae at 15 minutes (A) or 60 minutes (B) after opsonisation in HBSS, 20% 
heat treated (HT) or 20% human serum For both panels, error bars represent SDs, and * Ρ < 
0.001 (ANOVA with post-hoc tests).  
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4.2.2 Capsule prevents clearance of S. pneumoniae from the lungs in early infection 
To examine the effect of capsule in early lung infection, 5 x 10
5 CFU FAM-SE labelled  
S. pneumoniae were inoculated IN into CD1 mice in a pneumonia infection model. After 4 
hours, bronchoalveolar lavages (BALF) were performed and bacterial CFU in the BALF 
determined by precise serial dilutions. Even at this early time point there was over a two 
log reduction in bacterial CFU counts of TIGR4cps (Fig 4.3 A) and a one log reduction in 
D39-D  (Fig 4.3 B) compared to their parental strains, indicating a significant survival 
benefit of the capsule in early lung infection. Furthermore flow cytometry analysis of AMs 
indicated a significant increase in association of both unencapsulated strains with AMs 
compared to encapsulated strains observed (TIGR4 strains Ρ = 0.016, D39 strains Ρ = 0.008 
Mann  Whitney  U-test)  (Fig  4.4  A  and  B).  In  order  to  determine  if  this  increase  in 
association between AMs and TIGR4cps and D39-D  was due to increased cell surface 
adherence or also represented increased internalisation, the AMs from mice inoculated with 
the TIGR4 strains were stained with F4/80 and examined with confocal microscopy. Only a 
small  number  of  AMs  were  preserved  through  to  visualisation  with  the  confocal 
microscope, however there were not only more TIGR4cps bacteria associated with each 
AM (TIGR4cps 6 IQR 3 versus TIGR4 3 IQR 2), but also an greater proportion of the 
associated TIGR4cps bacteria were internalised in comparison with TIGR4 S. pneumoniae 
(TIGR4cps 4 IQR 2 versus TIGR4 1 IQR 2) (Fig 4.5).  
 
TNFα is an important pro-inflammatory cytokine released early in the immune response to 
bacterial infection, and is important in neutrophil recruitment to the lungs. Hence, the effect 
of the capsule on the inflammatory response was investigated by measuring TNFα levels in 
the BALF. Despite the decreased survival of unencapsulated strains, there was more TNFα 176 
 
in the BALF from mice infected with TIGR4cps or D39-D  compared to mice infected 
with the encapsulated, parental TIGR4 or D39 (TIGR4 Ρ = 0.032, D39 strains Ρ = 0.019 
Mann Whitney U-test) (Fig 4.6 A and B). 
 
The role of complement on the interactions with the S. pneumoniae capsule and AMs in 
early lung infection was investigated using C3
+/- and wild-type C57BL/6 mice. Both strains 
of mice were intranasally inoculated with 5 x 10
5 CFU FAM-SE labelled TIGR4cps or 
TIGR4  and  harvested  at  4  hours.  Only  a  maximum  of  2000  CFU  TIGR4cps  were 
recoverable from BALF of WT mice, whereas 2.75 log10 CFU TIGR4cps were recoverable 
from complement deficient mice (Fig 4.7 A). However, there was also an increase in the 
number  of  TIGR4  bacteria  recovered  from  the  lavage  fluid  of  C3
+/-  mice  over  that 
recovered from WT mice, although this increase was not as marked as that seen with the 
TIGR4cps strain (Fig 4.7 A).  There was also an increase in the association between the 
TIGR4cps  strain  and  AMs  from  C3
+/-  mice  over  AMs  from  wild-type  mice  (Ρ=0.004, 
Mann-Whitney U-Test), which was not accompanied by a similar increase in the TIGR4 
strain (Fig 4.7 B). In parallel with previous results, TNFα levels were increased in the 
BALF from mice inoculated with TIGR4cps than in mice inoculated with TIGR4. There 
was also a lower level of TNFα production in C3
+/- mice inoculated with TIGRcps than 
found in BALF from wild-type mice (Ρ=0.030, Mann-Whitney U-Test). However, there 
was no significant difference in TNFα level between WT and C3
+/- mice inoculated with 
TIGR4 (Fig 4.8). 177 
 
 
A
C
B
TIGR4                    TIGR4cps
6
5
4
3
2
1
0
L
o
g
 
c
f
u
 
B
A
L
 
f
l
u
i
d
6
5
4
3
2
1
0
L
o
g
 
c
f
u
 
B
A
L
 
f
l
u
i
d
D39                        D39-D 
D39
TIGR4
Ρ = 0.019
Ρ = 0.004
 
Fig 4.3 Capsule increases survival of S. pneumoniae in early lung infection 
(A), (B) Bacterial survival counts from BALF at 4 hours after intranasal inoculation of 5 x 
10
5 CFU TIGR4 (A) or D39 (B) S. pneumoniae strains into CD1 mice. For both panels, 
open  boxes  represent  encapsulated  strains  and  slashed  boxes  represent  results  for 
unencapsulated strains.  Ρ values are obtained using Mann-Whitney U-tests.    178 
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Fig 4.4 Association of S. pneumoniae with AMs in early lung infection 
(A), (B) Fluorescence of AMs obtained from BALF following 4 hours intranasal infection 
with 5 x 10
5 CFU FAM-SE labelled TIGR4 (A) and D39 (B) strains, as determined by flow 
cytometry. For both panels, diagonally slashed bars represent fluorescent index of AMs 
from mice inoculated with PBS, open bars indicate results from encapsulated strains and 
closed bars represent results from unencapsulated strains. Error bars represent SDs, and Ρ 
values were obtained using Mann-Whitney U-tests.  179 
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Fig 4.5 Confocal microscopy of AMs from infected mice 
(A), (B) Representative confocal microscope Z-stack images of AMs obtained from BALF 
of CD1 mice infected with TIGR4 (A) or TIGR4cps (B). For both panels, blue staining 
represents  DAPI,  red  represents  F4/80  and  green  indicates  the  FAM-SE  labelled  
S. pneumoniae. 180 
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Fig 4.6 The capsule reduces TNFα release during early lung infection 
(A), (B) TNFα levels in BALF following 4 hours intranasal infection with TIGR4 (A) and  
D39 (B) S. pneumoniae strains, as determined by ELISA. For both panels, open boxes 
represents encapsulated strains and slashed boxes unencapsulated strains, with Ρ values are 
obtained using Mann-Whitney U-tests.  181 
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Fig 4.7 The effect of the TIGR4 capsule and complement in early lung infection 
(A), (B) Bacterial CFU counts (A) and FI of AMs (B) as determined by flow cytometry on 
BAL fluid 4 hours after IN infection with FAM-SE labelled TIGR4 or TIGR4cps strains 
into C57BL/6 wild-type (open bars) or C3
+/- (diagonal slashed bars) mice. Ρ values are 
derived from Mann-Whitney U-tests.  
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Fig 4.8 The effect of the TIGR4 capsule and complement on TNFα release in early 
lung infection 
TNFα levels in BALF following 4 hours intranasal infection with FAM-SE labeled TIGR4 
or TIGR4cps strains into C57BL/6 wild-type (open bars) or C3
+/- mice (diagonal slashed 
bars), as determined by ELISA. Ρ values are derived from Mann-Whitney U-tests.  
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4.2.3 The capsule modulates TNFα production by RAW 264.7 cells 
The observed inhibition of TNFα release induced by the presence of the capsule in the early 
lung  infection  model  was  investigated  further  using  RAW  264.7  cells  in  vitro.  S. 
pneumoniae  strains  which  were  pre-opsonised  in  either  PBS,  20%  heat  treated  or  20% 
normal human serum were incubated with RAW 264.7 cells at a MOI of 10. At 3 hours 
there was a serum independent release of TNFα from RAW 264.7 macrophages stimulated 
with the TIGR4cps strain, which was not present in macrophages stimulated with TIGR4 
(Fig 4.9 A). TNFα production at 24 hours indicated that there was a greater response to 
TIGR4cps in all opsonising conditions, and that there was a large complement dependent 
effect,  as  shown  by  the  difference  between  TIGR4cps  opsonised  with  heat-treated  and 
normal human serum. Furthermore, there was very little TNFα production stimulated by the 
TIGR4 strain over 24 hours with any opsonin, indicating the ability of the TIGR4 capsule 
to inhibit TNFα production by macrophages (Fig 4.9 B). The D39 strains showed a similar 
response, although with a smaller complement dependent effect observable at 24 hours in 
macrophages stimulated with D39-D .  
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Fig 4.9 TNFα production by RAW 264.7 cells stimulated with TIGR4 strains 
(A), (B) TNFα release from 1 x 10
6 RAW 264.7 cells stimulated with 100 ng/ml LPS or 
MOI 10 TIGR4 or TIGR4cps opsonised with PBS, heat treated 20% serum (HT) or 20% 
serum for 3 hours (A) or 24 hours (B) as measured by ELISA. For both panels, error bars 
represent SDs and * Ρ<0.01 or ** Ρ<0.001 (ANOVA with post-hoc tests).  185 
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Fig 4.10 TNFα production by RAW 264.7 cells stimulated with D39 strains 
(A), (B) TNFα release from 1 x 10
6 RAW 264.7 cells stimulated with 100 ng/ml LPS or 
MOI 10 D39 or D39-D  opsonised with PBS, heat treated 20% serum (HT) or 20% serum 
after  3  hours  (A)  or  24  hours  (B)  as  measured  by  ELISA.  For  both  panels,  error  bars 
represent SDs and * Ρ<0.01 or ** Ρ<0.001 (ANOVA with post-hoc tests).  
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4.2.4 The S. pneumoniae capsule inhibits NFκB pathways activation of macrophages  
TNFα production is stimulated through the NFκB activation pathway. Hence quantitative 
confocal  immunofluorescence  assays  of  NFκB  RelA  (p65)  nuclear  translocation  were 
performed  to  investigate  innate  immune  cellular  activation  by  the  encapsulated  and 
unencapsulated strains. To follow the time course of NFκB translocation in activated RAW 
264.7  cells  they  were  stimulated  with  100ng/ml  LPS  over  4  hours.  RelA  staining  was 
mostly cytoplasmic in control cells, and in response to LPS reached the greatest nuclear 
staining at 2 hours (Fig 4.11). In order to determine if S. pneumoniae stimulated NFκB 
translocation,  the  study  was  repeated  selecting  a  1  hour  time  point.  Both  TIGR4  and 
TIGR4cps show greater nuclear NKκB staining than unstimulated RAW 264.7 cells, with 
an apparent increase in NKκB translocation present in cells stimulated with TIGR4cps (Fig 
4.12). This was investigated further by stimulating RAW 264.7 cells with increasing MOIs 
of 20% serum opsonised S. pneumoniae in a dose response study. Greater nuclear staining 
was  evident  in  response  to  increasing  MOIs  of  S.  pneumoniae,  and  quantitative  image 
analysis found that there was increased NFκB translocation in RAW 264.7 cells stimulated 
with TIGR4cps and D39-D  than TIGR4 or D39 (Fig 4.13 A and B). To see if this increase 
in innate activation was complement dependent or independent, RAW 264.7 cells were 
incubated with MOI 10 S. pneumoniae which had been opsonised in HBSS, 20% heat-
treated  or  20%  normal  human  serum.  In  all  opsonins,  unencapsulated  S.  pneumoniae 
induced increased NFκB nuclear translocation for both the TIGR4 and D39 strains (Fig 
4.14 A and B). 187 
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Fig 4.11 Time course study of NFκB translocation in RAW 264.7 cells 
(A)  Sample  confocal  microscopy  images  of  RAW  264.7  cells  when  unstimulated  or 
activated with 100ng/ml LPS for either 2 or 4 hours and stained for RelA (p65) (red). DAPI 
was used to stain the nucleus. (B) Quantification of nuclear:cytoplasmic RelA staining in a 
time course study of NFκB translocation in LPS stimulated RAW 264.7 cells. * Ρ < 0.01 or 
**  Ρ  <  0.01  for  stimulated  cells  compared  to  unstimulated  cells  (Kruskal-Wallis  with 
Dunn’s multiple comparison test).  
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Fig  4.12  NFκB  translocation  in  RAW  264.7  cells  stimulated  with  TIGR4  and 
TIGR4cps 
(A) to (D) Sample confocal microscopy images of RAW 264.7 cells when unstimulated (A) 
or activated with 100ng/ml LPS (B), MOI 10 TIGR4 (C) or TIGR4cps (D) for 1 hour. (E) 
Quantification  of  nuclear:cytoplasmic  RelA  (p65)  staining  in  a  1  hour  study  of  NFκB 
translocation  in  LPS  or  S.  pneumoniae  stimulated  RAW  264.7  cells.  *  Ρ  <  0.01  for 
stimulated  cells  compared  to  unstimulated  cells  (Kruskal-Wallis  with  Dunn’s  multiple 
comparison test).  189 
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Fig 4.13 Dose response of NFκB translocation in RAW 264.7 cells stimulated with  
S. pneumoniae 
(A),  (B)  Quantification  of  nuclear:cytoplasmic  RelA  (p65)  staining  in  a  dose-response 
study of NFκB translocation in RAW 264.7 cells stimulated with 100ng/ml LPS (slashed 
bars)  or  S.  pneumoniae  TIGR4  (A)  or  D39  (B)  encapsulated  strains  (open  bars)  or 
unencapsulated strains (closed bars). For both panels, * Ρ < 0.05 or ** Ρ < 0.01 (Mann-
Whitney U-test), and all stimulations produced significant NFκB translocation compared to 
unstimulated (basal) cells (Kruskal-Wallis with Dunn’s multiple comparison test).  190 
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Fig 4.14 Complement dependent and independent NFκB translocation in RAW 264.7 
cells 
 (A), (B) Quantification of nuclear:cytoplasmic RelA (p65) staining in a study of NFκB 
translocation  in  RAW  264.7  cells  stimulated  with  1ng/ml  LPS  (slashed  bars)  or  S. 
pneumoniae TIGR4 (A) or D39 (B) encapsulated strains (open bars) or to unencapsulated 
strains (closed bars) opsonised in PBS, heat-treated (HT) 20% serum or 20% serum. For 
both  panels,  *  Ρ  <  0.05  or  **  Ρ  <  0.01  (Mann-Whitney  U-test),  and  all  stimulations 
produced significant NFκB translocation compared to unstimulated (basal) cells (Kruskal-
Wallis with Dunn’s multiple comparison test).  191 
 
4.2.5 Innate immune cellular activation of RAW 264.7 cells by TIGR4 and TIGR4cps 
Classically,  IκBα  is  phosphorylated  by  IκB  kinase  and  is  degraded  by  ubiquitination, 
allowing for nuclear translocation of NFκB complex. Degradation of IκBα can be detected 
by western blotting; hence IκBα degradation was examined in a time course study of RAW 
264.7 cells stimulated with TIGR4 and TIGR4cps which were previously opsonised in 20% 
human  serum.  100ng/ml  LPS  was  used  as  a  control  to  monitor  the  activation  of  these 
pathways in RAW 264.7 cells. In RAW 264.7 cells that were stimulated with LPS the IκBα 
signal was diminished at 15 and 30 minutes, with the signal increasing in strength over the 
next  90  minutes.  RAW  264.7  cells  stimulated  with  TIGR4cps  also  showed  rapid 
degradation of IκBα within 15 minutes, and the signal intensity remained the same at 30 
and 60 minutes, and then decreased by 120 minutes. However, RAW 264.7 cells stimulated 
with TIGR4 did not show a reduced IκBα signal at 15 minutes, with IκBα signal only 
reducing at 30 minutes. At all time points studied, there was a stronger IκBα signal in RAW 
264.7 cells stimulated with TIGR4 than with TIGR4cps (Ρ<0.001 ANOVA with post hoc 
tests)  (Fig  4.15),  indicating  an  attenuation  of  IκBα  degradation  in  TIGR4  stimulated 
macrophages, supporting the results of the NFκB translocation assay (Fig 4.13). 
 
Since pneumococcal components can activate Toll like receptors (TLRs) it is also likely 
that  macrophage  responses  to  S.  pneumoniae  are  affected  by  mitogen  activated  protein 
kinases  (MAPKs).  These  innate  immune  cellular  pathways  operate  in  a  network  of 
molecules which converge to a limited number of intracellular signalling events, including 
the  ERK1/2  and  p38  signalling  pathways  which  have  been  shown  to  be  involved  in 
macrophage and epithelial cell inflammatory responses to S. pneumoniae (N'Guessan et al. 
2006; Kang et al. 2009). Immunoblots were therefore used to study phosphorylation of p38 192 
 
and ERK 1/2 in RAW 264.7 cells. For both MAP kinases, there was an increase in the level 
of phosphorylated protein detectable over time on stimulation with S. pneumoniae, with 
phosphorylated ERK 1/2 levels increasing until 60 minutes and then decreasing at 120 
minutes  (Fig  4.16).  Phosphorylated  p38  showed  a  similar  pattern,  however  levels  of 
detectable phosphorylated p38 did not decrease after 60 minutes (Fig 4.17). However, in 
contrast to the results obtained for IκBα, there was no detectable difference in the level of 
phosphorylation  of  either  ERK  1/2  or  p38  induced  by  TIGR4  and  TIGR4cps  (Ρ>0.05 
ANOVA with post-hoc tests) (Fig 4.16 and 4.17). This indicates an NFκB pathway specific 
effect  of  the  capsule  on  inhibition  of  innate  immune  activation,  which  is  not  merely 
attributable to increased adherence of TIGR4cps. 193 
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Fig 4.15 IκBα degradation in RAW 264.7 cells stimulated with TIGR4 and TIGR4cps 
(A) Representative western immunoblot of the time course of IκBα degradation at 15, 30, 
60 and 120 minutes in response to stimulation with 1ng/ml LPS or MOI 10 TIGR4 (+) or 
TIGR4cps (-). Actin expression is demonstrated in each assay to show equivalent sample 
loading.  (B)  Analysis  of  western  immunoblots  of  IκBα  degradation  from  triplicate 
experiments. Slashed bars represent samples from LPS stimulated RAW 264.7 cells, open 
bars TIGR4 and closed bars represent TIGR4cps. Error bars represent SDs, * Ρ<0.01 or ** 
Ρ<0.001 (ANOVA with post-hoc tests) for differences between basal IκBα. There was a 
significant difference in IκBα levels in the TIGR4 and TIGR4cps stimulated RAW 264.7 
cells at all time points (Ρ < 0.001, ANOVA with post-hoc tests). 
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Fig 4.16 Phosphorylation of ERK 1/2 in RAW 264.7 cells stimulated with TIGR4 and 
TIGR4cps  
(A) Representative western immunoblot of the time course of phosphorylation of ERK1/2 
at 15, 30, 60 and 120 minutes in response to stimulation with 1ng/ml LPS or MOI 10 
TIGR4  (+)  or  TIGR4cps  (-).  Actin  expression  is  demonstrated  in  each  assay  to  show 
equivalent  sample  loading.  (B)  Analysis  of  western  immunoblots  of  ERK1/2 
phosphorylation  from  triplicate  experiments.  Slashed  bars  represent  samples  from  LPS 
stimulated RAW 264.7 cells, open bars TIGR4 and closed bars represent TIGR4cps. Error 
bars represent SDs, * Ρ<0.01 or ** Ρ<0.001 (ANOVA with post-hoc tests) for differences 
between basal ERK1/2. There was no significant difference in phosphorylated ERK1/2 in 
the TIGR4 and TIGR4cps stimulated RAW 264.7 cells at all time points (ANOVA with 
post-hoc tests).  
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Fig  4.17  Phosphorylation  of  p38  in  RAW  264.7  cells  stimulated  with  TIGR4  and 
TIGR4cps 
(A) Representative western immunoblot of the time course of phosphorylation of p38 at 15, 
30, 60 and 120 minutes in response to stimulation with 1ng/ml LPS or MOI 10 TIGR4 (+) 
or TIGR4cps (-). Actin expression is demonstrated in each assay to show equivalent sample 
loading.  (B)  Analysis  of  western  immunoblots  of  p38  phosphorylation  from  triplicate 
experiments. Slashed bars represent samples from LPS stimulated RAW 264.7 cells, open 
bars TIGR4 and closed bars represent TIGR4cps. Error bars represent SDs, * Ρ<0.01 or ** 
Ρ<0.001 (ANOVA with post-hoc tests) for differences between basal p38. There was no 
significant difference in phosphorylated p38 in the TIGR4 and TIGR4cps stimulated RAW 
264.7 cells at all time points (ANOVA with post-hoc tests).  
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4.3  SUMMARY 
In  summary,  the  results  in  this  chapter  define  some  of  the  effects  of  capsule  with 
macrophages,  both  in  vitro  and  in  vivo.  The  S.  pneumoniae  capsule  prevents  a  rapid 
complement  dependent  association  with  RAW  264.7  macrophages,  and  there  is  also  a 
slower complement independent capsular effect in both the TIGR4 and D39 strains. This is 
also apparent in early lung infection, where the capsule decreases association with AMs at 
an  early  time  point  and  increases  S.  pneumoniae  survival.  Interestingly,  despite  the 
decreased bacterial survival, there is an increased TNFα inflammatory response within 4 
hours of infection in BALF from mice infected with either TIGR4cps or D39-D . Bacterial 
survival  and  the  increased  association  of  AMs  in  TIGR4cps  is  partially  dependent  on 
complement,  although  these  results  are  difficult  to  interpret  as  there  is  also  increased 
survival and decreased AM association in the TIGR4 strain.   
 
Further  investigation  of  the  innate  inflammatory  response  of  macrophages  using  RAW 
264.7 cells showed that both TNFα release at 3 hours and production within 24 hours are 
dependent  on  complement,  with  increased  TNFα  in  the  supernatant  of    macrophages 
stimulated with TIGR4cps and D39-D . However there were differences in the level of 
complement-independent capsule effect between the TIGR4 and D39 strains, and this was 
matched by the results of quantitative confocal immunofluorescence assays NFκB RelA 
translocation assays. Furthermore, immunoblot time course studies of IκBα degradation in 
RAW  264.7  cells  stimulated  with  serum  opsonised  TIGR4  strains  correlated  with  the 
confocal  NFκB  translocation  studies.  Interestingly,  the  effect  of  the  capsule  on  innate 
immune cellular activation in RAW 264.7 cells seems to be pathway specific, as there is 
differential activation between TIGR4 and TIGR4cps in the NFκB pathway but not the p38 197 
 
and the ERK 1/2 pathways. However, it remains unclear as to whether this pathway specific 
effect  is  dependent  on  complement  and  internalisation,  and  further  experiments  using 
different opsonisation conditions and in the presence of cytochalasin are required to define 
the full effects of capsule on this pathway.  198 
 
CHAPTER 5  
EFFECT OF CAPSULAR SEROTYPE ON COMPLEMENT MEDIATED 
IMMUNITY 
 
5.1 INTRODUCTION   
The  mechanisms  causing  capsular  serotype-dependent  variation  in  virulence  are  largely 
unknown,  but  may  reflect  differences  in  the  ability  between  serotypes  to  inhibit  host 
immune responses, and this hypothesis is partially supported by existing experimental data.  
Different capsular serotypes vary markedly in their virulence in mouse infection models, 
but since there is a weak relationship between virulence in mice and invasive potential in 
humans the clinical relevance of these findings is unclear (Briles et al. 1992; Sandgren et al. 
2005).  Additionally, complement resistance and phagocytosis varies between strains with 
different capsular serotypes (Winkelstein et al. 1976; Hostetter 1986; Yuste et al. 2008).  
However there is also considerable genetic variation between S. pneumoniae strains outside 
of  the  capsule  genetic  locus,  and  this  genetic  variation  is  partially  linked  to  capsular 
serotype (http://www.mlst.net/). Therefore, the relationship between capsular serotype and 
invasiveness could be due to non-capsular genetic variation rather than any direct effects of 
the  polysaccharide  capsule.  To  overcome  strain  genetic  variation  confounding  the 
assessment of capsular serotype interactions with the immune system, the capsular loci of 
one strain can be replaced with the capsular loci from another, creating otherwise isogenic 
strains expressing different capsular serotypes (Trzcinski et al. 2003; Nelson et al. 2007).  
Previous  studies  have  established  the  principle  that  capsular  serotype  can  affect 
complement sensitivity and virulence of S. pneumoniae independent of strain background 
(Kelly et al. 1994; Abeyta et al. 2003).  However, as yet there are only limited data on the 199 
 
effects of different capsular serotypes on immunity to S. pneumoniae and a more detailed 
assessment  is  required  to  help  understand  why  capsular  serotype  is  linked  to  invasive 
potential.  
 
In this chapter, I have used TIGR4 S. pneumoniae strains modified to express different 
capsular serotypes, two representative of relatively invasive serotypes (4 and 7F) and two 
representative  of  less  invasive  serotypes  (6A  and  23F)  in  order  to  investigate  capsular 
serotype-dependent effects on immunity. This chapter examines both the effect of capsular 
serotype  and  phase  variation  on  complement  deposition,  neutrophil  phagocytosis  and 
virulence in a mouse model of septicaemia using capsular switch TIGR4 strains. 
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5.2 RESULTS 
5.2.1 Measurement of capsule thickness in TIGR4 capsular switch strains 
S. pneumoniae TIGR4 strains which were genetically modified at the capsule gene locus 
but which are otherwise isogenic, were given as a gift from Prof J Weiser, University of 
Pennsylvania. The TIGR4 capsular switch strains were confirmed to be in either opaque or 
transparent phase by growth on Tryptone Soy agar with catalase. These strains were then 
assessed to determine the amount of capsule polysaccharide expressed by each strain. The 
mucopolysaccharide  Stains-All  assay  revealed  all  of  the  opaque  strains  contained  more 
capsular polysaccharide than the transparent phase variant (Ρ < 0.001, Fig 5.1). However, 
this  assay  depends  on  the  ratio  of  anionic  sugars  to  monosaccharides,  and  is  only 
appropriate  for  comparisons  within  a  serotype  but  not  between  structurally  distinct 
polysaccharides. Therefore, EM was used to measure the average thickness of the capsule 
polysaccharide.  The  TIGR4  capsular  switch  strains  were  grown  to  mid-log  phase  and 
prepared  for  electron  microscopy  using  a  ruthenium  red  and  lysine  acetate  protocol  to 
preserve capsule polysaccharide (Hammerschmidt et al. 2005). Image analysis was used to 
quantitate the area inside the cell wall and the total area of the bacterial cell including the 
capsule  layer,  and  by  making  a  presumption  of  circularity  the  diameter  of  each  was 
calculated thereby allowing the average capsule thickness to be determined. This method 
confirmed  that  the  capsules  of  the  opaque  strains  were  indeed  thicker  than  the 
polysaccharide capsules of the transparent strains (ANOVA Ρ > 0.001). Furthermore, there 
were no significant differences in the thickness of the capsule between the capsular switch 
strains in either the opaque phase or in the transparent phase (ANOVA Ρ > 0.05, Fig 5.2 
and Table 5.1).  201 
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Fig 5.1 Biochemical capsule assessment in TIGR4 capsule switch strains 
Results of the Stains-All semi-quantitative assay for the amount of bacterium-associated 
capsule polysaccharide for strains used in this chapter. Serotype 3 wild-type, and TIGR4 
encapsulated and unencapsulated strains (slashed bars) were used as controls and compared 
to TIGR4(-) capsular switch strains in either opaque (open bars) or transparent (closed bars) 
phase variants (unpaired student’s t-test * Ρ < 0.001).  
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. 
Fig 5.2 EM capsule measurement in TIGR4 capsular switch strains 
(A)-(H)  Representative  immunogold  EM  images  of  the  TIGR4(-)  +6A  opaque  (A)  and 
transparent (B), +7F opaque (C) and transparent (D), +23F opaque (E) and transparent (F) 
and +4 opaque (G) and transparent (H) phase variant strains which were prepared using a 
ruthenium red and lysine acetate with LR Resin protocol.  203 
 
 
 
Table  5.1  Analysis  of  capsule  thickness  of  10  random  bacteria  per  TIGR4(-)  capsular 
switch  strains  as  determined  by  measuring  the  total  area  within  the  cell  wall,  the  area 
including capsule polysaccharide and calculating an average capsule thickness using the 
formula area = Πr
2. There is no statistical difference between the thickness of the capsules 
of the opaque (ANOVA Ρ > 0.05) capsular switch strains. 
 
TIGR4(-)+ 
Strain 
Opaque Phase 
Capsule Thickness 
(nm ± SD) 
Transparent Phase 
Capsule Thickness 
(nm ± SD) 
Opaque v Transparent       
Ρ-value  
 
6A 
 
137 ± 20 
 
96 ± 15 
 
Ρ < 0.05 
 
7F 
 
148 ± 32 
 
88 ± 10 
 
Ρ < 0.001 
 
23F 
 
142 ± 23 
 
94 ± 9 
 
Ρ < 0.01 
 
4 
 
152 ± 26 
 
86 ± 13 
 
Ρ < 0.001 
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5.2.2 Effect of capsular serotype on C3b/iC3b deposition on S. pneumoniae in human 
serum 
To investigate the effect of capsular serotype on complement, C3b/iC3b deposition was 
investigated using flow cytometry on TIGR4 S. pneumoniae opaque phase variant strains.  
C3b/iC3b  deposition  was  dependent  on  capsular  serotype,  with  increased  C3b/iC3b 
deposition on the TIGR4(-)+23F and TIGR4(-)+6A strains compared to the TIGR4(-)+4 
and +7F strains (Ρ < 0.001, Fig 5.3). Results for C3b/iC3b deposition on the TIGR4 and 
TIGR4(-)+4 strains in 100% human sera were similar (FI of 5000 ± 1940 versus 3910 ±  
450 respectively, Fig 3.3A), demonstrating that the process of creating the mutant capsular 
switch strains did not have a significant affect C3b/iC3b deposition on S. pneumoniae. In 
addition,  C3b/iC3b  deposition  on  the  opaque  capsular  switch  strains  was  compared  to 
deposition on the same strains in transparent phase. The pattern of C3b/iC3b deposition on 
the transparent strains  was the same as on the opaque phase strains,  with a significant 
increase on the TIGR4(-)+23F and TIGR4(-)+6A strains (Ρ< 0.001, Fig. 5.4).  Furthermore, 
C3b/iC3b deposition was increased on each strain in transparent phase compared to the 
same strain in opaque phase, indicating that the thickness of the polysaccharide capsule 
affects C3b/iC3b deposition.  
 
Immunogold EM was used to identify the quantity and site of C3b/iC3b bound to opaque 
TIGR4 capsular switch strains.  In agreement with the flow cytometry results on the opaque 
strains, the TIGR4(-)+6A and +23F strains had a median of 29.0 and 22.5 gold particles per 
bacterium  respectively  compared  to  5.5  and  5.0  gold  particles  per  bacterium  for  the 
TIGR4(-)+4 and +7F strains respectively (Fig. 5.5 and 5.6). The increased number of gold 
particles on the TIGR4(-)+6A and +23F strains were concentrated in clusters of up to 26 205 
 
gold particles at one point on the bacterial surface (Fig. 5.6), whereas on the TIGR4(-)+4 
and +7F there were no more than 3 gold particles at a given point on the bacterial surface.  
These observations suggest on the TIGR4(-)+6A and +23F there has been greater focal 
amplification of C3b/iC3b deposition, which is known to be dependent on the alternative 
complement pathway (Walport 2001; Brown et al. 2002). This pattern was also found to be 
true for the transparent strains, with the +6A and +23F strains having an increased number 
of immunogold per bacterium compared to the +7F or +4 strains (Fig 5.7). Furthermore, 
there was increased immunogold staining on each transparent phase strain compared to the 
same  capsular  switch  strain  in  opaque  phase,  also  confirming  the  results  of  the  flow 
cytometry assay (Fig 5.5) and in accordance with results presented in Chapter 3.  206 
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Fig 5.3  C3b/iC3b deposition on opaque capsular switch strains in human serum 
(A)  FI  of  C3b/iC3b  deposition  measured  using  flow  cytometry  on  capsular  switched 
TIGR4(-)+ opaque phase strains expressing capsular serotypes 6A (￿), 7F (￿), 23F (￿) 
and 4 (￿) in increasing concentrations of human serum. (B) Examples of flow cytometry 
histograms for C3b/iC3b deposition on TIGR4(-)+ capsular switched strains in 50% human 
serum. Grey shadowing indicates the results for bacteria incubated in PBS alone. Error bars 
represent SDs, * Ρ < 0.01, ** Ρ < 0.001 (ANOVA with post-hoc tests).  207 
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Fig 5.4 C3b/iC3b deposition on TIGR4 capsular switch strains in human serum 
(A)  FI  of  C3b/iC3b  deposition  measured  using  flow  cytometry  on  capsular  switched 
TIGR4(-)+ strains expressing capsular serotypes 6A, 7F, 23F and 4 in opaque (open bars) 
and transparent (closed bars) phase in 25% human serum. Error bars represent SDs and *Ρ 
< 0.01 or **Ρ < 0.001 compared to the TIGR4(-)+4 strain (ANOVA with post hoc tests). 
(B), (C), (D), (E) Examples of flow cytometry histograms for C3b/iC3b deposition in 25% 
serum  on  TIGR4(-)  +  6A  (B),  7F  (C),  23F  (D)  and  4  (E)  opaque  (thick  lines)  and 
transparent (thin lines) strains. 208 
 
 
 
Fig 5.5 Immunogold against C3b/iC3b on TIGR4 capsular switch strains 
(A)  to  (H)  Representative  immunogold  EM  images  of  C3b/iC3b  deposition  on  the  
TIGR4(-) +6A opaque (A) and transparent (B), +7F opaque (C) and transparent (D), +23F 
opaque (E) and transparent (F) and +4 opaque (G) and transparent (H) strains.  209 
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Fig  5.6  Quantitation  of  immunogold  against  C3b/iC3b  on  TIGR4  capsular  switch 
strains 
Number of C3b/iC3b-labelled gold particles identified by immunogold EM deposited per 
bacterium for TIGR4(-)+ capsular switched strains (medians and interquartile range (IQR), 
n=10 per strain) in opaque (open bars) or transparent (slashed bars). *Ρ < 0.05 (Kruskal 
Wallis  with  Dunn’s  multiple  comparison  test)  compared  to  the  TIGR4(-)+4  strain.  For 
comparisons between the capsular switch strains in opaque phase, the serotype +6A and 
+23F were significantly different from the TIGR4(-) +4 strain (Ρ < 0.01 Kruskal Wallis 
with Dunn’s multiple comparison test).  
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5.2.3 The effect of capsular serotype on alternative and classical pathway activity 
To  provide  further  evidence  that  differences  in  C3b/iC3b  deposition  on  the  opaque  
TIGR4(-)+  strains  were  dependent  on  the  alternative  pathway,  the  C3b/iC3b  flow 
cytometry assays were repeated in sera depleted in specific components of the alternative 
(Bf
-) or classical (C1q
-) pathways, using C9
- serum as a control (Yuste et al. 2006; Yuste et 
al. 2008). As previously shown (Yuste et al. 2008) C3b/iC3b deposition was markedly 
reduced on all the TIGR4(-)+ strains in C1q
- and Bf
- sera  (Fig. 5.7  A, C and E). The 
patterns  of  C3b/iC3b  deposition  on  the  TIGR4(-)+strains  in  C1q
-  and  C9
-  serum  were 
similar to that obtained for normal human sera, with increased C3b/iC3b deposition on the 
TIGR4(-)+6A strain and smaller increases on the +23F strain. However, in Bf
- serum there 
were no differences in C3b/iC3b deposition between the TIGR4(-)+23F and +4 or +7F 
strains, and the increased in C3b/iC3b deposition on the +6A strains was proportionally less 
than that seen with C1q
- or C9
- sera.   
 
The  classical  pathway  can  be  activated  through  either  innate  or  adaptive  immune 
mechanisms, which may be differentially affected by the varying structures of the capsule 
polysaccharides. Differences in the binding of the classical complement pathway mediators 
C1q, CRP and SAP to the capsular switch strains were investigated using flow cytometry. 
There was increased binding of both C1q and CRP in the transparent strains, indicating that 
the thickness of the capsule affects binding of these complement mediators (Fig. 5.8 A and 
B). However, in contrast to the C3b/iC3b results, both the TIGR4(-) +6A and +7F strains 
showed high levels of C1q binding and there was no statistically significant difference in 
C1q binding between the TIGR4(-) +23F and +4 strain (ANOVA Ρ > 0.05, Fig. 5.8 A). 
CRP binding was significantly reduced on the TIGR4(-) +7F strain (ANOVA Ρ<0.05) but 211 
 
there  was  no  other  significant  difference  in  the  relative  binding  of  this  complement 
mediator to the other capsular switch strains (Fig. 5.8 D). In line with the results from 
TIGR4, TIGR4cps, D39 and D39-D  strains (Fig 3.13 A), there was increased SAP on the 
opaque phase variants compared to strains in transparent phase (Fig. 5.10 A).  There was 
decreased SAP binding on the +6A and +23F strains compared to the +7F and +4 capsular 
switch strains (ANOVA with post-hoc tests Ρ < 0.01). There was no correlation between 
the C3b/iC3b deposition results and binding of the classical pathway mediators C1q, SAP 
and CRP (Szalai et al. 1996; Brown et al. 2002; Yuste et al. 2007) to the TIGR4(-)+ strains.  
 
The activity of the alternative pathway is inhibited by the regulatory protein FH, which is 
known  to  interact  with  CbpA.  Whilst  CbpA  expression  is  increased  on  the  transparent 
variants, there may also be increased FH access to CbpA due to the thinner CPS. The 
transparent phase strains behaved in a similar manner to the unencapsulated strains (Fig 
3.13 B), with more FH binding compared to the opaque phase TIGR4 strains. However, 
there was no statistical difference in FH deposition between the 6A, 7F and 23F expressing 
strains, with a lower amount of FH deposited on the TIGR4(-) +4 strain (Fig. 5.10 D), 
indicating that increased FH binding was not accounting for the relatively low C3b/iC3b 
deposition on the TIGR4(-) +7F and +4 strains. Overall, these data suggest that the type of 
capsular serotype expressed by the TIGR4(-)+ strains has a marked effect on C3b/iC3b 
deposition  that  was  largely  dependent  on  alternative  rather  than  classical  complement 
pathway activity. 212 
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Fig 5.6 C3b/iC3b deposition on opaque TIGR4 capsular switch strains in complement 
depleted human serum 
(A), (C), (E). FI of C3b/iC3b deposition measured using flow cytometry on the opaque 
phase TIGR4(-)+ capsular switched strains in 25% human serum depleted of complement 
component C1q (A), factor B (C) or C9 (E). Error bars represent SDs and *Ρ < 0.01 or **Ρ 
< 0.001 compared to the TIGR4(-)+4 strain (ANOVA with post hoc tests). (B), (D), (F) 
Examples of flow cytometry histograms for C3b/iC3b deposition on TIGR4(-)+ 6A (thick 
black line), 7F (dotted line), 23F (dashed line) or 4 (thin solid line) strains in 25% C1q 
depleted (B), factor B depleted (D) or C9 depleted (F) human serum. 213 
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Fig 5.8 C1q and CRP binding to the TIGR4 capsular switch strains 
(A)  C1q  deposition  on  TIGR4(-)  capsular  switch  strains  in  opaque  (open  bars)  and 
transparent (solid bars) phase in 25% human serum. (B), (C) Representative flow cytometry 
histograms of C1q deposition on opaque (thick line) and transparent (thin line) TIGR4(-) + 
6A and +4 respectively. (D) CRP deposition on TIGR4(-) capsular switch strains in opaque 
(open bars) and transparent (solid bars) phase in 25% human serum. (E), (F) Representative 
flow cytometry histograms of CRP deposition on opaque (thick line) and transparent (thin 
line) TIGR4(-) + 6A and +4 respectively. For (A) and (D) error bars represent SDs and *Ρ 
< 0.01 or **Ρ < 0.001 (ANOVA with post hoc tests).  214 
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Fig 5.9 SAP and FH binding to the TIGR4 capsular switch strains 
(A)  SAP  deposition  on  TIGR4(-)  capsular  switch  strains  in  opaque  (open  bars)  and 
transparent (solid bars) phase in 25% human serum. (B), (C) Representative flow cytometry 
histograms of SAP deposition on opaque (thick line) and transparent (thin line) TIGR4(-) + 
6A and +4 respectively. (D) Factor H deposition on TIGR4(-) capsular switch strains in 
opaque  (open  bars)  and  transparent  (solid  bars)  phase  in  25%  human  serum.  (E),  (F) 
Representative flow cytometry histograms of factor H deposition on opaque (thick line) and 
transparent (thin line) TIGR4(-) + 6A and +4 respectively.  For (A) and (D) error bars 
represent SDs and *Ρ < 0.01 or **Ρ < 0.001 (ANOVA with post hoc tests).  
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5.2.4 The effect of antibody on C3b/iC3b deposition 
Since  antibody  can    activate  the  classical  complement  pathway,  the  levels  of  capsular 
specific IgG and IgM against serotype 6A, 7F, 4, 23F and 14 was quantitated using the 
WHO ELISA protocol (Wernette et al. 2003) (Fig. 5.10 A and B).  There was variation in 
the levels of both IgG and IgM in the human serum against the different capsular serotype. 
The IgG titres were found to correlate closely with C3b/iC3b deposition flow cytometry 
results for the TIGR4(-)+ strains (Pearson’s R
2 of 0.98 with P = 0.021), with high antibody 
levels against serotype 6A/6B (the ELISA is unable to distinguish between serotype 6A and 
6B). These data suggest the effects of capsular serotype on C3b/iC3b deposition could be 
due  to  differences  in  levels  of  capsule  specific  antibody.  However,  other  than  the 
polysaccharide capsule, S. pneumoniae has multiple antibody generating antigens which are 
present on the cell surface. Different capsule polysaccharides could affect the ability of 
these antibodies to bind to sub-capsular targets and therefore a flow cytometry assay which 
detects the relative total IgG and IgM binding to each TIGR4 capsular switch strain was 
performed.  Results  for  total  IgG  or  IgM  binding  to  the  +6A  and  +4  strain  were  not 
statistically significant (ANOVA Ρ > 0.05, Fig. 5.11 A and B), and overall there was no 
correlation between flow cytometry results for C3b/iC3b deposition and total IgG binding 
to the TIGR4(-)+ strains in human serum (Pearson’s R
2 < 0.0001, P = 1.0).  To clarify the 
importance  of  antibody  for  the  differences  in  C3b/iC3b  deposition  on  the  
TIGR4(-)+  strains,  C3b/iC3b  assays  were  repeated  using  baby  rabbit  complement  and 
mouse serum, both of which have no detectable IgG binding or capsular specific antibodies 
to S. pneumoniae (Yuste et al. 2008). As expected the absolute results for these sera were 
different to those for human sera due to differences in complement activity and the species-
specific  anti-C3  antibodies  used.  However,  the  pattern  of  C3b/iC3b  deposition  on  the 216 
 
TIGR4(-)+ strains in baby rabbit complement and mouse serum was similar to that obtained 
with normal human serum, with large increases on the TIGR4(-)+6A strain and (in baby 
rabbit complement) a less marked increase on the TIGR4(-)+23F strain, compared to the 
TIGR4(-)+4  and  +7F  strains  (Fig.  6.12  A  and  C).  Hence  the  differences  in  C3b/iC3b 
deposition  between  the  TIGR4(-)+  capsular  switched  strains  may  reflect  an  inherent 
property of capsular serotype.  
 
The pattern of C3b/iC3b deposition in C1q
- human serum (in which antibody mediated 
complement  activity  is  absent)  on  TIGR4(-)+  strains  was  similar  to  that  obtained  with 
complement sufficient serum (Fig. 5.7 A). Furthermore, repeated C3b/iC3b flow cytometry 
assays using test human serum which was depleted of IgG using IdeS demonstrated that in 
there  was  still  increased  C3b/iC3b  deposition  on  the  TIGR4(-)+6A  and  +23F  strains 
relative to the TIGR4(-)+4 and +7F strains when the effect of antibody was removed from 
human  serum  (Table  5.2).  Overall,  these  results  suggest  that  the  differences  between 
C3b/iC3b deposition on the TIGR4 capsular switch strains  cannot be  accounted for by 
differing levels of capsular specific antibody present in the serum.  
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Fig 5.10 Quantitation of capsular serotype specific IgG and IgM in human serum 
(A), (B) Quantitation using ELISA of levels of capsular serotype specific IgG (A) and IgM 
(B) in WT serum used in experiments throughout this thesis. For all panels, error bars 
represent SDs and *Ρ < 0.01 or **Ρ < 0.001 compared to the TIGR4 WT strain (ANOVA 
with post hoc tests). 218 
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Fig 5.11 IgG and IgM binding to opaque capsular switch strains 
(A), (B) FI of IgG (A) or IgM (B) deposition measured using flow cytometry on capsular 
switched TIGR4(-)+ opaque phase strains expressing capsular serotypes 6A, 7F, 23F and 4 
in 25% human serum. For both panels, error bars represent SDs and *Ρ < 0.05 compared to 
the TIGR4 WT strain (ANOVA with post hoc tests). 
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Fig 5.12 C3b/iC3b on opaque capsular switch strains opsonised in mouse or rabbit 
serum 
(A),  (C)  FI  of  C3b/iC3b  deposition  measured  using  flow  cytometry  on  the  TIGR4(-)+ 
capsular switched strains in 100% mouse serum (A) or 20% baby rabbit serum (C). Error 
bars represent SDs and  *Ρ < 0.01 or **Ρ  < 0.001 compared to the TIGR4(-)+4 strain 
(ANOVA  with  post  hoc  tests).  (B),  (D)  Examples  of  flow  cytometry  histograms  for 
C3b/iC3b deposition on TIGR4(-)+ 6A (thick black line), 7F (dotted line), 23F (dashed 
line) or 4 (thin solid line) strains in 100% mouse  (B) or 20% baby rabbit serum (D).  
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Table 5.2 Effects of IgG depletion using IdeS on mean FI +/- SDs of C3b/iC3b deposition 
and C1q binding to opaque TIGR4 capsular switch strains in 25% human serum. P values 
represent  comparisons  between  the  results  for  TIGR4(-)+6A,  7F  and  23F  against  the 
TIGR4(-)+4 strain using ANOVA with Dunnett’s multiple comparison. 
 
 
 
TIGR4(-)  
Strain 
 
C3b/iC3b deposition 
 (FI ± SD) 
BSA treated 
 
P value 
 
C3b/iC3b deposition 
 (FI ± SD) 
IdeS treated 
 
P value 
 
+6A 
 
55240 
± 7400 
 
 
< 0.01 
 
22440 
± 1670 
 
< 0.01 
 
+7F 
 
3930 
± 860 
 
 
> 0.05 
 
1200 
± 250 
 
> 0.05 
 
+23F 
 
16250 
± 450 
 
 
< 0.01 
 
4000 
± 170 
 
< 0.01 
 
+4 
 
5520 
± 620 
 
 
-- 
 
1650 
± 200 
 
-- 
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5.2.5  The  level  of  C3b/iC3b  deposition  on  capsular  switch  strains  correlates  with 
neutrophil phagocytosis 
The  functional  consequences  of  differences  in  C3b/iC3b  deposition  on  the  opaque  
TIGR4(-)+ strains were investigated using a flow cytometry neutrophil phagocytosis assay.  
This  assay  identifies  the  proportion  of  neutrophils  associated  with  fluorescent  bacteria, 
which data acquired using cytochalasin D suggests mainly represents internalisation of S. 
pneumoniae (Yuste et al. 2008). Bacteria were opsonised using mouse serum or baby rabbit 
complement to remove any complement independent antibody effects since levels varied 
against the different TIGR4(-)+ strains in test human serum. As expected phagocytosis of 
all strains was complement dependent, increasing with higher concentrations of serum, and 
with similar levels for bacteria incubated in heat treated (which inactivates complement) 
serum (Yuste et al. 2008) or buffer alone (Fig. 5.13 A and B). In buffer or heat inactivated 
serum there were no significant differences between the TIGR4(-)+ strains, but in both 
mouse serum and baby  rabbit complement the TIGR4(-)+6A and to a lesser extent the 
TIGR4(-)+23F strains were more susceptible to phagocytosis than the TIGR4(-)+4 and +7F 
strains (Fig. 5.13 A and B). There was a positive correlation for the results of phagocytosis 
with C3b/iC3b deposition measured by flow cytometry in 20% mouse serum (Pearson’s R
2 
0.93, P = 0.035)  and in 25% baby rabbit complement (Pearson’s R
2 0.93, P = 0.029).  
These  data  suggest  the  effects  of  capsular  serotype  on  C3b/iC3b  deposition  lead  to 
differences in phagocytosis.  
 
To demonstrate the effect of antibody and complement on opsonophagocytosis in human 
serum, assays were repeated using test human serum which had been treated with IdeS to 
cleave the Fc fragment of the IgG. There was reduced neutrophil phagocytosis of all of the 222 
 
capsular switch TIGR4 strains in IdeS treated serum compared to the control (BSA treated) 
human serum, and both the TIGR4(-)+6A and +23F strains showed increased association 
with neutrophils compared to the TIGR4(-)+7F and +4 strains. However when the opaque 
capsular switch strains were opsonised with serum in which complement was inactivated by 
heat treatment there was no difference between the different capsular serotypes (Table 5.3). 
In contrast to opsonisation with mouse and rabbit serum, the TIGR4(-) +7F showed the 
greatest  association  with  neutrophils  in  control  serum  compared  to  the  other  TIGR4 
capsular  switch  strains,  indicating  a  significant  effect  of  anti-capsular  antibody  on 
neutrophil phagocytosis against this serotype (Table 5.3).   
 
 
 223 
 
0
10
20
30
40
50
60
70
80 A
HBSS
%
 
a
s
s
o
c
i
a
t
i
o
n
C
+6A
+4
+23F
HBSS
10% sera HT 10% sera 5% sera 2.5% sera
0
20
40
60
80
100
HBSS 20% sera HT 20% sera
B
%
 
a
s
s
o
c
i
a
t
i
o
n
rabbit complement
mouse sera
20% rabbit complement
**
**
**
**
**
**
**
**
Fig 5.13 Neutrophil phagocytosis of TIGR4 capsular switch strains  
(A), (B) Neutrophil phagocytosis measured using flow cytometry of TIGR4(-)+6A (white 
columns), +7F (stippled columns), +23F (grey columns) or +4 (black columns) strains after 
incubation in HBSS buffer, heat treated (HT) 10% mouse serum, or 10%, 5% or 2.5% 
mouse serum (A), or heat treated (HT) 20% baby rabbit complement or 20% baby rabbit 
complement  (B).  Results  are  expressed  as  the  mean  (SD)  proportion  of  neutrophils 
associated with fluorescent bacteria (labelled with FAMSE), **Ρ < 0.001 (ANOVAs with 
post-hoc  tests)  compared  to  the  TIGR4(-)+4  strain.  (C)  Examples  of  flow  cytometry 
histograms for the association of TIGR4(-)+4, +6A and +23F capsular switched strains with 
neutrophils  after  opsonisation  with  20%  baby  rabbit  complement.  Grey  shadowing 
indicates  the  results  for  bacteria  incubated  in  HBSS  alone.  The  histogram  for  the  
TIGR4(-)+7F strain is not included for ease of interpretation of this Fig and because this 
strain had no significant differences to the TIGR4(-)+4 strain.  
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Table 5.3 Effects of IgG depletion using IdeS and complement depletion by heat treatment 
on mean +/- SDs percentage association of TIGR4 capsular switch strains with neutrophils 
after incubation in HBSS, 20% normal human serum (NHS) or 20% IdeS (IdeS) or heat 
treated (HT) serum. * P < 0.01 for comparisons between the results for TIGR4(-)+6A, 7F 
and 23F against the TIGR4(-)+4 strain using ANOVA with Dunnett’s multiple comparison. 
 
 
TIGR4(-)  
Strain 
 
HBSS 
 
20% HT 
Serum 
 
20% IdeS 
Serum 
 
20% NHS 
 
+6A 
 
11.30 
± 1.25 
 
20.50 
± 3.00 
 
 
58.90 
± 0.80 
 
69.90 
± 1.30 
 
+7F 
 
11.60 
± 1.35 
 
18.40 
± 1.00 
 
 
42.10 
± 1.85 
 
84.30 
± 0.95 
 
+23F 
 
11.90 
± 2.60 
 
19.00 
± 1.05 
 
 
55.60 
± 1.30 
 
76.10 
± 2.25 
 
+4 
 
11.30 
± 1.90 
 
18.30 
± 1.10 
 
 
44.70 
± 1.40 
 
69.40 
± 1.26 
 
 
* 
* 
* 
* 225 
 
5.2.6 The effect of capsular serotype on virulence in mouse models of infection 
To  determine  if  the  effects  of  capsular  serotype  on  complement  deposition  and 
phagocytosis were associated with differences in virulence a mouse model of septicaemia 
was used.  Groups of five mice were infected by IP inoculation with 2000 CFU of the 
TIGR4(-)+ strains, and bacterial CFU recovered from blood and spleens after 24 hours 
calculated by plating serial dilutions (Fig. 5.14).  In this model no unencapsulated TIGR4 
strain  are  recovered  from  either  spleen  or  blood  at  24  hours  (Chapter  3).    For  all  the 
TIGR4(-)+ strains large numbers of bacteria were recovered from the blood and spleens 
after 24 hours, compatible with the known virulence of the TIGR4 strain in mice (Fig. 5.14) 
(Sandgren et al. 2005).  The mean CFU in the spleens depended on capsular serotype, with 
significantly lower CFU recovered for the TIGR4(-)+6A and +23F strains (median CFU 
3.40 and 5.87 x 10
6 respectively) compared to the TIGR4(-)+7F and +4 strains (median 
CFU 8.4 and 13.2 x 10
6 respectively) (Fig. 5.14 A).  Similar results were obtained for the 
median CFU in blood (Fig. 5.14 B).  Hence the TIGR4(-)+ strains with increased levels of 
C3b/iC3b deposition and neutrophil phagocytosis were less virulent in a mouse model of 
septicaemia.  
 
Furthermore, we investigated the effects of capsular serotype in early lung infection by 
intranasally inoculating 5x10
6 CFU FAM-SE labelled TIGR4(-)+ strains, harvesting after 4 
hours and performing bronchoalveolar lavages on CD1 outbred mice. The +6A and +23F 
strains showed significantly lower bacterial counts than the +4 and +7F capsular switch 
strains (Fig. 5.15 A), indicating that within the first 4 hours of lung infection their survival 
was already impaired. In addition, alveolar macrophages isolated by flow cytometry from 
BALF of mice inoculated with the +6A and +23F strains showed increased fluorescence, 226 
 
suggesting that the decreased survival of these strains was associated with an increased 
uptake by resident alveolar macrophages (Fig. 5.15 B). TNFα levels in the BALF were 
significantly lower in mice inoculated with +6A and +23F strains compared to +7F and +4 
strains (Fig. 5.16) showing that these capsular  serotypes induced  a lower inflammatory 
response in early lung infection which may be related to the lower CFU in BALF at this 
time point.  227 
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Fig 5.14 Virulence of the capsular switched TIGR4(-)+ strains in a septicaemia model 
(A), (B) Median (IQR) bacterial CFU recovered from mouse spleens (A) or blood (B) 24 
hours after IP inoculation of 4000 CFU of the TIGR4(-)+6A, +7F, +23F or +4 strains. For 
both blood and spleen inoculation, P = 0.0005 (Kruskal-Wallis) for the overall comparison 
between  strains.  P  values  for  individual  strains  compared  to  the  TIGR4(-)+4  strain  are 
given above the respective box and whisker plot (Dunn’s multiple comparison test).  228 
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Fig 5.15 Virulence of the capsular switched TIGR4(-)+ strains in early lung infection 
(A) Median (IQR) bacterial CFU recovered from BALF 4 hours after IN inoculation of 
5x10
6 CFU of the TIGR4(-)+6A, +7F, +23F or +4 strains. (B) FI of alveolar macrophages 
following  4  hours  IN  inoculation.  For  both  panels,  P  =  0.001  (Kruskal-Wallis)  for  the 
overall  comparison  between  strains.  P  values  for  individual  strains  compared  to  the 
TIGR4(-)+4 strain are given above the respective box and whisker plot (Dunn’s multiple 
comparison test).  229 
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Fig 5.16 BALF TNFα levels 4hr after IN inoculation of TIGR4 capsule switch strains 
TNF-alpha  levels  quantitated  by  ELISA  from  bronchoalveolar  lavage  fluid  following  4 
hours IN inoculation of opaque capsular switch strains. P = 0.001 (Kruskal-Wallis) for the 
overall  comparison  between  strains.  P  values  for  individual  strains  compared  to  the 
TIGR4(-)+4 strain are given above the respective box and whisker plot (Dunn’s multiple 
comparison test).  230 
 
5.3 SUMMARY 
Flow  cytometry  and  immunogold  EM  demonstrated  increased  C3b/iC3b  deposition  on 
otherwise isogenic strains expressing serotype 23F and 6A capsules compared to strains 
expressing the ST4 and 7F capsules; however there was no difference in capsule thickness 
between  strains  in  the  same  phase.  Furthermore,  the  phase  variation  of  S.  pneumoniae 
strains was found to affect complement activity with increased C3b/iC3b deposition on 
transparent  phase  variants.  Whilst  capsule  serotype  specific  IgG  levels  correlated  with 
C3b/iC3b  deposition  on  the  TIGR4(-)+  capsular  switched  strains  in  human  test  serum, 
C3b/iC3b deposition was also increased on the TIGR4(-)+6A and +23F strains in naive 
mouse and baby rabbit serum which contain no S. pneumoniae specific IgG. Human serum 
depleted  of  C1q  (and  therefore  lacking  antibody-mediated  complement  activity)  also 
showed  a  similar  pattern,  suggesting  the  effects  are  largely  independent  of  antibody. 
Furthermore test human serum depleted of IgG function by IdeS also showed a similar 
pattern of C3b/iC3b deposition on the capsular switch strains. C3b/iC3b deposition results 
in sera deficient in alternative pathway activity and data on the binding of classical pathway 
mediators to the TIGR4(-)+ strains, as well as the immunogold EM demonstrating large 
clusters of C3b/iC3b only on the +6A and +23F strains, all indicated that the differences in 
C3b/iC3b deposition between strains are mainly alternative pathway dependent (Brown et 
al. 2002), as has previously been suggested for non-isogenic strains of different capsular 
serotypes (Winkelstein et al. 1976).   
 
Neutrophil phagocytosis of S. pneumoniae is largely complement dependent and there are 
significant differences in susceptibility to phagocytosis for different S. pneumoniae strains 
(Winkelstein et al. 1976; Kim et al. 1999; Yuste et al. 2008; Melin et al. 2009). Neutrophil 231 
 
phagocytosis  of  the  TIGR4(-)+  strains  correlated  closely  with  the  C3b/iC3b  deposition 
results when bacteria were opsonised in serum lacking anti-pneumococcal antibody. The 
TIGR4(-)+6A strain which had the highest level of C3b/iC3b deposition was also the most 
sensitive  to  neutrophil  phagocytosis,  with  an  intermediate  result  for  the  TIGR4(-)+23F 
strain  and  both  the  TIGR4(-)+4  and  +7F  strains  being  relatively  resistant  to  neutrophil 
phagocytosis.  These  differences  in  phagocytosis  were  abolished  when  the  TIGR4(-)+ 
strains  were  not  opsonised  with  C3b/iC3b.  Both  the  TIGR4(-)+6A  and  +23F  strains 
exhibited  reduced  virulence  in  a  mouse  septicaemia  model,  with  a  nearly  four-fold 
difference  in  recovered  bacterial  CFU  24  hours  after  infection  with  the  TIGR4(-)+6A 
compared  to  the  TIGR4(-)+4  strains,  correlating  with  C3b/iC3b  and  neutrophil 
phagocytosis results. Furthermore, the capsular serotype of these strains was found to have 
an effect in a lung infection model, with the TIGR4(-)+6A and +23F exhibiting decreased 
survival,  increased  association  with  alveolar  macrophages  and  a  lower  TNFα  response 
within the first 4 hours of lung infection in comparison to the serotype 7F and 4 expressing 
strains.  232 
 
CHAPTER 6  
THE EFFECT OF NON CAPSULAR GENETIC FACTORS ON COMPLEMENT 
MEDIATED IMMUNITY 
 
6.1 INTRODUCTION   
There is considerable genetic variation between S. pneumoniae strains independent of genes 
required  for  capsule  biosynthesis,  due  to  gene  insertions,  gene  deletions  and  allelic 
variation. Molecular epidemiology studies using multi locus sequence typing (MLST) show 
that  non-capsular  genetic  variation  is  partially  linked  to  capsular  serotype 
(http://www.mlst.net/),  and  hence  any  relationship  between  capsular  serotype  and 
complement resistance may not necessarily be caused by variations in capsule structure. At 
present the relative importance of capsular serotype or other genetic differences between S. 
pneumoniae strains for complement activity and whether there is a relationship between 
relative complement resistance and S. pneumoniae invasiveness is not known and needs 
clarification.  
 
To  investigate  whether  non-capsular  genetic  variation  between  S.  pneumoniae  strains 
causes  variation  in  susceptibility  to  complement,  complement  deposition  on  a  range  of  
S.  pneumoniae  clinical  isolates  expressing  common  capsular  serotypes  was  assessed. 
Results of these experiments were correlated with the invasive potential of the different 
strains to assess if there is a relationship between the invasiveness of a strain and its ability 
to resist complement mediated immunity. 
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6.2 RESULTS 
6.2.1 Measurement of capsule thickness in clinical isolates of S. pneumoniae 
Clinical  isolates  were  given  as  a  kind  gift  from  Dr  William  Hanage  and  Dr  Brigitta 
Henriques-Normark. The strains were all isolated from children under 5 years old with 
invasive  pneumococcal  disease  and  represent  a  range  of  serotypes  which  are  relatively 
highly invasive (1, 4, 14) and serotypes which are relatively lowly invasive (6A, 6B, 9V, 
19F and 23F). Serotype 1 is of concern due to its high incidence in empyema in children 
and the CPS of serotypes 6B and 6A differ in structure by a single bond.  
 
All clinical isolates were grown on Tryptone Soya agar with catalase and examined under a 
microscope  to  determine  phase  of  the  S.  pneumoniae  strains.  All  clinical  isolates  were 
found to be in opaque phase (data not shown). The Stains-All assay was used to measure 
the relative amount of capsule polysaccharide produced by the 6B or 23F serotype clinical 
isolates. There was no significant difference in the amount of polysaccharide quantified 
between the different MLST strains from within the 6B serotype, nor between strains from 
the 23F serotype (Ρ > 0.05, Fig. 6.1). Furthermore, there was no difference in capsule 
thickness between selected 6B and 23F clinical isolate strains when viewed by electron 
microscopy (Ρ > 0.05, Fig. 6.2). These results suggest that there is no major difference in 
capsule expression (ie capsule thickness) between the different strains of these capsular 
serotypes.  
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Fig 6.1 Biochemical capsule assessment in serotype 6B and 23F S. pneumoniae strains 
Stains-All  Assay  semi-quantitating  the  amount  of  bacterium-associated  capsule 
polysaccharide  in  strains  relevant  to  this  thesis  chapter.  Serotype  3  wild-type,  D39 
encapsulated TIGR4cps strains (black bars) were used as controls and compared to clinical 
isolates  strains  of  either  serotype  6B  (open  bars)  or  23F  (slashed  bars).    There  is  no 
statistically significant difference within strains of the 6B or 23F serotype.  
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Fig 6.2 EM capsule measurement in serotype 6B and 23F strains 
(A) to (D) Representative EM images of the serotype 6B ST 138 (A),  ST 176 (B), and the 
serotype 23F ST 515 (C) and ST 277 (D) strains respectively. (E) Analysis of capsule 
thickness of 10 random bacteria per S. pneumoniae strain as determined by measuring the 
total area within the cell wall, the area including capsule polysaccharide and calculating an 
average capsule thickness using the formula area = Πr
2. Kruskal-Wallis ANOVA shows no 
statistically significant difference between the strains.  
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6.2.2 Non-capsular factors influence C3b/iC3b deposition on S. pneumoniae 
To investigate whether other genetic variation between S. pneumoniae strains could affect 
complement activity independent of capsular serotype, C3b/iC3b deposition was assessed 
on opaque variants of genetically distinct clinical isolates for the capsular serotypes 4, 6B, 
14 and 23F. C3b/iC3b deposition varied between strains within serotypes, most noticeably 
for  6B  and  23F  isolates  (Fig.  6.3).  The  serotype  6B  ST176  and  ST90  strains  showed 
significantly less C3b/iC3b deposition than the ST273 and ST138 strains (ANOVA with 
post hoc tests Ρ<0.01), despite these strains expressing the same capsule polysaccharide 
with the same capsule thickness. All of the MLST strains from serotype 23F showed a 
statistically  significant  difference  in  C3b/iC3b  deposition  (ANOVA  with  post  hoc  tests  
Ρ <0.01). 4 different MLST isolates from serotype 6A were also assessed for C3b/iC3b 
deposition, and showed variation with genetic background. However, as with the TIGR4 
capsular switch strains (Fig 5.4), there was a high level of C3b/iC3b deposition on the 
serotype 6A strains in comparison to strains from other serotypes (Fig 6.4). Immunogold 
EM for C3b/iC3b deposition on selected 6B and 23F strains gave similar results as flow 
cytometry assays (Fig. 6.5). The serotype 6B isolate of ST138 and the serotype 23F isolate 
of ST217 with high levels of C3b/iC3b deposition on flow cytometry had 16 (IQR 11-34) 
and 17 (IQR 12-33) gold particles associated with each bacterium respectively, whereas the 
6B  isolate  of  ST176  and  23F  isolate  of  ST515  strains  with  lower  levels  of  C3b/iC3b 
deposition on flow cytometry had 5 (IQR 3-9) and 7 (IQR 4-13) gold particles associated 
with each bacterium respectively (P=0.01 for 23F strains, and <0.0001 for 6B strains, Mann 
Whitney U-test) (Fig. 6.4 E). These data show that there were large variations in C3b/iC3b 
deposition on S. pneumoniae strains independent of capsular serotype. 
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Fig 6.3 Effect of non-capsular serotype genetic variation on C3b/iC3b deposition 
(A) Mean (SD) FI of C3b/iC3b deposition measured using flow cytometry on capsular 
serotype 4 (white bars), 6B (diagonal slash bars), 14 (black bars) and 23F (horizontal slash 
bars) clinical isolates (labelled with their ST number) in 25% human serum. TIGR4(-)+4 
and +23F strains are included for comparison. *Ρ < 0.01, **Ρ < 0.001 (ANOVAs with 
post-hoc  tests)  comparing  results  within  a  serotype  to  the  TIGR4  (serotype  4),  ST176 
(serotype 6B), ST162 (serotype 14) and ST515 (serotype 23F) strains. (B), (C) Examples of 
a flow cytometry histograms for C3b/iC3b deposition on selected serotype 6B (B) and 23F 
(C) clinical isolates labeled by ST number.  238 
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Fig 6.4 C3b/iC3b on serotype 6A clinical isolates of S. pneumoniae 
(A) Mean (SD) FI of C3b/iC3b deposition measured using flow cytometry on capsular 
serotype  6A  clinical  isolates  (labelled  with  their  ST  number)  in  25%  human  serum. 
TIGR4(-)+6A  is  included  for  comparison.  *  Ρ  <  0.001  (ANOVAs  with  post-hoc  tests) 
comparing results to the ST1068 strain. (B) Examples of flow cytometry histograms for 
C3b/iC3b deposition on serotype 6A clinical isolates labelled by ST number. The histogram 
for the ST488 strain is not included for ease of interpretation of this figure and because this 
strain had no significant differences to the ST490 strain.  239 
 
6.2.3 The effect of capsular serotype on C3b/iC3b deposition on clinical isolates 
To further investigate complement interactions with S. pneumoniae, C3b/iC3b deposition 
on 32 S. pneumoniae strains representative of both relatively highly  (1, 4 and 14) and 
weakly invasive (6A, 6B, 9V, 19F and 23F) serotypes were compared. The total strains 
analysed included the clinical isolates described above of serotypes 4, 6B, 14 and 23F plus 
clinical isolates of capsular serotypes 1, 6A, 9V and 19F and an additional two serotype 6B 
and one serotype 14 strain (Table 6.1). There was considerable variation in results between 
strains, and between most serotypes there were marked overlap in results for individual 
strains. However, C3b/iC3b deposition on the serotype 6A strains remained higher than on 
other serotypes (median FIs of 134,800 versus 50950 respectively, P = 0.0054) (Fig 6.5). 
There  were  also  differences  in  C3b/iC3b  deposition  for  isolates  belonging  to  the  same 
clonal  complex  and  with  the  same  capsular  serotype  that  were  isolated  from  different 
geographical backgrounds (eg serotype 6B isolates of ST138 and ST176), a result that is 
compatible with recent data showing genetic variation between strains with the same ST 
and capsular serotype (Silva et al. 2006). 
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Fig 6.5 C3b/iC3b deposition on different serotypes of S. pneumoniae 
(A) Median FI of C3b/iC3b deposition measured using flow cytometry for clinical isolate 
strains from serotypes 1, 4, 14, 9V, 6B, 19F and 23F encompassing between 3-5 different 
MLST strains per serotype. *Ρ < 0.05 (Kruskal Wallis with Dunn’s multiple comparison 
test) compared to serotype 1. (B) Median FI of C3b/iC3b deposition measured using flow 
cytometry  on  6B  and  6A  clinical  isolate  strains,  representing  the  median  value  for 
C3b/iC3b deposition obtained from between 3 and 5 strains within each serotype. Mann-
Whitney U-test Ρ = 0.001.  241 
 
Table 6.1    Binding of C3b/iC3b, IgG, C1q and FH to clinical isolates of S. pneumoniae and 
percentage association of the clinical isolate strains with neutrophils when 
opsonised in 20% human serum.  
 
Serotype  ST  IgG  
Binding 
(FI ± SD)
a b  
C1q 
Binding 
(FI ± SD)
a 
b 
FH 
 Binding 
(FI ± SD)
a b 
C3b/iC3b  
Binding 
(FI ± SD)
a b  
% neutrophil 
association 
(± SD) 
14  124  1520 ± 180  1960 ± 110  1370 ± 160  45224 ± 4790  52.4 ± 4.2 
14  162  1660 ± 180  790 ± 140  2650 ± 220  9060 ± 1490  45.0 ± 0.2 
14  156  2700 ± 220  2720 ± 300  1480 ± 20  55800 ± 8190  59.2 ± 0.3 
14  307  2800 ± 260  4300 ± 170  2410 ± 110  34510 ± 6850  75.4 ± 1.4 
14  124  1550 ± 30  4280 ± 140  2960 ± 290  48640 ± 3840  71.1 ± 5.4 
23F  36  1450 ± 130  3300 ± 550  1280 ± 120  67080 ± 8280  55.2 ± 4.1 
23F  37  2810 ± 220  4030 ± 240  1600 ± 120  94130 ± 9770  71.9 ± 1.9 
23F  277  3450 ± 170  6350 ± 430  1020 ± 120  144780 ± 8240  92.3 ± 5.3 
23F  515  650 ± 30  910 ± 60  2190 ± 130  29250 ± 1190  45.0 ± 0.5 
6A  488  4470 ± 560  6700 ± 390  960 ± 280  484860±10920  65.0 ± 0.9 
6A  490  1800 ± 340  3740 ± 330  520 ± 20  313230 ± 9730  75.7 ± 2.2 
6A  518  2000 ± 460  4690 ± 390  980 ± 70  307290 ± 8370  47.1 ± 4.2 
6A  1068  6940 ± 80  7480 ± 170  480 ± 180  743240±13850  94.6 ± 0.6 
6B  90  2920 ± 740  2590 ± 40  3100 ± 30  38460 ± 8910  66.7 ± 4.2 
6B  138  1700 ± 330  5990 ± 430  1940 ± 180  83550 ± 10240  65.0 ± 5.0 
6B  176  2100 ± 20  3690  ± 330  2100 ± 250   46780 ± 6980   62.0 ± 3.2 
6B  273  1160 ± 300  1720 ± 60  1990 ± 70  28330 ± 3500  57.4 ± 0.9 
6B  138  4000 ± 200  6780 ± 160  1750 ± 230  118330 ± 1820  95.9 ± 1.9 
6B  176  1870 ± 90  5480 ± 70  1160 ± 440  99540 ± 6760  88.3 ± 2.4  
1  306  1150 ± 250  4360 ± 130  2908 ± 180  27600 ± 5930  63.9 ± 4.5 
1  228  1060 ± 50  1470 ± 120  3870 ± 400  14000 ± 3260  59.8 ± 3.1 
1  217  1090 ± 40  2790 ± 265  3760 ± 50  18340 ± 4000  46.2 ± 2.8 
4  1222  1360 ± 30  1530 ± 370  2170 ± 100  45590 ± 1780  55.5 ± 3.1 
4  205  1650 ± 50  3850 ± 520  2360 ± 160  38170 ± 1720  48.7 ± 3.2 
4  205  1440 ± 80  3380 ± 625  1430 ± 100  47130 ± 9080  68.7 ± 4.1 
4  259  1390 ± 40  1820 ± 490  1390 ± 160  43060 ± 13090  56.4 ± 3.9 
9V  162  1040 ± 100  4340 ± 130  2160 ± 200  41809 ± 8320  76.3 ± 3.0 
9V  162  1250 ± 290  4710 ± 880  2560 ± 100  60744 ± 7590  78.3 ± 2.5 
9V  156  1260 ± 90  3380 ± 100  1470 ± 250  88814 ± 10140  66.9 ± 4.2 
19F  425  800 ± 10  4480 ± 690  2100 ± 150  54470 ± 3950  63.7 ± 2.2 
19F  162  1170 ± 120  4220 ± 980  1490 ± 250  36980 ± 4000  63.3 ± 1.9 
19F  236  1810 ± 130   4220 ± 600  2430 ± 140  73880 ± 11990  80.3 ± 2.8 
19F  556  2610 ± 260  6350 ± 700  1030 ± 110   151280 ± 800  93.5 ± 5.6 
 
a FIs are expressed as arbitrary units    
b IgG, C1q and FH binding was measured in 25% human serum  
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6.2.4 The effect of antibody and complement mediators on C3b/iC3b deposition 
The variation in C3b/iC3b deposition between strains within a serotype might be accounted 
for by differences in the ability of strains to resist interactions with IgG, as well as classical 
complement pathway mediators (such as C1q) and alternative pathway regulators (FH). 
Hence  the  binding  of  IgG,  C1q  and  FH  to  the  clinical  isolates  of  S.  pneumoniae  was 
investigated using flow cytometry assays previously described, enabling correlations to be 
made between binding of these complement regulators and C3b/iC3b binding (Table 6.1). 
There was variation in the total IgG binding between strains of the same serotype, which 
may be due to variation in different sub-capsular antigens and hence different levels of 
specific IgG in the serum.  
 
IgG  activates  the  complement  system  through  the  classical  pathway  by  allowing  C1q 
binding to the Fc portion of the antibody molecule and thereby initiating the complement 
cascade resulting in increased cleavage of C3 into C3b. Total IgG binding to S. pneumoniae 
strains was found to moderately correlate to the results of the C3b/iC3b deposition assays 
(Pearson’s Correlation Co-efficient R
2=0.37) (Fig 6.6 A), although anti-capsular IgG did 
not correlate to C3b/iC3b (Pearson’s Correlation Co-efficient R
2=0.17, Ρ=0.34) (data not 
shown). The IgG was removed from human test serum by pre-incubation with IdeS, which 
acts to cleave the Fc fragment of the IgG, and used to examine the effect of antibody on 
C3b/iC3b deposition on the 6B and 23F clinical isolates (Table 6.2). As with previous 
results,  there  was  decreased  C3b/iC3b  deposition  on  all  S.  pneumoniae  strains  when 
antibody  was  removed  from  the  serum,  suggesting  the  importance  of  antibody  in 
complement mediated immunity against clinical isolates of pneumococcus. The serotype 243 
 
6B ST176 showed less C3b/iC3b deposition than both the ST138 and ST176 strains in both 
the  control  and  IdeS  treated  serum  (ANOVAs  with  post-hoc  tests  Ρ  <  0.01),  and  the 
serotype 23F ST515 strain showed significantly less C3b/iC3b deposition compared to the 
ST37 and ST277 strains (ANOVAs with post-hoc tests Ρ < 0.01). Hence in both the 6B and 
23F clinical isolates the overall pattern of C3b/iC3b deposition persisted in the absence of 
antibody (Table 6.2).   
 
Furthermore,  C1q  binding  was  found  to  correlate  with  C3b/iC3b  deposition  (Pearson’s 
Correlation  Co-efficient  R
2=0.56)  (Fig  6.6  B),  and  total  IgG  binding  correlated  to  C1q 
binding  (Pearson’s  Correlation  Co-efficient  R
2=0.41,  Ρ<0.0001).  The  alternative 
complement pathway is regulated by the inhibitory FH, which has been shown to bind 
CbpA which varies in structure between different S. pneumoniae strains. The binding of FH 
also  correlated  with  C3b/iC3b  deposition  on  these  strains  of  S.  pneumoniae  (Pearson’s 
Correlation  Co-efficient  R
2=0.37)  with  increased  FH  binding  associated  with  decreased 
C3b/iC3b deposition (Fig 6.7). 
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Fig 6.6 Correlation of IgG and C1q binding to C3b/iC3b deposition 
(A), (B) Correlation of FI  IgG (A) and C1q (B) to FI C3b/iC3b deposition on clinical 
isolates of S. pneumoniae measured opsonised with 25% human serum and measured using 
flow cytometry. For both panels, Pearson’s Correlation Co-efficient and associated Ρ-value 
are shown on the figure. Original data shown in Table 6.1. 
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Fig 6.7 Correlation of FH binding to C3b/iC3b deposition 
(A)  Correlation  of  FI  FH  binding  to  FI  C3b/iC3b  deposition  on  clinical  isolates  of  
S.  pneumoniae  measured  opsonised  with  25%  human  serum  and  measured  using  flow 
cytometry. Original data shown in Table 6.1. 246 
 
Table 6.2 Effects of IgG depletion using IdeS on mean FI +/- SDs of C3b/iC3b deposition 
and on S. pneumoniae clinical isolate strains from serotypes 6B and 23F in 50% human 
serum. P values represent comparisons between S. pneumoniae clinical isolates against the 
either control (BSA) or IdeS treated ST273 (6B isolates) or ST515 (23F isolates) using 
ANOVA with Dunnett’s multiple comparison test. 
 
Serotype  Strain 
(ST) 
IdeS 
treated 
C3b/iC3b Deposition 
(FI ± SD) 
P value 
   
90 
 
No 
 
7420 ± 870 
 
> 0.05 
    Yes  3600 ± 680 
 
> 0.05 
   
138 
 
No 
 
49340 ± 3900 
 
< 0.01 
6B    Yes  25510 ± 4040 
 
< 0.01 
 
 
 
 
176 
 
No 
 
4960 ± 1100 
 
< 0.01 
Yes  1730 ± 190  < 0.01 
 
273 
 
 
No 
 
11220 ± 390 
 
- 
Yes  4240 ± 1190  - 
   
36 
 
No 
 
14790 ± 1390 
 
> 0.05 
    Yes  5810 ± 320  >  0.05 
23F   
37 
 
No 
 
70470 ± 15840 
 
< 0.01 
    Yes  15380 ± 2780  < 0.01 
 
 
 
 
 
277 
 
No 
 
87770 ± 5960 
 
< 0.01 
Yes  46010 ± 4310  < 0.01 
 
515 
 
 
No 
 
9640 ± 840 
 
- 
Yes  2890 ± 380 
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6.2.5 C3b/iC3b deposition correlates with opsonophagocytosis 
To assess whether the differences in C3b/iC3b deposition between S. pneumoniae strains 
had functional consequences, phagocytosis of selected strains was measured using a flow 
cytometry assay and rabbit complement (to eliminate the effects of varying antibody levels 
to the different strains). Results were expressed as the proportion of neutrophils associated 
with fluorescent bacteria, known to be mainly due to phagocytosis (Yuste et al. 2008). The 
differences between serotype 6B and 23F clinical isolates in the results of the C3b/iC3b 
deposition  assays  seemed  to  persist  in  the  opsonophagocytosis  assay  (Fig  6.8  A),  with 
strains showing high levels of C3b/iC3b deposition also having high levels of phagocytosis. 
Furthermore there was a strong relationship between C3b/iC3b deposition in rabbit serum 
and association of neutrophils with the serotype 23F and 6B strains (Pearson’s Correlation 
Co-efficient R
2=0.952) (Fig 6.8 C). Although there was some variation in the results of the 
opsonophagocytosis  assay  between  rabbit  and  human  serum,  presumably  due  to  the 
complement-independent effect of anti-pneumococcal antibodies present in human serum, 
the results correlate significantly (Fig 6.9) (Pearson’s Correlation Co-efficient R
2=0.51). To 
see if this pattern persisted in the presence of antibody, opsonophagocytosis assays were 
repeated using human serum as an opsonin (Table 6.1). Correlation of C3b/iC3b deposition 
on S. pneumoniae with opsonophagocytosis using human serum found that the relationship 
between C3b/iC3b deposition and neutrophil association was maintained in human serum, 
albeit with a weaker correlation than in the absence of antibodies against pneumococcus 
(Pearson’s Correlation Co-efficient R
2=0.58) (Fig 6.9).  
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Fig 6.8 Neutrophil phagocytosis of serotype 6B and 23F S. pneumoniae clinical isolates 
(A) Neutrophil phagocytosis of serotype 6B (slashed bars) and 23F (grey bars) clinical 
isolates (labelled by ST number) incubated in 20% baby rabbit complement. Results are 
expressed as the mean (SD) proportion of neutrophils associated with fluorescent bacteria 
(labelled with FAMSE). Results obtained when bacteria were opsonised in BSA did not 
significantly differ between strains. *Ρ < 0.01 or **Ρ < 0.001 (ANOVAs with post-hoc 
tests) compared to ST176 for the serotype 6B strains, and to ST515 for the serotype 23F 
strains. (B) Examples of flow cytometry histograms for the association of serotype 23F 
strains with neutrophils after opsonisation with 20% rabbit complement. (C) Correlation 
between FI of C3b/iC3b deposition measured using flow cytometry and the proportion of 
neutrophils associated with fluorescent bacteria for the 23F and 6B clinical isolates (ST 
numbers adjacent to data points) with baby rabbit serum. Error bars represent SDs, and 
Pearson’s Correlation Coefficient was R
2 = 0.952 (Ρ < 0.001). 249 
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Fig 6.9 Correlation of C3b/iC3b results and neutrophil phagocytosis in human serum 
Correlation between FI of C3b/iC3b deposition measured using flow cytometry and the 
proportion  of  neutrophils  associated  with  fluorescent  bacteria  all  clinical  isolates  using 
human serum. Pearson’s Correlation Coefficient was R
2 = 0.58 (Ρ < 0.001). 250 
 
6.2.6 C3b/iC3b deposition correlates with invasiveness 
As complement is vital for preventing systemic infection (Yuste et al. 2005) and as capsular 
serotype  affects  C3b/iC3b  deposition  on  S.  pneumoniae  I  hypothesised  that  capsular 
serotypes particularly associated with IPD are likely to be relatively complement resistant. 
To  investigate  this  possibility,  mean  C3b/iC3b  deposition  on  12  S.  pneumoniae  strains 
representative of relatively highly invasive (1, 4, 7F and 14) and 21 S. pneumoniae strains 
representative of weakly invasive (3, 6A, 6B, 9V, 19F and 23F) serotypes were compared. 
Overall, median C3b/iC3b deposition on strains from invasive serotypes was significantly 
lower than the results for strains from weakly invasive serotypes (median FIs of 41600 IQR 
17200-55880 versus 88810 IQR 39410-105000 respectively, P = 0.0075) (Fig. 6.10 A). The 
results remained statistically significant even when the serotype 6A strains were excluded 
from  analysis  of  the  weakly  invasive  serotype  group  (to  prevent  the  high  C3b/iC3b 
deposition levels on 6A strains skewing data) (median FI 72680 IQR 36400-100200, P = 
0.0036) (Fig. 6.10 B). Furthermore, the median C3b/iC3b deposition for serotypes which 
are  relatively  highly  invasive  was  significantly  lower  than  the  median  C3b/iC3b  for 
relatively lowly invasive serotypes (median FI 42144 IQR 29152-44775 versus 72885 IQR 
62459-29230  respectively,  P  =  0.0095)  (Fig  6.11  A).  Again  these  results  remained 
statistically significant when the serotype 6A was excluded from analysis (median FI 65156 
IQR  62460-133100,  P  =  0.0159)  (Fig  6.11  B).  These  data  show  that  S.  pneumoniae 
capsular serotypes particularly associated with invasive infection are relatively resistant to 
complement  compared  to  serotypes  which  are  less  likely  to  cause  IPD,  providing  one 
possible reason why S.  pneumoniae strains can  vary in virulence and providing further 
evidence for the importance of complement for immunity to S. pneumoniae. 251 
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Fig 6.10 Relationship of C3b/iC3b results to invasiveness 
(A), (B) FI of C3b/iC3b deposition measured using flow cytometry on all clinical isolates 
from invasive serotypes (circles, serotypes 1, 4, 7F and 14) compared to the results for all 
strains from weakly invasive serotypes (triangles, serotypes 3, 6A, 6B, 9V, 19F, and 23F) 
including (A) or excluding (B) the results for serotype 6A strains. The symbols represent 
the mean value of three or more assays for each strain. Bars represent the median values for 
each group. P values were obtained using the Mann Whitney U-Test. 252 
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Fig 6.11 Relationship of C3b/iC3b results to invasiveness by serotype 
(A), (B) Median FI of C3b/iC3b deposition measured using flow cytometry from invasive 
serotypes (circles, serotypes 1, 4, 7F and 14) compared to the median results per serotype 
for weakly invasive serotypes (triangles, serotypes 3, 6A, 6B, 9V, 19F, and 23F) including 
(A) or excluding (B) the results for serotype 6A strains. The symbols represent the median 
value obtained for each serotype. P values were obtained using the Mann Whitney U-Test. 
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6.3 SUMMARY 
In summary, using several strains of representative STs for 4 different capsular serotypes 
the results in this chapter  demonstrate that, at least for some capsular serotypes, there were 
consistent  and  perhaps  surprisingly  large  variations  in  C3b/iC3b  deposition  on  
S. pneumoniae between strains with different genetic backgrounds but the same capsular 
serotype. The differences in C3b/iC3b deposition were not related to capsule thickness, and 
correlated  with  IgG,  C1q  and  inversely  correlated  with  FH  binding  on  S.  pneumoniae. 
Furthermore,  C3b/iC3b  deposition  correlated  closely  with  the  results  of  neutrophil 
phagocytosis  assays  in  both  rabbit  complement  and  human  serum.  There  were  even 
differences between strains that although they have the same ST and the same capsular 
serotype were isolated from different geographical backgrounds (e.g. the ST138 and 176 
serotype  6B  strains,  and  the  ST124  serotype  14  strains).  These  data  demonstrate  that 
complement activation by S. pneumoniae can be markedly affected by non-capsular factors, 
including differences in recognition of subcapsular antigen by IgG and possibly differing 
levels of FH binding.  
 
The hypothesis that relative resistance to complement activity may explain some of the 
differences  in  virulence  between  capsular  serotypes  was  investigated  by  comparing 
C3b/iC3b deposition on 12 strains from the invasive capsular serotypes 1, 4, 7F and 14 to 
the results for 21 strains from serotypes with relatively low invasive potential, using strains 
representative of prevalent STs for each capsular serotype. Strikingly, C3b/iC3b deposition 
on invasive serotypes was significantly reduced compared to the results for weakly invasive 
strains.  Hence  invasive  serotypes  seem  to  be  less  sensitive  to  complement-dependent 
bacterial  clearance and  this could partially explain why these serotypes are particularly 254 
 
capable  of  causing  systemic  infection.  These  data  suggest  that  the  varying  effects  of 
different capsular serotypes on complement activity against S. pneumoniae are clinically 
relevant. 255 
 
CHAPTER 7    DISCUSSION 
 
7.1 DISCUSSION 
Although  the  Streptococcus  pneumoniae  capsule  is  known  to  be  an  essential  virulence 
factor,  there  is  surprisingly  little  detailed  information  on  how  the  capsule  enables  both 
systemic and lung virulence. There is considerable data which supports the vital role of 
complement  in  immunity  against  S.  pneumoniae,  especially  for  preventing  systemic 
infection (Gross et al. 1978; Tu et al. 1999; Brown et al. 2002; Jonsson et al. 2005; Yuste et 
al. 2005; Khandavilli et al. 2008; Yuste et al. 2008), and inhibition of complement activity 
by the capsule is likely to be important for S. pneumoniae virulence. However, little is 
known about several aspects of the effects of the capsule on S. pneumoniae interactions 
with  complement  and  neutrophils.  These  include  which  complement  pathways  are 
inhibited,  the  potential  role  of  known  mediators  of  complement  activity,  and  whether 
inhibition of phagocytosis by the capsule is just a consequence of inhibition of opsonisation 
with  complement  or  is  also  due  to  the  effects  of  the  capsule  on  other  mediators  of 
phagocytosis. Additional phenotypes ascribed to the capsule such as resistance to NETs 
(Wartha  et  al.  2007)  may  also  influence  virulence,  and  overall  the  importance  for  the 
development of S. pneumoniae invasive disease of inhibition of complement activity by the 
capsule  requires  clarification.  A  more  complete  understanding  of  how  the  capsule  can 
affect virulence would help the investigation of why some capsular serotypes are more able 
to cause invasive disease in humans (Brueggemann et al. 2003; Brueggemann et al. 2004) 
and perhaps assist our understanding of the implications of capsular serotype replacement 
in response to vaccination campaigns (Jacobs et al. 2008). 256 
 
Both TIGR4 and D39 strains of S. pneumoniae have been used extensively for pathogenesis 
studies  and  these  strains  are  virulent  in  mice.  The  capsular  serotype  4  clinical  isolate 
TIGR4  belongs  to  a  relatively  invasive  serotype  and  D39  is  a  laboratory  strain  of  
S. pneumoniae which was originally derived from an invasive serotype 2 strain and has 
been one of the main strains used to investigate pneumococcal disease. The unencapsulated 
TIGR4 strain was constructed by complete replacement of the capsular locus with the Janus 
cassette (Nelson et al. 2007) whereas the unencapsulated D39 strain was constructed by an 
in-frame deletion of cpsD, a gene that encodes an enzyme required for regulation of capsule 
synthesis  (Morona  et  al.  2004).  Both  strains  have  been  previously  well  characterised, 
however  in  this  thesis  the  loss  of  capsule  was  confirmed  using  a  biochemical  method 
(Stains-All assay) as well as through visualisation by electron microscopy. Previous studies 
suggested that deletion of whole or parts of the cps locus affect growth of S. pneumoniae 
(Battig et al. 2007) and hence the effect of these mutations on the TIGR4cps and D39-D  
strains was investigated. In contrast to the results from Battig et al, the results showed that 
loss of capsule had no significant effect on S. pneumoniae growth in complete medium 
(THY broth). This may perhaps be accounted for by the cpsD mutation in the D39-D  
strain being less severe than the mutations analysed by Battig and additionally by the effect 
of  complete  disruption  to  the  cps  locus  differing  between  TIGR4  and  D39  strains. 
Furthermore  neither  unencapsulated  strain  exhibited  a  growth  defect  in  serum,  and  all 
strains showed greater growth in serum than in blood at each time point. There was also no 
apparent growth defect in the unencapsulated strains in blood, which was unexpected given 
the presence of neutrophils in the blood and the increased opsonophagocytosis of both 
TIGR4cps and D39-D  compared to their encapsulated parental strains. However since 2 x 
10
6 CFU S. pneumoniae were inoculated into 1ml of blood (which contains approximately 257 
 
6 x 10
3 PMNs/ml) there was a considerable excess of bacteria which overwhelmed the 
capacity of the neutrophils present in the blood to clear the S. pneumoniae. 
 
In accordance with the results of other investigators for the D39 strain (Quin et al. 2007), 
the flow cytometry analysis of C3b/iC3b deposition on S. pneumoniae confirmed that the 
capsule inhibits C3b/iC3b opsonisation of the D39 strain. Furthermore the TIGR4 capsule 
was also found to inhibit C3b/iC3b deposition. However the extent to which the capsule 
prevented C3b/iC3b deposition varied between the D39 and TIGR4 strains, with a larger 
difference in C3b/iC3b deposition on the TIGR4cps strain compared to the TIGR4 than 
between  the  D39-D   and  D39  strains.  It  is  possible  that  the  difference  in  C3b/iC3b 
deposition is due to differing levels of antibodies against the different antigens present on 
the TIGR4 and D39 strains as the level of total anti-pneumococcal antibodies against these 
strains  was  not  quantitated.  However,  in  the  presence  of  IdeS,  which  cleaves  the  Fab 
portion of IgG and thereby prevents IgG activating complement, there was still a relatively 
greater increase in C3b/iC3b deposition on the TIGR4cps strain compared to the D39-D  
strain suggesting that this effect is only partially dependent on antibody. Furthermore, since 
S. pneumoniae is not a natural pathogen of mice the results obtained using mouse serum to 
opsonise the bacteria are independent of antibody effects, providing further evidence that 
the capsule affects antibody independent complement mechanisms. Whilst this difference 
may be attributable to the structure of the polysaccharide capsule, the TIGR4 capsule was 
also thicker than the D39 capsule. There is a large amount of allelic variation between 
strains in complement inhibitory proteins such as CbpA and PspA (Briles et al. 1981; Crain 
et al. 1990; Iannelli et al. 2002; Bentley et al. 2006) which could also influence the effects 
of an individual capsule on complement activity. A full investigation of the relationship of 258 
 
capsular  serotype  to  complement  inhibition  would  require  studying  encapsulated  and 
unencapsulated strains from multiple serotypes and perhaps different strains of the same 
serotype,  but  would  be  important  given  the  relationship  between  capsular  serotype  and 
virulence.  
 
The increase in complement activity against unencapsulated strains was confirmed using an 
immunoblot  against  C3  to  look  for  C3  breakdown  products  with  different  doses  of  
S. pneumoniae. For both the TIGR4 and D39 strains there was increased C3 breakdown in 
the serum at all doses of inoculum used. These results support the flow cytometry data and 
confirm that the difference in C3b/iC3b deposition detected on the unencapsulated strains is 
not  merely  an  artefact  created  by  increased  antibody  access  to  cell  wall  surface  bound 
C3b/iC3b in the unencapsulated strains. Furthermore, flow cytometry indicated a decreased 
ratio of iC3b to total C3b/iC3b on the bacterial surface of both TIGR4 and D39 compared 
to TIGR4cps and D39-D  respectively, showing that the capsule inhibits breakdown of 
C3b to iC3b on the bacterial cell surface.  
 
It is thought that both innate and adaptive immune responses use the classical pathway to 
initiate  C3b/iC3b  deposition  on  S.  pneumoniae  and  are  activated  by  recognition  of  the 
bacteria  by  specific  IgG,  natural  IgM  and  the  pentraxins  CRP  and  SAP,  whereas  the 
alternative  pathway  acts  mainly  to  amplify  C3b/iC3b  deposition  (Szalai  et  al.  1996; 
Walport 2001; Xu et al. 2001; Brown et al. 2002; Yuste et al. 2007). Flow cytometry data 
obtained with both human and mouse sera depleted in either the first component of the 
classical pathway C1q or the alternative pathway protein factor B demonstrated that both 259 
 
pathways  are  required  for  the  increase  in  C3b/iC3b  deposition  on  unencapsulated  
S. pneumoniae.  
 
The capsule prevented recognition of both TIGR4 and D39 S. pneumoniae by the classical 
pathway mediators IgG, IgM and CRP (but interestingly not SAP) and this was associated 
with  an  increase  in  C1q  binding.  Depletion  of  IgG  using  IdeS  demonstrated  that  a 
substantial portion of the effects of the capsule on inhibition of C3b/iC3b deposition was 
due to prevention of IgG binding to S. pneumoniae and therefore activation of the classical 
complement  pathway.  Although,  in  vaccinated  individuals  anti-capsular  antibody  is 
important  for  immunity  to  S.  pneumoniae,  the  data  showing  that  IgG  binding  to  
S. pneumoniae is inhibited by the capsule suggest that most of the naturally occurring IgG 
in  unvaccinated  individuals  recognises  subcapsular  antigens,  presumably  cell  wall 
phosphocholine or cell surface protein antigens (Briles et al. 1981). Hence, as has been 
demonstrated for specific S. pneumoniae antigens and also for other bacteria (McDaniel et 
al. 1991; Daniels et al. 2006), the capsule masks subcapsular antigens from host IgG and 
this is one mechanism by which the capsule inhibits classical pathway activation. 
 
The  data  obtained  with  human  serum  depleted  of  IgG  and  mouse  sera,  especially  data 
obtained  with  C1qa
-/-  sera  which  cannot  support  either  IgG  or  natural  IgM  mediated 
complement activity (Brown et al. 2002; Yuste et al. 2008), shows persisting differences in 
C3b/iC3b deposition between encapsulated and unencapsulated strains. Therefore as well 
as inhibiting antibody-mediated complement activity, the capsule acts to directly inhibit 
complement  activity.  The  EM  immunogold  experiments  showed  large  clusters  of  C3 
particles  at  one  site  on  the  cell  wall  suggestive  of  focal  amplification  of  complement 260 
 
activity only in unencapsulated stains. Taken together with the increased CRP, IgG and 
C1q binding data, these results suggest that the capsule can prevent both recognition of  
S.  pneumoniae  by  the  classical  pathway  mediators  IgG  and  CRP  and  amplification  of 
C3b/iC3b  deposition  by  the  alternative  pathway.  Prevention  of  CRP  binding  to  
S.  pneumoniae  is  a  possible  IgG-independent  mechanism  through  which  the  capsule 
inhibits classical pathway activity, but there are likely to be other mechanisms as well. How 
the capsule prevents alternative pathway activity is less clear, but mechanical and perhaps 
charge-charge  inhibition  of  access  of  complement  pathway  proteins  to  S.  pneumoniae 
targets beneath the capsule is likely to be important. As expected given that FH binding by 
S. pneumoniae is mediated by the subcapsular proteins PspC and PhtD (Dave et al. 2001; 
Ogunniyi et al. 2009), FH binding on unencapsulated strains was increased, which would 
be expected to decrease rather than increase alternative pathway activity. However, the 
effects of increased FH binding are likely to be outweighed by other capsular effects on 
complement  activity  in  the  alternative  pathway.  For  example  the  alternative  pathway 
dependent increase in C3b/iC3b deposition on unencapsulated S. pneumoniae could reflect 
amplification of complement activity initiated through increased classical pathway activity, 
but  there  may  also  be  direct  inhibition  of  alternative  pathway  activity  by  the  capsule 
analogous to other pathogens (Maruvada et al. 2009). The non-IgG mediated mechanisms 
of capsule inhibition of complement activity require further investigation. 
 
The  EM  immunogold  pictures  suggest  that  complement  activation  only  occurs  at  a 
surprisingly limited number of sites on the cell wall of even unencapsulated S. pneumoniae. 
Whether the presence of cell wall complement inhibitory proteins such as PspA and CbpA 
(Jarva et al. 2002; Yuste et al. 2006) prevent more uniform C3b/iC3b deposition or whether 261 
 
the  C3b/iC3b  binding  sites  are  genuinely  restricted  in  number  will  require  further 
investigation. Variation in the distribution of cell surface proteins could affect the overall 
pattern  of  C3b/iC3b  deposition.  Protein  virulence  factors  have  a  metabolic  cost  to  the 
bacterium, and therefore it is likely that they would not necessarily be widely distributed 
throughout the bacterial surface. Hence sporadic distribution of virulence factors which are 
a complement target may account for the sporadic C3b/iC3b deposition on S. pneumoniae. 
Localisation  of  proteins  to  the  bacterial  poles  is  essential  for  the  correct  function  and 
regulation of cell division, and it may be that the C3b/iC3b deposition is targeted to a 
specific protein which is located at in higher concentration at the pole (Lybarger et al. 
2001). Heterogeneity within the cell wall of S. pneumoniae may prove to be important in 
the distribution of C3b/iC3b deposited on the bacterial cell surface (Vollmer et al. 2000; 
Vollmer et al. 2001). Certain pneumococcal enzymes involved in separation of daughter 
cells  during  bacterial  division  have  been  shown  to  be  more  concentrated  around  the 
bacterial pole, and these may potentially be a target for C3b/iC3b deposition, which could 
also explain the tendency for the C3b/iC3b clumps to be localised near the bacterial pole 
(Vollmer et al. 2001; De Las Rivas et al. 2002).  
 
Neutrophil  phagocytosis  is  considered  one  of  the  major  elements  of  immunity  to  
S.  pneumoniae,  and  is  markedly  dependent  on  S.  pneumoniae  opsonisation  with 
complement (Yuste et al. 2008). Hence the significant increases in phagocytosis of both the 
TIGR4cps and D39-D  strains compared to the corresponding encapsulated strains at all 
concentrations of complement used and in the commercially available C9, C1q and factor B 
depleted sera was expected due to the effects of the capsule on opsonisation of the bacteria 
with  C3b/iC3b.  In  normal  human  serum,  there  was  a  greater  relative  difference  in  the 262 
 
neutrophil  association  with  TIGR4cps  and  TIGR4  than  that  for  the  D39  and  D39-D  
strains, which paralleled the results of the C3b/iC3b deposition on these strains as measured 
by flow cytometry. As iC3b is thought to be a more efficient opsonin than C3b, the relative 
increase in iC3b on unencapsulated S. pneumoniae may also contribute to the increase in 
phagocytosis  of  these  strains  (Tohyama  et  al.  2006).  Experiments  with  cytochalasin  D 
demonstrated that the differences between unencapsulated and encapsulated bacteria were 
largely due to increased internalisation of unencapsulated bacteria. However as well as 
complement-dependent effects of the capsule on phagocytosis, there were also significant 
impairments of the association of encapsulated TIGR4 and D39 with neutrophils when the 
bacteria were incubated in HBSS, or heat treated or commercially available C3 depleted 
serum, all conditions in which bacteria are not opsonised with complement. These results 
show  that  as  well  as  inhibiting  neutrophil  phagocytosis  by  reducing  opsonisation  of  
S.  pneumoniae  with  C3b/iC3b,  the  capsule  also  prevents  complement-independent 
mechanisms  of  phagocytosis.  The  increased  IgG  binding  to  the  unencapsulated  strains 
(despite  loss  of  the  target  for  anti-capsular  antibodies)  could  increase  Fc-γ  receptor-
mediated antibody-dependent phagocytosis, but this would not account for the smaller but 
consistent and significant differences in phagocytosis seen for bacteria incubated in HBSS 
alone. Furthermore data obtained with IgG depleted and complement-deficient sera also 
demonstrated increased phagocytosis of S. pneumoniae. These data suggest that the capsule 
inhibits complement and IgG mediated phagocytosis, but also inhibits bacterial interactions 
with non-opsonic phagocytic receptors such as mannose or scavenger receptors. 
 
The  importance  of  the  effects  of  the  capsule  on  complement  activity  during  systemic 
infection was investigated using a mouse model of sepsis and genetically modified mice 263 
 
which were partially deficient in C3, or C1q (no classical pathway activity) or factor B (no 
alternative pathway activity). In wild-type mice although both the D39 and TIGR4 strains 
are highly virulent, even inoculation IP with large numbers of unencapsulated bacteria did 
not cause disease. In contrast, infection of C3
+/- mice with unencapsulated bacteria resulted 
in significant septicaemia, suggesting that complement activity is required for the effects of 
the  capsule  on  virulence.  This  was  confirmed  using  competitive  infection  experiments, 
which showed that the unencapsulated strains were avirulent in complement sufficient mice 
but regained virulence in reduced C3 levels, or the absence of C1q or factor B. However, 
for both the D39 and TIGR4 strains less than one unencapsulated bacterium was recovered 
from mouse spleens for every hundred encapsulated bacteria, with an even lower ratio for 
bacteria  recovered  from  blood.  Interestingly  in  the  D39  strain  loss  of  the  alternative 
pathway demonstrated a lower restoration of virulence, and hence this pathway has less of 
an effect in vivo, which is in line with previous data stating that the classical pathway is the 
dominant pathway for complement mediated immunity against this strain of S. pneumoniae 
(Brown et al. 2002). These data are compatible with neutrophil data showing a significant 
level  of  complement-independent  phagocytosis,  and  demonstrate  that  the  effects  of  the 
capsule  on  virulence  during  sepsis  are  mediated  through  both  complement  and 
complement-independent mechanisms. Whether the latter is due to capsule inhibition of 
NETs,  phagocytosis  mediated  by  Fc-γ  or  other  neutrophil  or  macrophage  phagocytic 
surface receptors, or other unknown effects of the capsule requires further investigation. 
 
Unfortunately, throughout this thesis the in vivo data were generated using C3
+/- mice due 
to  an  error  which  occurred  in  the  back-crossing  of  the  mouse  strain,  which  was  only 
recently  identified.  This  makes  interpreting  the  relative  importance  of  complement 264 
 
dependent  compared  to  non-complement  dependent  effects  of  the  capsule  difficult.  In 
humans,  the  C3
+/-  phenotype  is  associated  with  a  circulating  level  of  C3  which  is 
approximately 50% that found in C3
+/+ individuals, and it is likely that this is similar for 
C3
+/-  mice.  The  level  of  C3  in  the  serum  of  C3
+/-  mice  needs  to  be  measured,  or 
experiments  repeated  using  C3
-/-  mice.  Infection  with  pneumococcus  leads  to  rapid  C3 
consumption (Biozzi 1961; Brown et al. 1983) and hence the presumed lower level in C3
+/- 
mice could rapidly result in functional depletion of C3.  
 
Pulmonary immunity is distinctly different from systemic immunity and it is likely that 
AMs play a key role in early immune responses in the lung to S. pneumoniae infection. 
AMs are the resident specialised phagocytic cell in the lung  and have previously been 
shown to mediate both phagocytic and inflammatory responses to S. pneumoniae and other 
pathogens. However the effect of the capsule on early lung responses, in particular those 
from AMs, remains unclear and this was investigated using a in vitro mouse macrophage 
cell line (RAW 264.7 cells) as well an early pulmonary infection model. 
 
There were significant associations between RAW 264.7 cells and all S. pneumoniae strains 
at 15 minutes and a rapid complement dependent association with RAW 264.7 cells and the 
unencapsulated  strains.  There  was  also  a  slower  complement  independent  effect  of  the 
TIGR4 capsule on association with macrophages since at 60 minutes there was a significant 
increase  in  association  of  unencapsulated  S.  pneumoniae  opsonised  in  complement 
deficient  serum  or  HBSS  compared  to  encapsulated  S.  pneumoniae.  Both  encapsulated 
strains showed a high degree of resistance to association with RAW 264.7 cells, with a 
maximum of 10% of cells becoming associated with bacteria within 60 minutes regardless 265 
 
of  opsonic  conditions.  This  data  suggests  that  the  capsule  plays  an  important  role 
preventing association between S. pneumoniae and macrophages and that this effect may 
involve  both  complement  dependent  and  independent  mechanisms.  Macrophages  in  the 
lung are able to phagocytose bacteria and opsonisation with complement or antibody is 
important in this process (Jonsson et al. 1985). Internalised S. pneumoniae are killed by 
AMs  and  with  low  inoculae  are  able  to  clear  S.  pneumoniae  from  the  lungs  without 
requiring neutrophil recruitment (Gordon et al. 2000; Dockrell et al. 2003). 
  
To determine if the polysaccharide capsule has a role in lung infection a well established 
pneumonia model was used. For both TIGR4 and D39 the encapsulated parental strains 
showed increased survival over the unencapsulated strains within the first 4 hours of lung 
infection. There was a two log reduction in bacterial CFU counts of TIGR4cps and a one 
log reduction of D39-D , continuing the trend that loss of capsule in the TIGR4 strain has 
a  more  profound  effect  than  capsule  loss  in  the  D39  strain.  Flow  cytometry  analysis 
revealed a corresponding increase in association of the unencapsulated strains with AMs 
collected in the BAL fluid, implying that it is increased phagocytosis by AMs which are 
responsible for the increased clearance of the TIGR4cps and D39-D  strains. Furthermore 
there was increased internalisation of TIGR4cps by AMs compared to the TIGR4 strain 
when  viewed  using  a  Z-stacking  confocal  microscopy  method.  However  only  a  small 
number  of  AMs  were  visualised  in  this  manner  and  this  requires  more  extensive 
examination.  
 
In addition there was an increased TNFα response to the TIGR4cps and D39-D  strains 
despite  a  decreased  bacterial  CFU  load  at  this  time  point,  indicating  a  much  stronger 266 
 
inflammatory response induced in the absence of the capsule. Both AMS and epithelial 
cells are capable of producing TNFα and the capsule could potentially affect inflammatory 
responses by either cell type. Clarification of the effect of the S. pneumoniae capsule on 
AMs in terms of both bacterial clearance and immune response in early lung infection can 
be investigated using a local AM depletion method via liposomal clodronate (Dockrell et al. 
2003).  However  other  investigators  have  outlined  the  importance  of  AMs  in  the  pro-
inflammatory response (Franke-Ullmann et al. 1996). 
 
The mechanism by which the capsule could inhibit AM phagocytosis also requires further 
clarification. Although this could be due to secondary effects on complement, the effect of 
complement in pulmonary immunity remains unclear since levels of complement in BALF 
are  approximately  10%  that  found  in  the  circulation  (Gross  et  al.  1978).  Furthermore 
complement factors found in BALF are predominately alternative pathway components and 
previous data has indicated that the classical pathway is the dominant complement pathway 
for host immune responses to pneumococcus (Brown et al. 2002). There are also other 
innate immune mechanisms present in the lung, including opsonisation with surfactant and 
IgG  or  cell  surface  scavenger  receptors  such  as  MARCO  which  could  play  a  role  in 
phagocytosis and hence clearance of S. pneumoniae (Dallaire et al. 2001; Arredouani et al. 
2004). 
 
To investigate the relative importance of complement for the capsule effects on AMs, early 
lung infection experiments were repeated in mice with a partial complement deficiency. 
C3
+/- mice had increased bacterial CFU of both TIGR4 and TIGR4cps within 4 hours of 
infection,  indicating  a  role  for  complement  in  early  lung  clearance  of  S.  pneumoniae. 267 
 
However there was a greater relative increase in the survival of the TIGR4cps compared to 
the TIGR4 strain which suggests that the capsule prevents an early complement-mediated 
pulmonary  clearance.  Decreased  bacterial  survival  of  the  TIGR4cps  strain  was  again 
accompanied with an increased association with AMs. However there was no statistically 
significant increase in association of the TIGR4 strain with AMs from wild-type and C3
+/- 
mice.  C3
-/-  mice  are  more  likely  to  have  a  more  significant  phenotype  and  repeat 
experiments in C3
-/- mice are necessary to fully characterise the role of C3 in the lungs of 
these mice. In parallel with previous results there was an increase in TNFα levels in the 
BAL fluid from mice inoculated with TIGR4cps compared to TIGR4. Furthermore mice 
with a partial C3 deficiency showed reduced TNFα response compared to wild-type mice, 
suggesting a role for complement activation in the inflammatory response. C5a and C3a are 
potent pro-inflammatory mediators released by complement activation, and also stimulate 
phagocytosis (Janoff et al. 1999; Walport 2001; Mollnes et al. 2002; Skokowa et al. 2005). 
Hence increased complement activation could have indirect effects on immunity as well as 
increased  opsonisation  of  unencapsulated  strains.  Overall  these  results  suggest  that 
complement may indeed play a role in early lung immune responses and that the TIGR4 
capsule may act to prevent complement mediated clearance. However they are difficult to 
interpret, likely to under estimate the effect of complement and require repetition with C3
-/- 
mice.  Furthermore  additional  work  to  investigate  if  these  observations  are  true  for  
S. pneumoniae strains other than TIGR4 is required.  
 
The observed difference in the early pulmonary TNFα response to encapsulated TIGR4 and 
D39 compared to the TIGR4cps and D39-D  strains respectively was investigated further 
using RAW 264.7 macrophages. TNFα levels produced by these cells was comparable to 268 
 
levels noted by other investigators in response to LPS and bacterial stimuli including E. coli 
and S. pneumoniae (Yoon et al. 2007; Aldridge et al. 2008; Kang et al. 2009). Time points 
of 3 and 24 hours were chosen to represent release of pre-formed TNFα and production of 
TNFα  respectively.  There  was  an  early  serum  independent  release  of  TNFα  from 
macrophages stimulated with TIGR4cps and D39-D , however at 24 hours both strains 
induced  a  mainly  complement  dependent  production  of  TNFα.  However  there  was  a 
smaller complement dependent effect observable in the D39-D  strain at 24 hours than in 
the TIGR4cps strain. Neither the TIGR4 nor D39 strain induced a TNFα level which was 
greater than 25ng/ml over the 24 hour stimulation, demonstrating the anti-inflammatory 
properties of encapsulated S. pneumoniae.   
 
Since TNFα production is classically mediated through the NFκB pathway (Baldwin 1996), 
quantitative  confocal  immunofluorescence  assays  of  NFκB  RelA  (p65)  nuclear 
translocation were performed on RAW 264.7 cells stimulated with TIGR4, TIGR4cps, D39 
and  D39-D   (Noursadeghi  et  al.  2008).  All  strains  of  S.  pneumoniae  induced  a 
translocation of NFκB from the cytoplasm to the nucleus when opsonised in human serum. 
Furthermore in an MOI dose response, the unencapsulated TIGR4cps and D39-D  strains 
induced  greater  nuclear  staining  of  p65  than  the  corresponding  TIGR4  and  D39  strain 
respectively. Again there was a smaller difference between the D39 and D39-D  strain 
than  between  the  TIGR4  strains.  The  increased  nuclear  translocation  of  NFκB  in  cells 
stimulated  with  TIGR4cps  and  D39-D   was  found  to  have  a  significant  complement 
dependent component, as demonstrated by differences observed between bacteria opsonised 
with  heat-treated  (complement  deficient)  and  normal  human  serum.  However,  as  with 
previous results, there was a larger complement independent effect in the D39 strains.  269 
 
 
NFκB activation is tightly regulated through signals that control the breakdown of IκBα 
(Baldwin  1996),  and  immunoblots  against  IκBα  in  cell  lysates  from  RAW  264.7  cells 
stimulated with TIGR4 S. pneumoniae opsonised in serum showed a statistically significant 
reduction  in  signal  when  macrophages  were  stimulated  with  TIGR4cps  compared  to 
TIGR4. This confirmed the results of the quantitative confocal immunofluorescence assays 
and furthermore demonstrated that the TIGR4cps stimulation of RAW 264.7 cells showed a 
similar  pattern  of  IκBα  degradation  to  stimulation  with  LPS.  The  IκBα  signal  did  not 
significantly  decrease  until  after  30  minutes  stimulation  with  the  encapsulated  TIGR4 
strain, indicating a delay in the response of the macrophages to TIGR4 S. pneumoniae 
compared to the unencapsulated strain. 
 
Studies have shown that patients with deficiencies in IRAK4 and NEMO-dependent NFκB 
activation have a marked increased in incidence of IPD (Ku et al. 2005; Ku et al. 2007; Ku 
et  al.  2007),  highlighting  the  importance  of  the  inflammatory  response  in  immunity  to  
S.  pneumoniae.  Furthermore  common  polymorphisms  in  the  IκB  genes  NFKBIA  and 
NFKBIE    genes  are  associated  with  increased  frequency  of  S.  pneumoniae  infection 
(Chapman et al. 2007). However conversely there is also data indicating that mice with 
increased inflammation have increased susceptibility S. pneumoniae (Marriott et al. 2006; 
Hinojosa  et  al.  2009).  Other  investigators  have  outlined  the  importance  of  the  MAPK 
signalling pathways in host immunity to S. pneumoniae (Schmeck et al. 2004; N'Guessan et 
al. 2006; Kang et al. 2009) and I have found that both the p38 and ERK 1/2 pathways are 
activated  after  RAW  264.7  macrophages  are  incubated  with  TIGR4  S.  pneumoniae. 
However,  interestingly  there  were  no  significant  differences  in  the  response  to 270 
 
unencapsulated and encapsulated bacteria for these pathways, contrasting with the results 
for  the  IκBα  pathway.  Hence  TIGR4  CPS  specifically  inhibits  the  NFκB  activation 
pathway in macrophages. This is a potentially interesting finding which may provide some 
explanation for the greatly increased susceptibly of individuals with deficiency of IRAK4 
and NEMO-dependent NFκB activation to S. pneumoniae infections. However, this should 
be  clarified  to  establish  the  effect  occurs  for  more  than  one  capsule  serotype  of  
S. pneumoniae. Furthermore, whether this effect persists in the absence of complement and 
is dependent on phagocytosis should also be established. Various hypotheses could account 
for how the S. pneumoniae capsule specifically inhibits the NFκB activation pathway in 
macrophages.  It  is  possible  that  the  reduced  NFκB  activation  is  a  consequence  of 
complement  activation  through  pro-inflammatory  C5a  acting  on  the  C5a  receptor,  and 
therefore  internalisation  of  S.  pneumoniae  does  not  necessarily  have  to  occur  for  the 
capsule to reduce NFκB activation. However it is also possible that increased bacterial 
association  and/or  internalisation  of  the  unencapsulated  S.  pneumoniae  specifically 
activates a certain receptor that signals through the NFκB pathway rather than p38 or ERK 
1/2 in response to this stimulus. 
 
It  remains  unclear  which  pro-inflammatory  macrophage  receptors  the  S.  pneumoniae 
capsule affects, but important candidates are TLR (2, 4 and 9) and NOD due to increased 
phagocytosis. In addition, although CR1 and CR3 mediated phagocytosis is thought to be 
pro-inflammatory (Klickstein et al. 2000; Xia et al. 2000), phagocytosis mediated by the 
Fcγ  receptor  is  pro-inflammatory  and  furthermore  increased  phagocytosis  may  increase 
NOD activation. Increased complement activation could also be pro-inflammatory through 
increased C3a and C5a mediated inflammation. The data on the S. pneumoniae capsule 271 
 
affecting different aspects of complement and phagocytosis suggest capsule would also 
affect  a  range  of  cell-surface  pro-inflammatory  receptors.  How  the  capsule  may 
differentially  affect  inflammation  requires  more  detailed  investigation  using  assays  in 
which phagocytosis in inhibited using cytochalasin D. Furthermore macrophages isolated 
from  MyD88-/-TRIF-/-  mice  in  which  there  is  no  TLR  mediated  cell  signalling  would 
provide insights as to whether this receptors are involved in the inflammatory response to  
S. pneumoniae, as well as in vivo studies in these mice. Experiments carried out using 
individual TLR knock-out mice and reporter cells which were previously transfected with 
TLRs would also indicate the role of these receptors in macrophage activation.   
 
Clinical and epidemiological data suggest that different S. pneumoniae strains vary in their 
ability  to  cause  severe  disease  and  that  this  is  linked  to  capsular  serotype,  with 
nasopharyngeal  colonisation  with  strains  expressing  some  capsular  serotypes  associated 
with a greatly increased incidence of septicaemia and meningitis (Brueggemann et al. 2003; 
Brueggemann et al. 2004; Sandgren et al. 2004; Hanage et al. 2005).  However, the recent 
genome  sequence  data  showing  considerable  genetic  variation  between  S.  pneumoniae 
strains unrelated but linked to capsular serotype (Hakenbeck et al. 2001; Hiller et al. 2007) 
suggest phenotypic differences between strains cannot be assumed to be due to the effects 
of the capsular serotype alone. Therefore otherwise isogenic bacterial strains expressing 
four different capsular serotypes were used to investigate the influence of capsular serotype 
independent of other genetic variation on S. pneumoniae interactions with the host immune 
response.  
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The flow cytometry and immunogold EM data shows increased C3b/iC3b deposition on 
otherwise isogenic strains expressing serotype 23F and 6A capsules compared to strains 
expressing the serotype 4 and 7F capsules. Capsule thickness and phase variation influence 
complement-mediated  immunity  to  S.  pneumoniae  (MacLeod  et  al.  1950;  Nelson  et  al. 
2007),  but  the  strains  investigated  were  opaque  phase  variants  and  had  similar  capsule 
thickness when measured using EM. The results contrast with those from Weinberger et al, 
who found that TIGR4 capsular switch strains expressing capsular serotypes representing a 
wide range of S. pneumoniae strains did show differences in capsule thickness (Weinberger 
et al. 2009). Different methodology was used by Weinberger et al to determine capsule 
thickness  than  those  in  this  thesis,  as  they  used  an  approach  based  upon  the  Quellung 
Reaction  with  FITC-Dextran  exclusion.  It  is  intriguing  that  our  results  differ,  and  this 
highlights the issue of quantitating the amount of polysaccharide capsule expressed by a 
given strain of S. pneumoniae. It is possible that the FITC-Dextran methodology is subject 
to variation in the ability of different capsule polysaccharides to swell, and due to their 
chemical structure it is also possible that light is refracted differentially by different capsule 
polysaccharides thereby creating artificial differences in the capsule thicknesses. The EM 
method used in this thesis is novel, and part of the fixation method requires the dehydration 
of  the  sample  preparations.  It  is  possible  that  different  capsular  polysaccharides  have 
different levels of hydration, and therefore this step may artificially  create no apparent 
difference  between  capsule  thicknesses.  Furthermore  it  is  possible  that  the  strategy  of 
selecting spherical and non-dividing bacteria has in some way biased the data towards a 
particular thickness of capsule. The results of the Stains-All assay for the opaque strains are 
towards the maximum end of the measurable optical density range, and hence may not 
accurately reflect differences between the capsular switch strains. However, both the EM 273 
 
and the Stains-All assay showed significantly less capsule polysaccharide expressed by the 
transparent  phase  variants  compared  to  the  respective  opaque  phase  TIGR4(-)+  S. 
pneumoniae strain, which correlates with data published by other researchers (Weiser et al. 
1994; Kim et al. 1998). Hence EM can distinguish the capsule thickness between strains in 
different phenotypes and may provide an accurate method to quantitate the thickness of the 
capsule polysaccharide. An ELISA method has used by other researchers, though this relies 
upon  capsule  polysaccharide  extracts  to  quantitate  the  CPS,  and  these  preparations  are 
known to be contaminated with teichoic acid and other cell wall components (Kim et al. 
1998).  It  would  be  helpful  to  have  a  standardised  methodology  for  quantitating  the 
thickness  or  amount  of  polysaccharide  capsule  expressed  by  a  strain,  but  all  current 
methodologies have drawbacks and no-one method seems preferable.  
 
There were differences in the binding of C1q, CRP, SAP and FH to the TIGR4 capsular 
switch strains. However the binding of these complement mediators did not correlate with 
the C3b/iC3b results, providing no potential explanation for the increased C3b/iC3b on the 
TIGR4(-) +6A and +23F strains relative to the TIGR4(-) +7F and +4. The differences in the 
binding  levels  of  these  complement  mediators  were  very  small,  and  it  is  questionable 
whether these differences would be immunologically relevant.  In keeping with the results 
of  the  TIGR4,  TIGR4cps,  D39  and  D39-D   strains,  there  was  increased  C3b/iC3b 
deposition  on  the  transparent  phase  variant  TIGR4(-)+  strains  which  express  a  thinner 
polysaccharide capsule than the corresponding opaque TIGR4(-)+ strains. Furthermore the 
results of the complement mediator binding to TIGR4 capsular switch strains also mirrored 
the results of the unencapsulated TIGR4 and D39 strains. There was increased binding of 274 
 
C1q,  CRP,  and  FH  on  the  transparent  phase  strains  and  reduced  SAP  binding  when 
compared to the opaque phase variants.  
 
Antibodies to capsular polysaccharide increase complement deposition on S. pneumoniae, 
and indeed capsule serotype specific IgG levels did correlate with C3b/iC3b deposition on 
the  TIGR4(-)+  capsular  switched  strains  in  the  human  test  serum.  The  levels  of  anti-
capsular serotype specific antibody in the test serum did not correlate with the total IgG 
binding as detected by flow cytometry. It should be noted that the fluorescent indexes are 
quite low for these results, and it would ideally be best to replicate this data set with a 
whole cell ELISA to measure total antibody binding to the capsular switch strains (Roche et 
al. 2007).  However if this result is accurate it suggests that antibody against non-capsular 
antigens  significantly  contribute  to  the  total  IgG  deposition  on  a  given  strain  of  
S. pneumoniae. C3b/iC3b deposition was also increased on the TIGR4(-)+6A and +23F 
strains in both baby rabbit and mouse serum which contain no S. pneumoniae specific IgG 
and in human serum deficient in C1q and therefore lacking antibody-mediated complement 
activity, suggesting the effects are largely independent of antibody. Repeated C3b/iC3b 
flow  cytometry  assays  using  human  test  serum  which  was  depleted  of  IgG  using  IdeS 
confirmed  that  there  was  still  increased  C3b/iC3b  deposition  on  the  TIGR4(-)+6A  and 
+23F strains relative to the TIGR4(-)+7F and +4 strains when the effect of antibody was 
removed from human serum. Overall, these results suggest that the differences between 
C3b/iC3b deposition on the TIGR4 capsular switch strains  cannot be  accounted for by 
differing levels of anti-pneumococcal antibody present in the serum.  
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Furthermore, C3b/iC3b deposition results in sera deficient in alternative pathway activity 
and data on the binding of classical pathway mediators to the TIGR4(-)+ strains, as well as 
the immunogold EM demonstrating large clusters of C3b/iC3b on the +6A and +23F strains 
only, all indicate that the differences in C3b/iC3b deposition between strains are alternative 
pathway dependent (Brown et al. 2002). The importance of the alternative pathway has 
previously  been  suggested  for  non-isogenic  strains  of  different  capsular  serotypes 
(Winkelstein et al. 1976). Overall this data provide evidence that differences in C3b/iC3b 
deposition  between  isogenic  strains  expressing  different  capsular  serotypes  reflect 
differences  between  capsular  serotypes  in  inhibiting  complement  activity,  and  support 
existing data showing that expression of capsular  serotype 3 in a serotype 2 strain affected 
complement deposition (Abeyta et al. 2003).  
 
Neutrophil phagocytosis of S. pneumoniae is largely complement dependent and there are 
significant differences in susceptibility to phagocytosis for different S. pneumoniae strains 
(Winkelstein et al. 1976; Kim et al. 1999; Yuste et al. 2008; Melin et al. 2009; Weinberger 
et al. 2009). Therefore neutrophil phagocytosis of the TIGR4(-)+ capsular switched strains 
was investigated. When the effect of antibody was removed from human serum using IdeS 
the  TIGR4(-)  +6A  and  +23F  strains  were  more  sensitive  to  neutrophil  phagocytosis 
compared to the TIGR4(-) +7F and +4 strains, although in the presence of antibody this 
pattern was not apparent. Furthermore, mouse serum or baby rabbit complement was used 
to opsonise the bacteria to prevent the whole cell and capsular specific antibody levels in 
human  serum  confounding  the  results  through  antibody-Fcg  receptor  interactions. 
Neutrophil  phagocytosis  of  the  TIGR4(-)+  strains  correlated  closely  with  the  C3b/iC3b 
deposition  results.  The  TIGR4(-)+6A  strain  which  had  the  highest  level  of  C3b/iC3b 276 
 
deposition was also the most sensitive to neutrophil phagocytosis, with an intermediate 
result  for  the  TIGR4(-)+23F  strain  and  both  the  TIGR4(-)+4  and  +7F  strains  being 
relatively  resistant  to  neutrophil  phagocytosis.  These  differences  in  phagocytosis  were 
abolished when the capsular switch strains were not opsonised with C3b/iC3b, confirming 
they  were  due  to  complement  activity  rather  than  other  potential  differences  between 
capsular  serotypes  in  their  interactions  with  non-complement  phagocytic  receptors.  The 
results of the phagocytosis data suggest that variations between S. pneumoniae strains in 
their  sensitivity  to  phagocytosis  can  be  partially  dependent  on  capsular  serotype  and 
complement-sensitivity. 
   
Intriguingly,  the  TIGR(-)+  strains  expressing  serotypes  associated  with  invasive  
S.  pneumoniae  infection  (ST4  and  7F)  had  the  lowest  level  of  C3b/iC3b  deposition, 
suggesting  perhaps  that  resistance  to  complement-mediated  immunity  may  influence 
invasiveness. However, whether capsular serotype effects on complement truly correlate 
with S. pneumoniae invasive potential can only be answered using a much larger range of 
capsular switched strains. The recent Weinberger et al paper found that differences in the 
structure  of  the  capsular  polysaccharides  correlated  to  the  prevalence  of  difference  
S. pneumoniae serotypes, and suggested this was due to the different energy costs of the 
polysaccharides (Weinberger et al. 2009). In addition these investigators demonstrate that 
the TIGR4(-)+4 strain is relatively poor at surviving non-opsonic PMN killing, whereas the 
TIGR4(-)+6A  and  +7F  an  intermediate  survival  and  the  TIGR4(-)+23F  strain  shows 
significant  survival  (Weinberger  et  al.  2009).  However  whether  the  differences  in 
polysaccharide  structure  affect  complement  mediated  immunity  was  not  investigated. 
Precisely how different capsular serotype structures can have varying effects on C3b/iC3b 277 
 
deposition is not clear; ST6A and 23F capsules may allow greater access of complement to 
the bacterial surface, but capsular serotype could also influence complement deposition 
indirectly by modifying the interactions of surface proteins such as PspA and CbpA with 
complement factors (Tu et al. 1999; Yuste et al. 2005; Quin et al. 2007).  
 
Complement is an essential component of the host immune response to systemic infection 
with S. pneumoniae (Winkelstein 1981; Tu et al. 1999; Brown et al. 2002; Jonsson et al. 
2005; Yuste et al. 2005; Yuste et al. 2008), and the differences in C3b/iC3b deposition 
between  the  TIGR4(-)+  strains  would  therefore  be  predicted  to  have  significant 
consequences  for  virulence.  Indeed  the  TIGR4(-)+6A  and  +23F  strains  had  reduced 
virulence  in  a  mouse  model  of  sepsis,  with  a  nearly  four-fold  difference  in  recovered 
bacterial CFU 24 hours after infection with the TIGR4(-)+6A compared to the TIGR4(-)+4 
strains. These results support previously published data showing that expression of capsular 
serotype 3 can decrease, increase or have no effect on virulence in a mouse model of sepsis 
depending on the strain background, and show that capsular serotype can affect virulence 
independent of other genetic variation between strains (Kelly et al. 1994). However the 
effects  of  expression  of  different  capsular  serotypes  affecting  the  virulence  of  the  
TIGR4(-)+  strains  were  relatively  weak,  and  all  these  strains  still  caused  significant 
infection  in  mice.  This  contrasts  with  previous  data  showing  that  clinical  isolates  of 
serotype 7F and serotype 23F are not virulent in mice (Briles et al. 1992; Sandgren et al. 
2005).  Furthermore  there  are  marked  differences  in  virulence  in  mice  between  
S. pneumoniae strains of the same capsular serotype (Briles et al. 1992; Sandgren et al. 
2004). These data suggest that although capsular serotype can modulate virulence there is 
also  a  considerable,  perhaps  dominant,  effect  of  non-capsular  genetic  variation  on  the 278 
 
development  of  S.  pneumoniae  infections  in  mice.  The  importance  of  complement  for 
systemic  immunity  to  S.  pneumoniae  makes  it  plausible  that  the  increased  C3b/iC3b 
deposition  and  neutrophil  phagocytosis  of  the  TIGR4(-)+6A  and  +23F  strains  are 
responsible for the reduced virulence of these strains.  However, the differences between 
capsular  serotypes  in  C3b/iC3b  deposition  could  also  correlate  with  effects  on  a  wider 
range of host protein / bacterial interactions, for example recognition by macrophages via 
the lectin SIGN-R1 (which specifically recognises the S. pneumoniae capsule) or other non-
complement cell surface receptors, which may also influence virulence in the mouse model 
(Winkelstein et al. 1976; Winkelstein 1981; Arredouani et al. 2004; Kang et al. 2006).   
 
The  intranasal  infection  model  showed  that  the  TIGR4(-)  +6A  and  +23F  strains  have 
reduced  virulence  in  the  lung  compared  to  the  TIGR4(-)  +7F  and  +4  capsular  switch 
strains. There was also increased association with AMs of the TIGR4(-) +6A and +23F 
capsular strains in comparison to the +7F and +4 expressing strains. These results show a 
similar  pattern  to  the  results  of  the  C3b/iC3b  binding  assay  and  the  PMN  association 
assays.  However,  the  effect  of  expression  of  different  capsular  serotypes  was  again 
relatively  weak,  indicating  that  other  non-capsular  genetic  factors  have  an  impact  on 
pulmonary virulence of S. pneumoniae in mice. Furthermore there was also an increased 
TNFα response to the TIGR4(-) +6A and +23F strains despite the reduced bacteria survival. 
These  suggest  these  capsular  serotypes  are  less  anti-inflammatory.  Overall  the  capsular 
serotype  TIGR4(-)  +6A  and  +23F  have  a  phenotype  closer  to  the  TIGR4cps  than  the 
TIGR4(-)  +7F  and  +4  i.e.  these  capsule  serotypes  are  less  effective  at  preventing 
host/pathogen interactions. Hence the affects of the S. pneumoniae capsule on AM response 279 
 
is  likely  to  vary  with  capsular  serotype,  and  may  affect  the  ability  of  different  
S. pneumoniae serotypes to cause respiratory infections.  
 
Currently there are only limited data on the mechanisms by which the conjugate vaccine 
may induce protection against S. pneumoniae pneumonia, obtained mainly with a serotype 
1  strain  only  (Jakobsen  et  al.  1999;  Saeland  et  al.  2001;  Jakobsen  et  al.  2002).  Innate 
immune responses have a significant impact on adaptive immune responses to vaccines 
(Ross  et  al.  2000;  Ferreira  et  al.  2009;  Jones  et  al.  2009),  suggesting  that  serotype-
dependent  effects  on  innate  immunity  may  also  affect  the  efficacy  of  the  vaccine  in 
inducing  immunity  to  S.  pneumoniae.  This  leads  to  the  hypothesis  that  the  relative 
resistance to innate immunity of the capsular serotype 4 and 7F capsular switch strains may 
lead to a reduced efficacy of conjugate vaccines against these serotypes. At present the 
relative  importance  of  capsular  serotype  or  other  genetic  differences  between  
S. pneumoniae strains for complement activity and whether there is a relationship between 
relative complement resistance and S. pneumoniae invasiveness is not known and needs 
clarification.  Therefore  the  effect  of  non-capsular  genetic  variation  on  complement 
mediated immunity was investigated using clinical isolate strains of S. pneumoniae which 
represented several serotypes with different clones from each capsular serotype.  
 
Clinically isolated strains of S. pneumoniae were obtained from previous epidemiology 
studies of invasive pneumococcal disease in children under 5  years old in Sweden and 
Finland (Sandgren et al. 2004; Hanage et al. 2005). Strains were inclusive of isolates from 
serotypes 1, 4, 14, 9V, 6B, 6A, 19F and 23F. Serotypes 1, 4 and 14 represent serotypes 280 
 
which molecular epidemiology studies show have a high invasive disease potential whereas 
serotypes 9V, 6B, 6A, 19F and 23F have a relatively low invasive disease potential but a 
high disease incidence presumably due to increase carriage rates (Brueggemann et al. 2003; 
Sandgren et al. 2004; Hanage et al. 2005; Sjostrom et al. 2006). Furthermore at least 3 
different  ST  strains  with  known  MLST  profiles  were  available  from  each  of  these 
serotypes, which enabled experiments to be performed to assess the relative contribution of 
capsular serotype and non-capsular genetic variation to the resistance of S. pneumoniae to 
complement deposition and phagocytosis.  
 
Experiments performed with clinical isolates of S. pneumoniae also show that C3b/iC3b 
deposition varies with capsular serotype. Mean C3b/iC3b deposition varied with capsular 
serotype, although there was also variation in C3b/iC3b deposition between different clones 
of the same serotype which was not sufficient to affect a serotype dependent difference. It 
is difficult to state whether this is due to differences in capsule thickness between isolates 
of different serotypes. However, all the clinical isolates where in opaque phase variation, 
suggesting  a  relatively  thick  capsule,  and  EM  showed  no  variation  in  the  degree  of 
encapsulation between two strains from a 6B and 23F serotype background (Kim et al. 
1998;  Weiser  et  al.  2001).  Furthermore  the  Stains-All  biochemical  assay  revealed  no 
difference in the amount of capsule associated by either the 6B or 23F strains, although 
since  this  assay  relies  on  detection  of  acidic  polysaccharides  it  is  not  necessarily  an 
appropriate  assay  to  compare  degrees  of  encapsulation  between  different  serotypes 
consisting of different monosaccharides (Edstrom 1969; Hammerschmidt et al. 2005). As 
previously  discussed,  it  is  relatively  difficult  to  quantitate  the  amount  of  capsule 
polysaccharide expressed by S. pneumoniae, although this should be attempted for all the 281 
 
clinical  isolate  strains  to  determine  if  these  results  are  truly  independent  of  capsule 
thickness.  However,  since  C3b/iC3b  deposition  does  vary  by  serotype  in  strains  of  
S. pneumoniae which have been isolated from invasive pneumococcal disease, this suggests 
that differences in the ability of a given serotype to resist complement deposition may have 
a functional consequence in disease states. The differences in C3b/iC3b deposition on the  
S. pneumoniae strains correlated closely with the results of neutrophil phagocytosis assays, 
demonstrating a functional significance for the ability to resist complement deposition. 
 
C3b/iC3b deposition also varied on S. pneumoniae strains which had the same capsular 
serotype but a different genetic background. This was demonstrated using several strains of 
representative STs for 4 different capsular serotypes. There were consistent and perhaps 
surprisingly large variations in C3b/iC3b deposition on S. pneumoniae between strains with 
different genetic backgrounds but the same capsular serotype. There were even differences 
between strains that although they have the same ST and the same capsular serotype were 
isolated  from  different  geographical  backgrounds  (eg  the  ST138  and  176  serotype  6B 
strains, and the ST124 serotype 14 strains). These results concur with data obtained by a 
previous student in the lab (Sophia Opel) who performed similar assays in 2004. This gives 
a consistency to the data despite the different investigators, date of experiments and stock 
sets used suggesting that this result is likely to be accurate.  
 
Antibody  levels  against  the  different  S.  pneumoniae  serotypes  varied,  as  did  total  IgG 
binding  to  the  different  strains.  There  was  an  overall  positive  correlation  between  IgG 
binding  and  C3b/iC3b  deposition,  suggesting  the  importance  of  the  antibody  effect  for 282 
 
differences in C3b/iC3b deposition between strains. However this correlation of antibody to 
C3b/iC3b is only moderate, and after the removal of IgG from serum the differences in 
C3b/iC3b deposition between strains was maintained, indicating that the strain variation in 
resistance to complement deposition is at least partially independent of IgG.  
 
Interestingly there were differences in the level of IgG binding between strains of the same 
serotype but different ST, indicating the importance of non-capsular antigens in eliciting 
and modulating the antibody response to S. pneumoniae. These results indicate that non-
serotype  dependent  differences  between  strains  can  have  quite  marked  effects  on 
complement activity. Recent data using micro-arrays has shown that strains with the same 
ST and serotype are not necessarily genetically identical (Dagerhamn et al. 2008). This is a 
potentially  powerful  finding,  as  the  genetic  variation  between  strains  with  the  same 
serotype  and  ST  is  relatively  limited  and  therefore  the  genetic  basis  for  differences  in 
C3b/iC3b  deposition  could  be  more  readily  identified.  There  are  several  potential 
mechanisms  for  non-capsular  serotype  variation  in  C3b/iC3b  deposition,  including  the 
known allelic variation in S. pneumoniae proteins that affect complement activity such as 
PspA and CbpA, the effects of as yet unidentified proteins encoded by regions of diversity 
present only in selected strains, and varying expression between strains of target molecules 
for thioester bond formation with C3. Furthermore, the significant difference in C3b/iC3b 
deposition  between  6A  and  6B  strains  whose  capsular  loci  only  differ  by  a  single 
polymorphism in wciP encoding a rhamnosyl transferase (Mavroidi et al. 2004) perhaps 
suggests that subtle differences in capsule structure that do not affect capsular serotype 
could still influence complement activity. Identifying which of these potential mechanisms 
influence  non-capsular  serotype-dependent  variation  in  C3b/iC3b  deposition  will  be 283 
 
complex, but may help clarify why strains with otherwise similar genetic backgrounds vary 
in  their  virulence  potential,  analogous  to  recent  data  on  variations  in  sensitivity  to 
complement for Neisseria meningitides strains (Uria et al. 2008).  
 
Hence  I  also  investigated  binding  of  the  complement  factors  C1q  and  FH  between 
difference isolates of S. pneumoniae. Binding of both the classical pathway mediator C1q 
and the alternative pathway mediator FH also varied between different STs with the same 
capsular serotype. C1q binding correlated with C3b/iC3b deposition, and this correlation 
was in fact tighter than that between IgG binding and C3b/iC3b deposition. This suggests 
that direct C1q binding to direct targets such as pneumolysin and phosphorylcholine also 
significantly affects the total C3 binding to a strain along with binding to IgG (Paton et al. 
1984; Mitchell et al. 1991; Agrawal et al. 2001).  
 
FH  was  found  to  inversely  correlate  with  C3b/iC3b  deposition  on  the  S.  pneumoniae 
clinical isolates. FH is an inhibitor of the alternative pathway and binds mainly to CbpA, 
and the considerable allelic variation of CbpA could lead to variation in its ability to bind 
FH  (Iannelli  et  al.  2002;  Quin  et  al.  2006;  Lu  et  al.  2008).  This  result  conflicts  with 
previous data from other investigators, and this may be due to the reduced numbers of 
strains  that  Melin  et  al  investigated  compared  to  the  strain  library  used  in  these 
experiments, or simply the result of analysis of different S. pneumoniae strains (Melin et al. 
2009). If the result in this thesis is correct, it suggests that activity of CbpA is likely to be 
important in mediating complement resistance in pneumococcal disease. To investigate this 
further  would  require  sequencing  CbpA  from  the  clinical  isolates  to  try  and  correlate 
differences in the derived amino acid sequence with variation in FH binding. In addition 284 
 
mutant strains of the clinical isolates lacking the CbpA protein could be used to measure 
the consequence of loss of this virulence factor from clinically isolated strains. 
 
Given the vital role for complement in preventing systemic infection by S. pneumoniae 
(Brown et al. 2002; Yuste et al. 2005) and the wide variation in complement activation 
between strains it was hypothesised that relative resistance to complement activity may 
explain some of the differences in virulence between capsular serotypes. To investigate this 
hypothesis  C3b/iC3b  deposition  was  compared  on  12  S.  pneumoniae  strains  from  the 
invasive capsular serotypes 1, 4, 7F and 14 to the results for 21 strains from serotypes with 
relatively  low  invasive  potential,  using  strains  representative  of  prevalent  STs  for  each 
capsular serotype. C3b/iC3b deposition on invasive serotypes was significantly  reduced 
compared  to  the  results  for  weakly  invasive  strains.  Hence  invasive  serotypes  are  on 
average less sensitive to complement-dependent bacterial clearance and this could partially 
explain why these serotypes are particularly capable of causing systemic infection. There 
was  a  wide  range  for  results  of  C3b/iC3b  deposition  on  strains  from  weakly-invasive 
serotypes which significantly overlapped with the results for invasive serotypes, consistent 
with  the  observation  that  weakly-invasive  serotypes  are  genetically  more  diverse  than 
invasive serotypes (Sandgren et al. 2004). These data suggest that the varying effects of 
different capsular serotypes on complement activity against S. pneumoniae are clinically 
relevant.  Although  complement  resistance  is  likely  to  be  only  one  of  many  factors 
influencing  differences  in  invasive  potential  between  S.  pneumoniae  strains,  serotype-
dependent effects on complement-dependent immunity and invasiveness are of particular 
importance as existing vaccines are serotype specific and cause profound changes in the 
ecology of different S. pneumoniae capsular serotypes. 285 
 
7.2 SUMMARY 
In summary the results presented in this thesis show:  
1. The S. pneumoniae capsule can affect several aspects of complement activity against S. 
pneumoniae, including inhibition of recognition of the bacteria by the classical pathway 
mediators IgG and CRP, and reducing degradation of C3b bound to the bacterial surface to 
iC3b.  
2. The effects of the capsule on C3b/iC3b deposition results in reduced phagocytosis of 
encapsulated bacteria, but the capsule also inhibits non-complement dependent mechanisms 
of  neutrophil  phagocytosis.  These  data  clarify  the  contribution  of  the  capsule  to  S. 
pneumoniae immune evasion.  
 
I have also shown: 
3. The capsule is vital for evasion of evasion of early pulmonary immune responses, and 
affects complement dependent and independent interactions with alveolar macrophages.  
 
4.  The  capsule  affects  the  inflammatory  response  of  alveolar  macrophages,  which  may 
contribute to its effect on virulence. Interestingly, although S. pneumoniae stimulate the 
NFκB,  p38  and  ERK1/2  innate  activation  pathways  the  capsule  seems  to  specifically 
modulate  activation  of  the  NFκB  transcription  pathway.  This  finding  requires  further 
investigation to clarify the mechanisms involved.    
 
5. Opsonisation with C3b/iC3b of S. pneumoniae TIGR4(-)+strains varied markedly with 
capsular  serotype,  with  a  higher  level  on  capsular  serotypes  associated  with  weakly 
invasive  strains.  Differences  between  capsular  serotypes  in  opsonisation  with  C3b/iC3b 286 
 
were  correlated  closely  with  differences  in  neutrophil  phagocytosis  and  in  virulence  in 
mice.  Overall,  this  thesis  indicates  that  capsular  serotype  can  affect  S.  pneumoniae 
resistance to host immune responses, and suggest this maybe one possible cause of some of 
the variation in invasive potential between strains of this important pathogen. Interestingly, 
experiments  using  otherwise  isogenic  bacteria  expressing  different  capsular  serotypes 
demonstrated  that  serotypes  associated  with  low  frequency  of  invasive  disease  showed 
more rapid pulmonary clearance and induced lower inflammatory responses than serotypes 
frequently associated with invasive disease. 
 
6. Data from the clinical isolated S. pneumoniae strains indicate that opsonisation of with 
C3b/iC3b varies markedly with capsular serotype and with strain variation independent of 
capsular  serotype,  and  is  associated  with  the  invasive  potential  of  different  capsular 
serotypes.  These  results  suggest  that  differing  sensitivity  to  host  immunity  can  explain 
some of the differences in invasiveness between S. pneumoniae strains, and may represent a 
step forward in our understanding of why particular S. pneumoniae strains frequently cause 
invasive disease. In addition, the importance of complement for immunity to a variety of 
bacteria suggests these results have broader implications for understanding variations in 
virulence between strains of other bacterial pathogens as well as S. pneumoniae. 287 
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APPENDIX 1 
 
Cden MEDIUM 
 
  200ml   Cden Base 
  50ml    HYR 
  10ml    1mg/ml Glutamine         (Sigma) 
  10ml    Vitamins without choline solution  
  5ml    2% Sodium Pyruvate        (Sigma)   
  40ml    SAC Solution 
  13ml    Supplement 
  15ml    1M  KPO4, pH 8.0        (Sigma) 
  10ml     10mg/ml Leucine         (Sigma) 
  5ml    10mg/ml Phenylalanine      (Sigma) 
  9ml    10mg/ml Lysine        (Sigma) 
  2ml    1mg/ml Choline        (Sigma) 
 
The above reagents were filtered through 0.45µm filter to produce sterile medium.  
 
 
SUPPLEMENT 
  60ml     ‘3 in 1’ Salts 
  120ml   20% Glucose          (Sigma) 
  6ml    50% Sucrose          (Sigma) 
  120ml   2mg/ml Adenosine        (Sigma) 
  120ml    2mg/ml Uridine        (Sigma) 
 
The above reagents were filtered through 0.45µm filter to produce a sterile solution. 
 
SAC 
  12g     NaCl            (Sigma) 
  12g    Anhydrous sodium acetate      (Sigma) 
      Distilled water to a final volume of 1L 
 
VITAMINS WITHOUT CHOLINE 
  12ml     Adam’s I solution 
  32ml    5mg/ml Asparagine        (Sigma) 
  36ml    Distilled water 
The above reagents were filtered through 0.45µm filter to produce a sterile solution. 
 
 
HYR 
  640mg   Histidine          (Sigma) 
  122mg   Tyrosine          (Sigma) 
  800mg   Arginine          (Sigma) 
      Distilled water to a final volume of 1L 
 
The above reagents were filtered through 0.45µm filter to produce a sterile solution. 345 
 
Cden BASE 
 
  190mg   Glycine          (Sigma) 
  350mg   Alanine          (Sigma) 
  720mg   Valine           (Sigma) 
  760mg   Isoleucine          (Sigma) 
  1160mg  Proline           (Sigma)   
  590mg   Serine            (Sigma) 
  450mg   Threonine          (Sigma) 
  310mg   Methionine          (Sigma) 
  140mg   Tryptophan          (Sigma) 
  720mg   Asppartic acid         (Sigma) 
  2200mg  Glutamic acid         (Sigma) 
  150mg   L-Cysteine          (Sigma) 
      Distilled water to a final volume of 2L 
       
The above reagents adjusted to pH 7.0 and were filtered through 0.45µm filter to produce a 
sterile solution. 
 
ADAM’S I SOLUTION 
 
  60µl    0.5mg/ml Biotin        (Sigma) 
  30mg    Nicotinic Acid         (Sigma) 
  35mg    Pyridoxine          (Sigma) 
  120mg   Calcium Pantothenate       (Sigma) 
  32mg    Thiamine HCl         (Sigma) 
  14mg    Riboflavin          (Sigma) 
      Distilled water to a final volume of 200ml 
 
The above mixture was filtered through 0.45µm filter to produce a sterile solution, which 
was stored in the dark. 
 
 
‘3 IN 1’ SALTS 
 
  100g    MgCl2
.6H2O          (Sigma) 
  0.5g    Anhydrous CaCl2        (Sigma) 
  200µl    0.1M MnSO4         (Sigma) 
      Distilled water to a final volume of 1L 
 
The above mixture was autoclaved to ensure sterility.  346 
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